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Abstract
An increasing interest in non-canonical nucleic acid structures has
drawn the attention of the scientific community during the last few
decades. One such structure, the G-quadruplex, has been the focus of
an increasing number of scientists as G-quadruplexes are believed to
play a role in biological processes such as telomere integrity and gene
expression. Their existence in vivo is largely unproven but they have
stimulated a lot of research into small molecules that interact with
them. The development of a new class of such molecules is described
in this thesis. A member of this family showed to be very selective
in stabilising one particular G-quadruplex. The further development
of another family of G-quadruplex interacting small molecules is also
presented in this thesis and some of their effects in cellulo were as-
sessed. Based on the scaffold of this family, an affinity probe was
developed, which can mediate the isolation of its nucleic acid targets
from human cells. This is the first example of the use of a small mo-
lecule with an affinity tag that has been used to isolate a nucleic acid
target in a structure specific manner from human cells.
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Chapter 1
Introduction
1.1 G-quadruplex nucleic acids
Nucleic acids play fundamental roles in cells and constitute an important class of
biological macromolecules. They can adopt complex secondary structures which
are functionally important in the cellular context. The discovery of the DNA
double helix and A.T and G .C base pairing in 1953 [1–3] paved the way for the
burgeoning research on nucleic acids and their importance in genetics. Whereas
it is now established that RNA molecules adopt various complex secondary struc-
tures, the general belief still holds that DNA exists mainly in its double-stranded
helical form with only a few exceptions. It has been known since 1901 [4] that
guanylic acid can form gels in solution, which suggests molecular interactions
between guanines. However, it was not discovered until 1962 [5] that guanine-rich
sequences can form alternative structures to the double helix proposed by Watson
and Crick. It has now been demonstrated by crystallographic [6–10] and NMR spec-
troscopic [11–15] studies, that single-stranded guanine-rich strands can fold into G-
quadruplexes (also termed G-tetraplexes), secondary nucleic acid structures with
stacks [5,16,17] of guanine tetrads in their central cores. Each tetrad comprises four
Hoogsteen hydrogen-bonded guanines. The hydrogen bonds observed in A.T and
G .C base pairs and those in guanine tetrads are depicted in Figure 1.1. Like B-
DNA helices, G-quadruplexes also have a right-handed helical twist but contain
around 12 tetrads per turn [18,19] as opposed to 10 base pairs in B-DNA.
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Figure 1.1: Left: A.T and G .C base pairs. Right: Guanine tetrad formed by four
guanines and a monovalent cation in the centre. Hydrogen bonds are indicated as
dashed lines.
G-quadruplexes can be formed by a single strand (intramolecular) or sev-
eral strands (intermolecular) and often exhibit dynamic and polymorphic struc-
tures [20–22] in solution depending on factors such as cation nature, [8,23] loop (i.e.,
sequences connecting the tetrads) length and topology, [24,25] DNA concentration,
associated proteins and molecular crowding. [26] The DNA strands that run along
the periphery of G-quadruplexes can be parallel or antiparallel defining the di-
rectionality/polarity of the strands in relation to each other. The angle of the
glycosylic bond, as depicted in Figure 1.2, is syn if the strands are parallel and
anti if the strands are antiparallel. The syn/anti nature of the gycosylic bonds
determines the groove widths of G-quadruplexes, whereas the loop lengths highly
influence G-quadruplex topology and stability. [24,25] Figure 1.3 depicts examples
of schematic views of some parallel and anti-parallel intra-and intermolecular qua-
druplexes. It is noteworthy that the stacked guanines are neither exactly symmet-
ric nor exactly planar. Depending on the loop length and nature, the guanines of
the top and/or bottom tetrad can tilt or buckle to accommodate conformational
strain. The size of the cations residing in the centre of G-quadruplexes also highly
influence G-quadruplex conformation and topology. For instance, ammonium and
potassium ions coordinate between two quartets, whereas the smaller sodium ion
2
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can reside within the plane of a guanosine quartet. G-quadruplex polymorphism
gives great scope for the possibility of differential recognition by other molecules,
including proteins and synthetic small molecules.
N
OR2
O
N
N
NH
O
NH2R1O N
OR2
O
R1O
N
HN
N
H2N
O
syn anti
χ
Figure 1.2: Guanosine can adopt syn and anti conformations. The bond determining
the glycosylic angle χ is indicated.
Figure 1.3: Examples of G-quadruplex conformations. Depicted are examples of
intra-and intermolecular parallel and anti-parallel G-quadruplexes.
Human chromosome ends (telomeres) possess a repetitive G-rich sequence
with a single-stranded overhang of the sequence 5′-(GGTTAG)n-3′. The human
telomeric sequence can adopt different G-quadruplex structures depending on
cation nature and concentration. [8] It is likely that these structures are dynamic
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in their natural context and it has been shown in vitro by Ying et al. that the
parallel and anti-parallel structures of this sequence readily interconvert in solu-
tion by using single-molecule fluorescence resonance energy transfer. [27] Figure 1.4
depicts the human telomeric repeat sequence and a schematic view of a possible
G-quadruplex conformation it can adopt. Illustrated is an anti-parallel confor-
mation.
Figure 1.4: Left: Human telomeric sequence. Right: Diagram of an antiparallel
G-quadruplex that can be formed by this sequence.
In cells, with the exception of the single-stranded telomeric G-overhang, the
formation of intramolecular DNA G-quadruplexes is in competition with hybridi-
sation to the complementary strand. In human cells, DNA G-quadruplexes have
been hypothesised to form at telomeres, [28] in promoter regions of genes, [29] in
parts of rDNA [30] and they are also believed to form throughout the genome
during replication, [31] as described in section 1.3. G-quadruplexes can also be
formed by G-rich RNA. [32–36] RNA G-quadruplexes tend to be even more stable
than their DNA-counterparts and are not in competition with a complementary
strand. However, RNA can adopt complex secondary structures such as hairpins,
bulges and loops, which can compete with G-quadruplex formation.
Intramolecular G-quadruplexes may be of relevance in biology. An algo-
rithm based on observed stable G-quadruplexes has been proposed: at least
four G-tracts of three guanines which are joined by 1-7 bases of any nature,
i.e., GGG(X)1-7GGG(X)1-7GGG(X)1-7GGG where X is any nucleobase, are re-
quired to form intramolecular G-quadruplexes. Using this algorithm, approxi-
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mately 376,000 putative DNA G-quadruplex sequences have been identified in
the human genome. [37] This publication was complemented by another study by
Todd et al., [38] which was also based on an algorithm to assess intramolecular
G-quadruplexes in the genome. Both papers were published back-to-back in the
same journal. However, these motifs have not yet been mapped experimentally
in the genome and their formation in human cells has not yet been proven. An
experimental approach to identify these structures in the human genome could
potentially shed light on the existence of G-quadruplexes in human cells.
1.2 G-quadruplex interacting small molecules
It was proposed in 1991 by Zahler et al. [28] that telomerase can be inhibited by
G-quadruplex formation. Molecules were later identified that inhibit the action
of human telomerase [39,40] by interacting with and by stabilising telomeric G-
quadruplexes in vitro. In 2001 the natural product telomestatin (Figure 1.5),
isolated from Streptomyces anulatus, [41] was found to be a potent inhibitor of
telomerase function, which was linked to its G-quadruplex interacting properties.
The same molecule was later shown to disrupt the protein complexes associated
with telomeres. [42]
N
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N N
N
N
N
S O
O
O
O
O
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O
H
telomestatin
Figure 1.5: Molecular structure of telomestatin.
Targeting G-quadruplex DNA is challenging given that this canonical DNA
structure is highly polymorphic and not very abundant in comparison with double-
stranded DNA. Nonetheless, there are several classes of G-quadruplex interacting
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small molecules described in the literature, notably: acridine derivatives, [39,43–51]
amidoanthracene derivatives, [52,53] amidofluorenone derivatives, [54] ethidium deri-
vatives, [55] porphyrins, [40,56–59] dibenzophenanthrolines, [60] perylenes, [61,62] quino-
xaline derivatives, [63] indoloquinolines, [64] diarylureas, [65,66] isoalloxazines, [67] oxa-
zole-containing macrocycles, [68–71] a family to which telomestatin [41,42] belongs,
triazine derivatives, [72,73] acridones, [74,75] quinacridine derivatives, [76–78] triarylpy-
ridines [79] and 2,6-pyridine-dicarboxamide derivatives. [80] This shows, that during
the last two decades a great number of publications involving G-quadruplex in-
teracting molecules have emerged developing the field exponentially. [39–104]
Small molecules can interact with G-quadruplexes in potentially different
ways, especially given that they are highly polymorphic structures. Interactions
with the G-tetrad, an obvious site for ligands designed to target G-quadruplexes
generically, can be via hydrophobic or via stacking interactions. In fact, many G-
quadruplex ligands have been designed to contain a flat aromatic scaffold. Struc-
tural evidence for the interaction with the tetrads has been reported. [105] Other
binding sites for small molecules are the loops [24,25,106] and grooves, [99,107] which
are highly variable between different G-quadruplexes. This could potentially be
exploited to achieve differential recognition between different G-quadruplexes in
order to achieve specificity towards a single one of these structural elements. It is
noteworthy that G-quadruplex ligand interactions determined by different experi-
mental techniques can differ. This has been exemplified by studies on the binding
of the G-quadruplex interacting small molecule TMPyP4, a phenol quaternary
ammonium porphyrin which is depicted in Figure 1.6. Whereas solution NMR
studies carried out by Patel and co-workers showed how the molecule can in-
teract with the tetrad of a G-quadruplex target, [86] Neidle and co-workers later
proposed using X-ray crystallography, that the molecule preferentially interacts
with the loops of the nucleic acid target. [59] This molecule has been used in
many studies involving G-quadruplexes. [57,108,109] However, it has been observed
that TMPyP4 does not exhibit high selectivity for G-quadruplex DNA over ds-
DNA [57,109] in contrast to other G-quadruplex interacting small molecules such
as telomestatin. [110] Porphyrins such as TMPyP4 have inspired the synthesis
of related G-quadruplex interacting compounds, such as Se2SAP (depicted in
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Figure 1.6) which was shown to be selective for G-quadruplexes formed in the
promoter of the gene c-Myc. [58]
TMPyP4
N
HN
N
NH
N N
N N
N
Se
N N
H
Se
N
N N
N
Se2SAP
4Cl- 4I-
Figure 1.6: Molecular structures of TMPyP4 and Se2SAP.
It is important to note that many of the biological hypotheses in the field are
based on experimental data from proposed interactions of chemical agents with
these non-canonical DNA structures. There have been a few reports on the de-
velopment of therapeutic anti-cancer agents based on G-quadruplex ligands, such
as CX-3543 [30,111] which has now entered phase II clinical trials. Other syn-
thetic small molecules which have certainly been milestones in the G-quadruplex
field are BRACO-19 [44,46] and RHPS4. [80,105,112,113] However, the latter two
have not progressed beyond the experimental stage into clinical trials, despite
showing promising anti-tumor growth effects. [46,113,114] These three molecules are
illustrated in Figure 1.7.
CX-3543
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RHPS4BRACO-19
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Figure 1.7: Molecular structures of CX-3543, BRACO-19 and RHPS4.
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Despite the extensive list of reported G-quadruplex interacting small mole-
cules, it would be advantageous to develop new molecules which either exhibit
differential cytotoxicity between cancerous and non-cancerous cells as had been
demonstrated by 4,5-di-substituted acridone ligands, [75] or show a large concen-
tration dependence on their cytotoxic as compared to growth-inhibitory (cyto-
static) properties. Such compounds could target highly proliferative cells, a prop-
erty that could potentially be exploited in the treatment of cancer. There has been
some success in the development of small molecules that show some cancer cell
selectivity in short term growth assays, for example substituted diarylureas. [65]
The triazine derivative 12459 (Figure 1.8) has been shown to cause long-term
growth arrest of human A549 lung carcinoma cells that correlates with telomere
shortening and the induction of senescence. [72]
Small molecules are very powerful tools for studying biological processes.
There have been a few reports on the development of biochemical tools, such
as fluorescent G-quadruplex interacting molecules, [115] that may be used to study
these structures in cellulo. They may also be exploited to study phases of the
cell-cycle since there have been reports of cell-cycle alterations caused by G-
quadruplex interacting small molecules. [116,117] The 2,6-pyridine-dicarboxamide
360A has been shown to cause severe cell cycle alterations and also to induce
apoptosis in telomerase-positive glioma cell lines. [117] The structure of the mole-
cule is depicted in Figure 1.8.
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N N
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N
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N
N N
2Cl- 2Cl-
Figure 1.8: Molecular structures of 12459 and 360A.
However, there is still great scope for the development of chemical tools to
better study these nucleic acid structures, particularly in cellulo. It would for
instance be of great interest to develop a G-quadruplex specific small molecule
with an affinity tag, which could be used to mediate the isolation of its target from
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cells. The initial steps towards the development of such a probe are described in
this thesis.
1.3 Biological significance of G-quadruplexes
Despite the mounting evidence that G-quadruplexes can form in vitro, only re-
cently has evidence started to accumulate for their existence and function in
cellulo. [118] DNA as well as RNA G-quadruplexes have now been proposed to
play biological roles in cells. Although there is compelling evidence for in cellulo
G-quadruplex formation in ciliates such as Stylonichia lemnae using immunos-
taining of their telomeric intermolecular G-quadruplexes, [119] the evidence is less
direct for human cells as their low concentration of telomeres is believed to have so
far precluded visualisation using this technique. [118,120] In addition, human telom-
eres are heavily sheltered by protein complexes, are highly dynamic and are only
believed to form intramolecular quadruplexes. This section will give an overview
of the different areas where these structures may play an important biological
role, mainly focussing on human cells.
1.3.1 Protein interaction
Proteins have been shown to modulate the formation of G-quadruplexes in Oxytri-
cha. The organism’s telomere-binding protein functions as a molecular chaperone
to promote the formation of higher order complexes of telomeric DNA stabilised
by G-tetrads. This has now been observed in vitro [121,122] and in vivo. [120] There
have been reports of proteins interacting with G-quadruplex structures in hu-
man cells, supporting their existence in vivo. Helicases help maintain genome
stability and some helicases, such as BML, [123] WRN [124] and FANCJ [31] have
been shown to unwind DNA G-quadruplexes. Recently, it has also been reported
that these secondary nucleic acid structures interact with poly(ADP-ribose) poly-
merase. [125] RNA G-quadruplex protein interactions have also been described in
some pioneering work by Moine and co-workers on the fragile X mental retar-
dation protein, [126] which inspired subsequent research on RNA G-quadruplexes.
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The telomeric G-quadruplex has also been shown to be unwound by hnRNP pro-
teins. [127] The protein hnRNP A1 has for instance been demonstrated to unfold
G-quadruplex DNA in the human KRAS promoter. [128] Furthermore, it has been
shown that nucleolin interacts with rDNA, which can adopt G-quadruplex struc-
tures. [30] The same protein has also been demonstrated to bind to a G-quadruplex
in the promoter region of c-Myc. [129] These studies show some of the most com-
pelling evidence of the formation of G-quadruplexes in human cells.
1.3.2 Telomeres
The most widely studied DNA G-quadruplexes are those formed from the G-rich
strand of human telomeric DNA, which has the sequence (GGTTAG)n. Part of
this repeat sequence is single-stranded, the 3′-G-overhang. The human telomere is
protected by a protein complex called telosome [130] or shelterin [131] which protects
the DNA from degradation, non-homologous end-joining and the activation of the
DNA damage response (DDR) machinery that involves ATM and ATR kinases.
Furthermore, it allows the cell to distinguish the G-overhang from DNA strand
breaks. Shelterin is a six-protein complex comprising of three DNA-binding pro-
teins (TRF1, TRF2 and POT1), TIN2, which binds to TRF1 and TRF2, Rap1
which interacts with TRF2 and TPP1 which is in contact with TIN2 and POT1
(Figure 1.9). [131] This complex interacts with the double-stranded telomeric re-
peat and the single-stranded G-overhang. Telomerase is an enzyme active in
approximately 85% of human cancers and many immortalised cell-lines that can
extend the G-overhang and thus confer infinite proliferative capacity on cells.
POT1 interacts with TPP1 to recruit and thereby modulate the activity of telom-
erase. [132] It has been shown that the G-rich telomeric overhang can fold into G-
quadruplexes, rendering it resistant to the extension by telomerase. [28] Telomere
shortening, which occurs in the absence of telomerase or if the ALT mechanism
malfunctions in ALT-positive [133] tumour cells, appears to be a tumour suppres-
sor mechanism. [134] Telomeres in telomerase- and ALT-negative somatic cells are
gradually shortened as the cells progress through the cell-cycle, and once telom-
eric DNA reaches a critically short length, cells can enter p53 and Rb-dependent
replicative cellular senescence and apoptosis. The exact mechanism of cell-cycle
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arrest and/or resulting cell death differs between different cells depending on
the expression status of tumour suppressor proteins like p53 and Rb. Human
cells employ signaling pathways that can down-regulate the cell cycle if DNA-
damage occurs, which can give sufficient time for repair prior to cell division, [135]
a mechanism crucial to pertain the stability of the genome. The stabilisation of
telomeric G-quadruplexes has been proposed to disrupt telomere function and in-
hibit telomerase. [136] It has been shown that small molecules interacting with this
structural element can disrupt shelterin by uncapping POT1 in human HT1080
cells. [42,48] The G-quadruplex interacting small molecules BRACO-19, RHPS4
and telomestatin induce rapid replicative senescence in human cancer cells and
activate a DDR analogous to that following DNA double-strand breaks. The pro-
teins p53, ATM and p16INK4a have been characterised to be involved in particular
in these responses. [46,113,137,138] The telosome and the effect of G-quadruplex for-
mation in the G-overhang are depicted in Figure 1.9.
Figure 1.9: Top: Schematic view of shelterin and the G-overhang which gets extended
by telomerase in many cancer cells. Bottom: G-quadruplex formation uncaps POT1
and prevents extension of the G-overhang by telomerase.
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G-quadruplex ligands may not only target telomerase-positive tumourigenic
cells and inhibit their proliferation, but can also uncap telomeres in ALT cells. [139]
Interestingly, another hypothesis has been proposed as to how a G-quadruplex in-
teracting small molecule may interfere with telomere integrity. The G-quadruplex
interacting small molecule 12459 has been found to stabilise RNA G-quadruplexes
in the mRNA of hTERT, the catalytic subunit of human telomerase. [140] The mo-
lecule has been hypothesised to interfere with the splicing machinery. This mo-
lecule also causes telomere shortening and replicative senescence. [72] An RNA G-
quadruplex has also been identified in the mRNA of TRF2. [141] A small molecule
that interacts with this structure may also interfere significantly with telomere
integrity (see section 1.3.5).
It is noteworthy that an alternative model for shelterin exists where the G-
overhang has been proposed to invade double-stranded telomeric DNA to displace
base pairing with the complementary strand in order to form a t-loop [142,143] as
depicted in Figure 1.10.
Figure 1.10: T-loop formation at human chromosome ends.
Extensive research is being carried out on the identification and further de-
velopment of small molecules that interact with telomeric regions in human cells,
and which may therefore have an anti-proliferative activity in human cancer
cells. [41,46,48,73,144,145]
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1.3.3 Replication stalling
G-quadruplexes have been proposed to stall replication forks due to their forma-
tion in single-stranded DNA that exists during replication. This is supported by
the existence of helicases that unwind G-quadruplex DNA. [31,123,124] This theory
was first proposed for BML in 1998 by Sun et al. [123] It is possible that when
the DNA strands are single-stranded G-quadruplexes form during replication de-
laying fork progression. The helicases would then help defend genome stability,
which would explain the existence of G-quadruplex specific helicases. It has been
shown that stabilisation of telomeric quadruplexes perturbs replication of telom-
eres which can cause activation of ATM and ATR kinases leading to a DNA
damage response. [112] Small molecules interacting with G-quadruplexes could in-
terfere with the replication process and cause replication fork stalling at G-rich
stretches. A scheme of how replication stalling could be caused by G-quadruplex
formation is depicted in Figure 1.11.
Figure 1.11: G-quadruplex formation stalls the replication fork. Left: Replication
progressing normally. Right: Replication fork stalling due to the formation of G-
quadruplexes. A G-quadruplex stabilising molecule would drive the equilibrium to the
right.
1.3.4 Transcriptional control
Computational studies have predicted that more than 40% of all promoters of
human genes contain a putative G-quadruplex forming sequence (PQS). [29] In
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particular, oncogenic promoters are enriched in PQSs by almost 70% using the
bioinformatic algorithm described in section 1.1. This prediction has to be taken
with precaution, as these numbers have not been confirmed experimentally. How-
ever, the hypothesis that these nucleic acid structural elements could have an
effect on promoter regulation and hence transcriptional activity has stimulated
the research on several PQSs in several genes, such as c-Myc, [15,58,84,86,92,146] c-
kit, [147–149] VEGF, [87] bcl-2, [150,151], KRAS [152,153] and PDGFR-β. [154] A schematic
view of gene transcription altered by G-quadruplex formation in the promoter
is depicted in Figure 1.12. Pioneering studies by Howell et al. [155] showed that
G-quadruplexes can form in the nuclease hypersensitive region of the chicken
β-globin gene promoter. A poly(dG)-binding protein called BGP1 has been iden-
tified to specifically bind to the G-tract of the β-globin gene promoter to activate
gene expression. [156] It has been proposed that this G-quadruplex forming region
could act as a conformational switch subject to modulation by BGP1. There
have been reports that G-quadruplex interacting small molecules can alter gene
expression, for instance that of the human genes c-Myc, [84,92,157] c-kit, [67,104,158]
KRAS [152] and bcl-2. [159] This has been linked to the interaction with the respec-
tive promoter G-quadruplexes.
Figure 1.12: Top: Schematic view of an eukaryotic gene with a promoter and tran-
scription initiation complex (TIC). Bottom: G-quadruplex formation in the promoter
alters transcription possibly through alteration of TIC binding.
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However, most of the studies performed only look at the effect of the transcrip-
tion of a single gene and/or the change in expression of the protein it encodes.
A down-regulation of the c-Myc gene for example, which encodes for a tran-
scription factor, is inherently linked to the expression of other genes. Hence, if
the transcriptional network is influenced as a whole, a change in the transcrip-
tion and expression of c-Myc is highly likely. This makes it difficult to attribute
transcriptional alterations to the formation of G-quadruplexes. There have been
studies using plasmid constructs with the promoters under investigation, [84] but
that system is somewhat removed from chromatinised DNA. For the c-kit pro-
moter sequence, it has been postulated that double-stranded DNA is practically
the only species present at pH 7.0, and G-quadruplex formation is only observed
at a lower pH that facilitates i-motif formation in the complementary strand in
vitro. [160] The i-motif is a secondary nucleic acid structure that can be formed
by a cytosine-rich strand such as the complementary strand of a G-quadruplex
forming sequence. These structures are normally not very stable under physio-
logical conditions. However, it has been demonstrated that G-quadruplexes and
the i-motif can form in the c-Myc promoter facilitated by DNA superhelicity. [161]
Also, it has now been demonstrated that the complementary strand can form
intermediate partially folded structures at physiological pH which are i-motif-like
in structure. [162]
Transcriptional control in human cells is highly complex. For example, the G-
quadruplex forming sequence in the promoter of c-Myc is situated in the nuclease
hypersensitive element NHE III1. Proteins, such as CNBP
[163] (cellular nucleic
acid binding protein), Sp1 transcription factor and hnRNP K [164] (heterogeneous
nuclear ribonucleoprotein K) have been shown to interact with the DNA of NHE
III1. Michelotti et al.
[165] proposed that this NHE III1 adopts at least three
different states as depicted in Figure 1.13.
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Figure 1.13: Top: Sp1 binding to the NHE III1 in the promoter of c-Myc activates
gene transcription. Middle: G-quadruplex formation inhibits gene transcription. Bot-
tom: CNPB and hnRNP K binding activate gene transcription.
This model illustrates the biological complexity that researchers have to face
when trying to understand the involvement of transient DNA structures in gene
regulation. Targeting promoter G-quadruplexes is a very active field of research
and very promising for the purpose of chemical intervention. However, compelling
in cellulo evidence of this hypothesis is still missing and it remains a controversy
whether transcriptional control influenced by G-quadruplexes occurs in vivo.
1.3.5 Translational control
Non-coding cis-acting secondary nucleic acid structures in the 5′-UTR, such as
hairpins, control mRNA-specific translation. [166] The 3′-UTR of mRNAs is re-
sponsible for protein and miRNA binding which influences the stability and
transport of the mRNA and can have a role in translation termination. [167] G-
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quadruplexes have been proposed to exist as higher order structures in RNA at
the 3′ [32]-and 5′ [126]-UTR regions of mRNA. This stimulated research into bioin-
formatic predictions [35] of UTR-sequences with a PQS and also work on trans-
lational regulation due to G-quadruplexes in mRNA specifically at the 5′-end,
as it poses a direct influence on translational control. [34,36,168] It has been shown
that a G-quadruplex within the 5′-UTR of certain genes causes a reduction in
the translational activity from the corresponding mRNA. [34,169,170] This might be
due to interference with the assembly of the translation initiation complex or
hindrance of the complex migrating along the 5′-UTR before translation starts.
G-quadruplexes could also act as binding sites for proteins that interfere with the
initiation of translation. The effect of G-quadruplex formation in the 5′-UTR of
mRNA is depicted in Figure 1.14.
It has now also been demonstrated that small molecules interacting with RNA
G-quadruplexes in the 5′-UTR can down-regulate translational activity by sta-
bilising this secondary structure, which may add additional steric bulk that can
no longer be resolved. [36,141] This may present another way for therapeutic inter-
vention using G-quadruplex interacting small molecules.
Figure 1.14: Top: Schematic view of an mRNA. Bottom: G-quadruplex formation
in the mRNA alters translational activity.
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There has been intensive research on G-quadruplexes during recent decades and a
plethora of small molecules has been developed to target these structures. How-
ever, there is still limited evidence of their formation in cells and a lot of the
molecules reported in the literature have not been or cannot be developed into
drugs for chemical intervention as they are not inherently drug-like. Now there
is a need for more evidence for the formation of these structures in cellulo and
also to develop molecules which could potentially be used to improve the hu-
man condition, one of the ultimate goals of scientific research. The development
of drug-like G-quadruplex interacting small molecules and chemical probes that
could help elucidate the underlying biology is the current focus in this scientific
field.
The next chapter will describe the synthesis and evaluation of a new family
of G-quadruplex interacting small molecules. They have been designed to be
able to adopt different conformations influenced by a methyl substitution on the
molecular scaffold. The different conformations result in differential recognition of
various G-quadruplexes but retain the ability of the molecules to selectively recog-
nise G-quadruplex over double-stranded DNA. Chapter 3 chronicles the synthesis
and some biological evaluation of a class of G-quadruplex binding small molecules
based on a N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaffold. Chapter 4
outlines the development of a novel chemical probe based on the same scaffold
that can mediate the isolation of these nucleic acid structures directly from hu-
man cells. The last chapter details all the experimental procedures corresponding
to chapters 2, 3 and 4.
18
Chapter 2
Controlled-folding of a small
molecule modulates
G-quadruplex recognition
2.1 Background
As outlined in the previous chapter, intensive research has been conducted on the
development and synthesis of G-quadruplex interacting small molecules. [39–104] A
great number of these synthetic molecules comprise a flat aromatic scaffold. Such
a design is aimed at facilitating stacking or hydrophobic interactions with the top
or bottom tetrad of their target and thus a flat aromatic molecule can potentially
interact with a variety of different G-quadruplexes. However, there are reports
of ligands that are in contact with the loops of G-quadruplexes. [59,106] Some of
these compounds show excellent selectivity for G-quadruplex DNA over ds-DNA.
Many of the scaffolds have attached side chains to enable interactions with the
loops of the nucleic-acid targets. However, for a molecule to discriminate be-
tween different G-quadruplex targets, the focus on its design should lie in the
differences between the desired targets, which are mainly the loops and grooves
of G-tetraplexes. Because of the predicted abundance of these non-canonical
structures in the genome, [37,38] such discrimination is highly sought after. There
are some reports of exploiting loop [106] and groove-recognition [99,107,171] specifi-
cally for small molecule G-quadruplex interactions. Neidle and co-workers [106]
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showed by X-ray crystallography that disubstituted acridine ligands can interact
preferentially with a bimolecular DNA G-quadruplex as these ligands have amino
end groups of varying sizes. The diagonal loop in the quadruplex studied results
in a large cavity which can accommodate these groups. Thus, loop nature has a
significant influence on ligand selectivity for particular quadruplex folds. Deriva-
tives of Distamycin A, a classical ds-DNA binder, have been shown by Moore et
al. to selectively interact with the grooves of DNA G-quadruplexes. [171] However,
these ligands did not show great selectivity for G-quadruplex DNA over ds-DNA.
The specificity of G-quadruplex interacting small molecules has been enhanced by
varying the nature, [71] position [95] and stereochemistry [68] of attached side chains.
There has been some success in the development of molecules that can recognise
one particular G-quadruplex topology. [50,64,97,172] For example, Rodriguez et al.
showed that a small molecule based on a polyamine can induce the formation of
the antiparallel conformation of the telomeric G-quadruplex from a mixed pop-
ulation. [50] However, the challenge for compounds to effectively recognise only
one particular G-quadruplex from a single sequence still remains. This might
be attributed to the fact that the core of many of those molecules is rigid and
inflexible, which facilitates interactions with the G-tetrads of all G-quadruplexes.
This calls for the exploration of different approaches. An alternative strategy to
achieve this goal is presented in this chapter.
2.2 Objectives
The aim of this work was to create a new family of G-quadruplex ligands for
which the conformation could be controlled by a simple substitution on a cen-
tral molecular scaffold. The scaffold was designed to allow a certain degree of
conformational freedom which differs to the rigid nature of many other reported
G-quadruplex ligands. [93] Although very similar in structure, the molecules were
designed in a way that their conformation would differ depending on a methyl
substitution on the scaffold. This could influence their potential to stabilise G-
quadruplex DNA. The final aim was to investigate if such an approach could
be employed to achieve discrimination in stabilisation of the molecules between
different G-quadruplex DNA targets.
20
2.3 Design of the new molecules
2.3 Design of the new molecules
As an alternative strategy to achieve discrimination in molecular recognition be-
tween different G-quadruplex targets, a 1,3-[di-quinolin-2-yl-diureido] benzene
scaffold was devised. It allows flexibility as opposed to the rigid structure of
many other reported G-quadruplex interacting molecules, [93] including macro-
cycles such as telomestatin. [41] A new class of molecules was designed which
incorporated some of the structural features of some known G-quadruplex bind-
ing ligands, [93] such as an aromatic scaffold and positively charged appendages.
There is a selection of quinoline-based G-quadruplex ligands that can be found in
the literature, [36,110,117,144,173,174] suggesting that quinolines may be a good struc-
tural feature of a variety of ligands. Two urea functionalities which link two
quinolines to a central benzene core were included, and these urea bonds confer a
degree of conformational freedom to these molecules. [175–177] Methyl substituted
benzene was used to direct the conformation as a consequence of a possible steric
clash with the oxygens of the urea bonds [178] (Figure 2.1).
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Figure 2.1: Left: Molecular structure of the 1,3-[di-quinolin-2-yl-diureido] benzene
scaffold with substitutions at the 4-position of the quinoline moieties. The rotatable
bonds are indicated in green and with green arrows. The quinolines are highlighted in
blue. The hydrogen bonds that help keep the urea bonds in a plane with the quinoline
moieties are highlighted with a dashed line in magenta. Right: Steric clash that would
arise if the methyl substituent and the oxygens or hydrogens of the urea bonds were in
close proximity.
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An internal hydrogen bonding network keeps the urea bonds in a plane with the
quinoline moieties. It restricts conformational freedom mainly to the bonds as
indicated on the scaffold of the new ligand series in Figure 2.1. A methyl group
at position R2 would cause a potential steric clash with the oxygen and force the
urea bond on that side of the benzene ring and the quinoline out of the plane.
Alternatively, a methyl group at position R3 would cause steric clash with the
internal hydrogen bond network, also forcing the quinolines out of the plane. The
figure shows the molecular framework and highlights the steric clash that would
arise between the oxygen and a methyl at R2 and R3 if in close proximity. The
quinolines which constitute part of the molecular scaffold are highlighted in blue.
The internal hydrogen bonds restrict rotational freedom of the bond between the
2-position of the quinoline and the nitrogen of the urea bond as indicated in
Figure 2.1 in magenta.
Two analogous series of molecules were synthesised: one with primary amine
side chains (1a-3a) and the other with pyrrolidine appendages (1b-3b) as de-
picted in Figure 2.2. This would allow to also investigate whether the nature
of the side chain could influence the nucleic acid recognition properties of the
different conformations of the ligands.
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Figure 2.2: Molecular structure of molecules 1a-3b. Series a carries a primary amine
and series b a pyrrolidine as the terminal group on the chain.
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Molecules 1a-3b were synthesised using a short and high yielding synthetic pro-
cedure as depicted in Scheme 2.1. Compounds 1a-3a were synthesised in three
and compounds 1b-3b in two steps. Firstly, 2-aminoquinolin-4(1H )-one (4) was
reacted with N -Boc ethanolamine or N -(2-hydroxyethyl)-pyrrolidine under Mit-
sunobu reaction conditions to obtain the quinoline building-blocks 5a and 5b
in 53-65% yield. [176] The products were subsequently reacted with commercially
available 1,3-phenylene diisocyanate (6a), 2,4-toluene diisocyanate (6b) or 2,6-
toluene diisocyanate (6c) to synthesise the desired bis-ureas in 86-92% yield.
This step required heating at 50 ◦C overnight. The Boc-protecting groups on
the precursors of molecules 1a-3a were removed in the presence of TFA in DCM.
Molecules 1a-3b were finally purified by HPLC to yield the TFA salts of the
products.
N NH2
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N NH2
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OCN NCO
R3
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(ii)
O N
4
5a: R1= O(CH2)2NHBoc
5b: R1=
1a-3b
6a: R2=R3=H
6b: R2=Me, R3=H
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Scheme 2.1: Synthetic scheme of the synthesis of molecules 1a-3b. (i) N -Boc
ethanolamine or N -(2-hydroxyethyl)-pyrrolidine, PPh3, DIAD, THF, 0 ◦C then rt.,
3 d; (ii) DCM, 50 ◦C, overnight; then for 1a, 2a and 3a TFA/DCM, rt, 1 h.
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2.5.1 Molecular modelling
The conformation adopted by a flexible G-quadruplex ligand may have profound
implications on its target recognition properties. In order to gain an insight
into the folding of the molecules in aqueous solution, molecular modelling of
compounds 1a, 2a and 3a was performed using HyperChem R© with the PM3
semi-empirical method [179,180] including water as solvent. The rotational barriers
for atoms 1-2, 4-5, 7-8 and 10-11, as illustrated for molecule 1a in Figure 2.3, were
calculated. This work was carried out in collaboration with Dr. G. D. Pantos¸.
Figure 2.3: Model of molecule 1a with atom labels. Rotational barriers were calcu-
lated for the bonds indicated with an arrow.
Using this method, it was predicted that molecule 1a has the conformation in
aqueous solution as depicted in Figure 2.4. It is a coiled conformation with one
of the quinolines pointing out of the plane below the benzene ring and the other
above. Displayed are both, the top and the side view. Molecule 2a shows a twisted
conformation, with one of the quinolines pointing upwards; a conformation that
is supported by nOe cross-peaks between the hydrogens of the methyl substituent
on the benzene ring and one of the hydrogens of one of the quinolines (presented
in Figure 2.5). The displayed top and side views show how this conformation is
different to that of molecule 1a.
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Figure 2.4: Coiled conformation adopted by 1a in water. Both the side and top view
are shown.
Figure 2.5: Twisted conformation adopted by 2a in water. The nOe cross-peaks are
indicated by arrows. Both the side and top view are illustrated.
The predicted conformation for compound 3a in water is W-shaped as displayed
in Figure 2.6 and also differs from those anticipated for 1a and 2a.
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Figure 2.6: W-shaped conformation of 3a in water. The nOe cross-peaks are indicated
by arrows. Both the side and top view are shown.
This was supported experimentally by nOe cross-peaks between the methyl sub-
stituent on the benzene ring with hydrogens on both quinolines (see section 2.5.2).
The structural data supports the hypothesis that the conformation can be con-
trolled by the methyl substitution on the benzene ring. This predicts that the
three molecules adopt different conformations in aqueous solution which could
make differential interaction with a nucleic acid target likely.
2.5.2 2D NMR studies
In order to gain experimental support for the proposed folding, I performed 2D
NMR experiments in D2O on molecules 2a and 3a. The protons were assigned
after performing 1H COSY, 1H NOESY, 1H-13C HMBC and 1H-13C HMQC NMR
experiments. The COSY and NOESY spectra of 2a are depicted in Figure 2.7
and of 3a in Figure 2.8. The NOESY spectrum displayed in Figure 2.7 shows
that hydrogens 4 and 6a interact via nOe, placing them in close proximity. This
supports the proposed model we obtained by molecular modelling as illustrated
in Figure 2.5.
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Figure 2.7: Top: Molecular structure of 2a with labelled hydrogens. The nOe
between hydrogens 4 and 6a is indicated with a red arrow. Bottom left: COSY of 2a
in D2O. Bottom right: NOESY of 2a in D2O.
The NOESY spectrum displayed in Figure 2.8 shows that hydrogens 3 and
5 interact via nOe, which suggests that the quinolines are either both pointed
downwards, or one pointed upwards and the other downwards. This supports
the conformation we obtained by molecular modelling as shown in Figure 2.6, in
which both the quinoline moieties are pointed upwards.
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Figure 2.8: Top: Molecular structure of 3a with labelled hydrogens. The nOe
between hydrogens 3 and 5 is indicated with a red arrow. Bottom left: COSY of 3a
in D2O. Bottom right: NOESY of 3a in D2O.
It was found that molecules 1b, 2b and 3b gave the same results in terms of
folding with molecular modelling and NMR experiments as detailed for 2a and 3a
above. This suggests, that changing the nature of the side chain from a primary
amine to a pyrrolidine does not change the folding of the molecules.
2.6 DNA G-quadruplex recognition
It was next explored how distinct folding of these molecules could influence their
ability to interact with DNA. This would evaluate the ability of the compounds to
stabilise DNA G-quadruplexes and test the hypothesis that controlled-folding can
be used to modulate inter-quadruplex specificity of small molecules. Ligand-DNA
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interactions were assessed using FRET (Fo¨rster Resonance Energy Transfer)-
melting experiments. [181]
2.6.1 FRET-melting to assess G-quadruplex stabilisation
by small molecules
Energy can be transferred between two fluorophores placed in close proximity.
FRET is a non-radiative energy transfer from a donor fluorophore to an acceptor
fluorophore and is distance dependent with a typical range of 15 to 60 A˚. FRET
efficiency can be calculated using equation 2.1:
E =
R0
6
R06 + r6
(2.1)
E = FRET efficiency, R0 = Fo¨rster distance in A˚, where energy transfer
between fluorophores is 50%, r = distance between the fluorophores in A˚.
This phenomenon was exploited by J.-L. Mergny and J.-C. Maurizot [181] to
develop an assay that allows assessing G-quadruplex stabilisation potentials of
small molecules. An oligonucleotide, which has a donor chromophore on one end
and an acceptor chromophore on the other, is used in this assay. These are in
close proximity when the strand is in a folded conformation, e.g. a G-quadruplex
as depicted in Figure 2.9. Excitation of the donor fluorophore will result in
non-radiative energy transfer from the donor to the acceptor fluorophore if the
oligonucleotide is folded. If the strand is unfolded, the fluorophores are too far
apart for efficient FRET to occur. Exploiting the fact that elevated temperatures
drive the equilibrium towards the unfolded form, heat is supplied to the system.
By following the fluorescence emission of the fluorophores upon excitation and
heating, information about the folding of the oligonucleotide can be inferred. A
graph of temperature against relative fluorescence is then plotted. The temper-
ature at the inflection point of the sigmoidal graph is the temperature at which
half the population of the oligonucleotide is folded into its secondary structure.
It is also termed melting temperature or Tm. This technique can also be applied
for other structures, such as DNA hairpins. By measuring the Tm upon increas-
ing amounts of small molecule, the change in melting temperature (∆Tm) can
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be obtained at a given ligand concentration. However, attaching fluorophores on
the oligonucleotides may significantly affect the kinetics of folding and unfolding.
Also, any compound can potentially interact with with the fluorophores and thus
influence their excitation and emission properties. The technique is depicted in
Figure 2.9.
Figure 2.9: Drawing of a FRET system with an oligonucleotide that can fold into
a G-quadruplex structure. FRET efficiency decreases heavily when the G-quadruplex
(on the left) is unfolded (right).
The stability of a secondary nucleic acid structure is dependent on the se-
quence and length of the oligonucleotide and thus, different oligonucleotides ex-
hibit different melting temperatures (Tm). Therefore, different amounts of energy
are needed to induce the same shift in melting temperature. Hence, it is diffi-
cult to directly compare ∆Tm values induced by a small molecule on different
G-quadruplex targets, although comparisons have been made in the literature
before. [65] It has to be noted that experimental conditions are limited to a max-
imum temperature of 95 ◦C. Hence, the biggest measurable change in melting
temperature (∆Tm(max)) is calculated as shown by equation 2.2:
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∆Tm(max) = 95
◦C− Tm(0) (2.2)
∆Tm(max) = maximal shift in melting temperature, Tm(0) = melting
temperature of the oligonucleotide in absence of small molecule.
2.6.2 FRET-melting studies on molecules 1a-3b
Using FRET melting, the aptitude of compounds 1a-6b to stabilise an array
of biologically relevant G-quadruplex forming DNA sequences was determined,
namely: the human telomeric G-quadruplex (H-telo), sequences from the pro-
moter regions of c-kit [147–149] (including the two G-quadruplex forming sequences
C-kit1 and C-kit2), c-Myc [15,58,84,86,92,146] and k-ras [152,153] (the sequences can be
found in Chapter 5). The thermal shift profiles, in which changes in melting
temperature (∆Tm) are plotted as a function against ligand concentration, are
depicted for molecules 1a-3b in Figure 2.10.
Figure 2.10: Thermal shift profiles for molecules 1a, 2a and 3a obtained by FRET-
melting: • (H-telo), • (C-kit1), • (C-kit2), • (C-myc), • (K-ras) and • (ds-DNA).
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Tables showing ∆Tm at 1 µM ligand as conventionally quoted in the litera-
ture [68,79,93,96,181] (Table 2.1) and [ligand] in µM at half maximal ∆Tm (Table 2.2)
are displayed for compounds 1a-3b to help compare the thermal shift profiles. It
was found that the melting shift profiles of all the G-quadruplexes studies var-
ied greatly between molecules 1a, 2a and 3a as illustrated in Figure 2.10. This
implies that the folding of these ligands could influence their molecular mode of
interaction. It is possible that the methyl group interacts with the target DNA in-
fluencing the FRET-melting results. It is a relatively small and unfunctionalised
chemical group and unlikely to be the main contributor to the vast differences in
stabilisation seen between the molecules. The melting shift profiles for molecules
1b, 2b and 3b also vary (Figure 2.10), but the differences are not as pronounced
as for the molecules carrying a primary amine. No detectable stabilisation of
ds-DNA with any of the ligands was detected at the concentrations used, which
is consistent with a high level of discrimination between quadruplex and ds-DNA.
∆Tm (K)
Target1 1a 2a 3a 1b 2b 3b
H-telo 27.3±0.32 2.8±0.3 3.9±0.4 16.7±0.5 20.0±0.5 25.9±0.5
C-kit1 34.0±0.4 6.6±0.7 0.0±0.3 19.8±0.4 20.1±0.3 0.7±0.3
C-kit2 16.2±0.9 4.2±0.2 1.0±0.8 9.3±0.6 6.1±0.2 14.9±0.7
C-myc 17.7±0.4 6.2±0.4 14.1±0.3 7.5±0.5 7.1±0.4 13.8±0.5
K-ras 16.7±0.5 4.0±0.4 2.7±0.3 16.0±0.6 9.4±0.4 20.8±0.3
ds-DNA 0.0±0.2 0.0±0.1 0.0±0.4 0.0±0.2 0.5±0.5 0.4±0.3
Table 2.1: ∆Tm at 1 µM ligand in K.
Molecule 1a caused a very high ∆Tm value for each of the G-quadruplexes
studied (corresponding to ∆Tm(max)). Although these are very high stabilisation
potentials, there is very little discrimination between different G-quadruplexes.
The stabilisation temperature of the human telomeric G-quadruplex with a ∆Tm
of 27.3±0.3 K is in the range of the most potent ligands reported in the litera-
ture, [110,144] for example a quinoline macrocycle that showed 33.8 K at 1 µM. [110]
1The Tm of the quadruplexes in 60 mM K+ in the absence of ligand (Tm(0)) are: 59.4
◦C (H-telo), 54.5 ◦C (C-kit1), 72.7 ◦C (C-kit2), 79.3 ◦C (C-myc), 45.9 ◦C (K-ras), 62.7 ◦C
(ds-DNA); measurements could be taken up to 95.0 ◦C under the experimental conditions.
2Errors were calculated as SD of three independent experiments.
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Compound 1a exhibits the highest ∆Tm that can be measured with this
method for all the G-quadruplexes tested which is visualised by the plateauing of
the curves in Figure 2.10. The concentrations needed to achieve this saturation
were 2.8 µM for H-telo, 2.0 µM for C-kit1, 2.5 µM for C-kit2, 0.8 µM for C-myc
and 5.0 µM for K-ras. Ligand 2a did not exhibit strong stabilisation potentials
at lower concentrations for any of the G-quadruplex targets investigated, but
good stabilisation at higher concentrations. Much higher ligand concentrations
were required to reach saturation of the curves as compared to molecule 1a, in-
dicating that this ligand is less potent as a G-quadruplex stabilising molecule. In
contrast, 3a showed selective stabilisation for one of the G-quadruplexes inves-
tigated. ∆Tm(max) for the C-myc quadruplex was measured at 0.4 µM whereas
much higher concentrations of ligand were needed to stabilise the other targets
significantly. Table 2.2 displays the concentrations needed to induce half the
maximal ∆Tm.
cpd. (µM)
Target 1a 2a 3a 1b 2b 3b
H-telo 0.5 5.6 1.9 1.0 0.9 0.5
C-kit1 0.6 3.7 >10.0 1.1 0.9 >10.0
C-kit2 0.4 3.4 4.8 1.2 1.9 0.5
C-myc 0.2 2.3 0.2 1.0 1.0 0.3
K-ras 1.5 4.0 3.7 2.0 3.6 1.5
ds-DNA >10.0 >10.0 >10.0 >10.0 >10.0 >10.0
Table 2.2: [Compound] in µM at half maximal ∆Tm.
Striking is the comparison of molecules 2a and 3a. Whereas 0.2 µM of com-
pound 1a were required to induce half the maximal stabilisation for C-myc (see
Table 2.2), the other targets required much higher concentrations. Similar concen-
trations were needed as compared to ligand 3a to achieve maximal stabilisation
for C-kit2 and K-ras, but higher concentrations for H-telo, as half the maximum
stabilisation was reached at 5.6 µM as compared to 1.9 µM. Ligand 3a did not
stabilise the C-kit1 G-quadruplex at any of the concentrations measured. To the
best of my knowledge, this was the first example of a molecule that caused a large
∆Tm for one or more G-quadruplexes, yet no detectable stabilisation for another.
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These results demonstrate, that it is possible to achieve differential recognition
and even quadruplex specificity by controlling the folding of a particular molec-
ular scaffold.
The G-quadruplex stabilisation potential was altered when the side chains
were changed from primary amines to pyrrolidines. This substitution reduced
the stabilisation properties of molecules of type 1 but enhanced those of type 2
and 3. Compound 3b did not stabilise the C-kit quadruplex like its analogue 3a,
which could be a general recognition property of molecules of this scaffold with a
W-shaped conformation. However, this compound showed better stabilisation for
all the other G-quadruplexes studied by FRET-melting than 3a (see Table 2.1).
These results demonstrate that it is possible to combine controlled-folding with
side chain variation to fine-tune the molecular recognition properties of a partic-
ular scaffold. It is possible that the conformation of the ligands changes from our
predicted structures when interacting with the nucleic acids, as the molecules are
inherently flexible.
2.7 Conclusions and future work
It has been demonstrated that a simple methyl substitution of molecules with a
1,3-[di-quinolin-2-yl-diureido] benzene scaffold can influence their folded confor-
mation. This hypothesis was supported by molecular modelling and confirmed by
NMR spectroscopy experiments. The new compounds stabilise G-quadruplexes
selectively over ds-DNA which was assessed by FRET-melting experiments. Some
of the compounds compare favourably to the most potent ligands reported in the
literature as assessed by this method. Controlling the ligand conformation has
an effect on the molecular recognition properties of a compound towards nucleic
acid targets. This can be fine-tuned by varying the side chains of the molecules.
This approach was successfully implemented to obtain a G-quadruplex ligand
that preferentially stabilises one particular G-quadruplex out of the nucleic acid
targets studied. These studies did not reveal how the ligands interact with the
G-quadruplexes, but I postulate that they most likely interact with the loops of
the target. That could be investigated with additional NMR spectroscopic stud-
ies, which would help understand how the compounds can be derivatised further
to achieve differential recognition of G-quadruplex targets.
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To further explore how the conformation of molecules with a 1,3-[di-quinolin-2-
yl-diureido] benzene scaffold could be influenced by substitutions on the benzene
ring, potentially leading to differential G-quadruplex recognition, the molecules
depicted in Figure 2.11 could be synthesised. These two molecules have have two
and three methyl substitutions, respectively. This would constrict the conforma-
tions of the ligands further to that of the mono-substituted compounds 2a, 2b,
3a or 3b.
N N NH
O
HN
O
N N
RR
H H
N N NH
O
HN
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N N
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H H
Figure 2.11: Possible molecules with two or three methyl substitutions on the central
benzene ring.
Furthermore, the methyl groups could be changed to bulkier groups (such as
ethyl) to exaggerate the potential steric clash influencing the conformation adopted
by the molecules. Ligand 3a, which stabilised the C-myc G-quadruplex prefer-
entially as assessed by FRET-melting, might also influence c-Myc expression by
stabilising the promoter G-quadruplex of the gene. The data presented in this
chapter might also be useful to design new ligands to achieve better inter-G-
quadruplex discrimination.
However, during the course of these studies another family of small molecules
based on quinolines was developed in our lab and was found to have striking
biological implications in human cells. Research was therefore directed towards
these compounds and will be the theme of the remaining chapters of this thesis.
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Chapter 3
N,N ′-Bis(quinolinyl)pyridine-2,6
dicarboxamides: G-quadruplex
interacting small molecules and
their cellular effects
3.1 Background
Our group previously reported on a small molecule, named pyridostatin, [144]
based on a N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaffold as depicted
in Figure 3.1. The ligand was designed by Dr. Raphae¨l Rodriguez based on
structural features of other potent G-quadruplex binding molecules, with partic-
ular emphasis on: 1) the ability to adopt a mainly flat conformation facilitated
by an internal hydrogen bonding network, [182] 2) an electron-rich aromatic sur-
face with alkoxy-substituents carrying positively charged aliphatic amines and 3)
the presence of nitrogen lone pairs able to hydrogen-bond a molecule of water
in the middle, which helps the scaffold adopt a flat conformation. [183] The inter-
nal hydrogen bonds give the molecule a flat character with some flexibility [182]
that can facilitate binding. As discussed in section 1.1 (Chapter 1), the tetrad is
not exactly planar. A flat molecule which is not completely rigid has therefore
better chances to interact with the aromatic surface of the G-tetrad. Quinolines
were incorporated into the molecular scaffold, which is similar to that presented
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in Chapter 2, but does not allow as much conformational freedom as molecules
of the 1,3-[di-quinolin-2-yl-diureido] benzene family. The scaffold was designed
to be able to generally interact with G-quadruplex structures and not primar-
ily to achieve inter-quadruplex selectivity. The molecule was shown to stabilise
the telomeric G-quadruplex with a ∆Tm of 35.0 K in 60 mM K
+ as assessed by
FRET-melting. The molecule also exhibited negligible stabilisation of ds-DNA
and its G-quadruplex stabilisation potential was hardly altered by the presence
of 25 mole equivalents of competitor ds-DNA. These data represent the highest
induced shift in Tm for the telomeric G-quadruplex by a small molecule to date
assessed by this method, with a very high level of selectivity over ds-DNA. Py-
ridostatin is structurally related to 360A [173] (depicted in Figure 1.8) but the
latter may not adopt the same conformation in solution as it cannot form the
same internal hydrogen-bond network and is electron-poor.
NO
N
O
N
N N
O O
O
H2N
H2N NH2
O HH
H H
Pyridostatin
Figure 3.1: Molecular structure of pyridostatin. Water (in red) can hydrogen-bond
in the centre as depicted.
It has been demonstrated that telomestatin uncaps POT1 from telomeres
leading to loss of telomeric DNA and senescence in human HT-1080 tumour
cells. [42] HT-1080GFP-POT1 transfected cells were used in the study presented
here, to assess the effect of pyridostatin on POT1 uncapping. This work was
carried out by Dr. Raphae¨l Rodriguez and Dr. Jean-Franc¸ois Riou. It was found
that after 72 h incubation of the cells with 1 µM pyridostatin, a concentration
where most of the cells were still viable, the fluorescent green signal associated
with telomeres decreased dramatically. [144] It was postulated that the folding of
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the G-overhang into quadruplexes induced by the small molecule led to POT1
uncapping from telomeres in cells as depicted in Figure 3.2.1 Unprotected telom-
eres have been associated with nuclear foci of γH2AX, a phosphorylated histone
that is an early DNA-damage marker. It was demonstrated that pyridostatin
induced DNA-damage as seen by immunofluorescence microscopy against γH2AX
which was partially colocalised with GFP-POT1 at telomeres (Figure 3.3).
Figure 3.2: POT1 uncapping by pyridostatin. Left: HT-1080 cells after 72 h
without treatment. Right: HT-1080 cells treated with 1 µM pyridostatin after 72 h.
The number of green dots associated with GFP-POT1 decreases dramatically.
This suggests that the removal of POT1 by the compound induces a DNA dam-
age response. However, partial colocalisation could be indicative that the DDR
may be triggered elsewhere in the genome, possibly due to the interaction of the
molecule with other G-quadruplexes throughout the genome.
Figure 3.3: Left: DNA damage shown by red foci of γH2AX. Right: Partial colo-
calisation with GFP-POT1 as indicated with arrows.
1Pictures for Figure 3.2 and Figure 3.3 have been adopted from the literature. [144]
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The interaction of G-quadruplex ligands with telomeres can not only lead to
POT1-uncapping and telomere shortening, [42,48,144] but also to replicative senes-
cence in certain tumour cell lines, such as HT-1080. [44,57,72,82,138] Moreover, an-
other molecule based on the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaf-
fold has also been shown to interact with the NRAS RNA G-quadruplex in the
5′-UTR of the mRNA, altering translation, [36] a process that is described in Chap-
ter 1 in section 1.3.5. Pyridostatin did not cause the same selective effect. This
suggests that different molecules based on this scaffold interact with different
G-quadruplexes and the recognition might be fine-tuned to preferentially target
certain G-quadruplexes. These results prompted us to develop this family of
compounds in our laboratory by synthesising pyridostatin analogues and com-
paring their biophysical and cellular effects. Compounds targeting telomeres are
particularly promising for the development of anti-cancer drugs, as they might
have anti-proliferative effects.
3.2 Objectives
The aim of this work was to design and synthesise G-quadruplex interacting small
molecules based on the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaffold
and evaluate them for their potential to stabilise G-quadruplex DNA. Further-
more, the prospect was to investigate the effect of the compounds on telomere
biology. The aim was also to assess the growth-inhibitory and cytotoxic prop-
erties of these molecules and carry out initial investigations as to whether they
could potentially be developed into drug molecules.
3.3 Synthesis of pyridostatin analogues
Based on the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaffold, 28 small
molecules were synthesised in 2-7 steps. In order to gain an insight into struc-
ture activity relationships (SAR) of the potential interactions of the compounds
with DNA, the nature and length of the side chains R1 and R2, as depicted in
Scheme 3.1, was varied. It was decided to keep the oxygen on the 4-substitution
on the quinoline moieties for all the molecules as it had been proven to be an
excellent structural feature by the successful design of pyridostatin and by the
39
3.3 Synthesis of pyridostatin analogues
molecules presented in Chapter 2. This would keep the electron density of the
quinoline moieties the same.
NO O
HNNH
N N
R1O OR1
R2
Scheme 3.1: N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide scaffold (highlighted in
red) with side chains. The nature and length of the side chains R1 and R2, highlighted
in black and green respectively, were altered in order to gain an insight into the SAR
of the molecules with G-quadruplex targets.
3.3.1 First generation molecules
A list of first generation ligands, which encompasses compounds 18-37, was syn-
thesised. The scaffold can be assembled from one pyridine-based building block
and two quinoline-based building blocks, followed by any necessary modifications
to obtain the desired target G-quadruplex ligands. The pyridine building block
used was either the commercially available 2,6-pyridinedicarbonyl dichloride (7),
or was obtained from chelidamic acid (8) as illustrated in Scheme 3.2, Scheme 3.3
and Scheme 3.4.
N
H
O
HO2C CO2H N
R1
MeO2C CO2Me N
R1
HO2C CO2H
(i) (iii)
N
H
O
MeO2C CO2Me
(ii)
8 9 10 11a-d
11a: OCH2CH2NHBoc
O N
11c: OCH2CCH
O
F
11d:11b:
R1
Scheme 3.2: (i) SOCl2, MeOH, 0 ◦C, 1h; then 8; then rt, overnight; (ii) PPh3, DIAD,
THF, 0 ◦C, 1 h; then ROH, rt, 3 d; (iii) NaOH, MeOH, H2O, rt, 1 h.
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Pyridine building-blocks 11a-d were synthesised as depicted in Scheme 3.2. The
acid groups of compound 8 were first protected as methyl esters using SOCl2/MeOH.
The alcohol on the 4-position of the resulting chelidamic dimethyl ester (9) was
derivatised using Mitsunobu reaction conditions. The products were purified by
column chromatography and the resulting intermediates 10 were deprotected us-
ing base catalysed ester hydrolysis to obtain 11a-d in 57-77% yield over two
steps.
N
H
O
HO2C CO2H N
Cl
MeO2C CO2Me N
Cl
HO2C CO2H
(i) (ii)
8 12 13
Scheme 3.3: (i) SOCl2, MeOH, 0 ◦C, 1 h; then 8; then reflux, overnight; (ii) NaOH,
MeOH, H2O, rt, 1 h.
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HO2C CO2H N
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MeO2C CO2Me N
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HO2C CO2H
(i) (ii)
8 14 15
Scheme 3.4: (i) Me3SiCHN2, PhMe/MeOH, rt, 30 min; (ii) NaOH, MeOH, H2O, rt,
1 h.
Whilst following a published procedure [184] to obtain the chelidamic acid dimethyl
ester (9), dimethyl 4-chloropyridine-2,6 dicarboxylate (12) was obtained as a
by-product as shown in Scheme 3.3. Compound 12 was obtained in mediocre
yield (28%). Thus, it was facile to easily obtain N,N ′-bis(quinolinyl)pyridine-
2,6 dicarboxamides with a chlorine substituent at the 4-position on the pyridine
ring. It was later found that the reaction yielded exclusively 9 in high yield (85%)
when stirred at rt overnight and not refluxed as described in the literature. [184]
The diacid (13) was obtained from 12 analogous to the procedure to obtain
11a-d. Me3SiCHN2 was used to synthesise the dimethyl 4-methoxypyridine-2,6
dicarboxylate (14) in 90% yield. The diester was subsequently hydrolysed using
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basic conditions to afford 4-methoxypyridine-2,6 dicarboxylate (15) as illustrated
in Scheme 3.4. The quinoline-based building blocks were prepared using the two
routes depicted in Scheme 3.5 and Scheme 3.6. Two of the molecules (5a and
5b) were previously presented in Chapter 2 (Scheme 2.1). Mitsunobu reaction
conditions were employed (Scheme 3.5), analogous to the synthesis of the pyridine
building-blocks, to afford the products in 53-71% yield.
(ii)
4 16a-e
N NH2
OH
N NH2
R2
5a:   O(CH2)2NHBoc
16a: O(CH2)3NHBoc
5b:
O N
16b: O(CH2)2NMe2
16c: O(CH2)3NMe2
R2
Scheme 3.5: (i) PPh3, DIAD, THF, 0 ◦C, 1 h; then ROH, rt, 3 d.
A quinoline building block with a methoxy substituent at position 4 (17) was
synthesised using Me3SiCHN2 as depicted in Scheme 3.6.
(ii)
4 17
N NH2
OH
N NH2
OMe
Scheme 3.6: (i) Me3SiCHN2, PhMe/MeOH, rt, 30 min.
To assemble molecules with a N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide
scaffold, one mole equivalent of the pyridine building-blocks (7, 11a-e, 13 or
15) was reacted with two identical mole equivalents of the synthesised quinoline
building-blocks (16a-e or 17). Two different routes were employed as depicted
in Scheme 3.7 and Scheme 3.8.
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Five molecules with the desired scaffold (18-22), without a substituent present
on the 4-position of the pyridine ring, were synthesised (Scheme 3.7). The com-
mercially available 2,6-pyridinedicarbonyl dichloride (7) was used as the pyridine
building block. Yields increased significantly by adding TEA to the acyl chloride
prior to coupling. The primary amines of compounds 18 and 19 were obtained by
removing the Boc-protecting group with TFA/DCM. All final compounds were
purified using HPLC to obtain pure products for subsequent biophysical and
biological evaluation and molecules 18-22 were obtained in 62-82% yield.
N
HN
O
NH
O
N N
R2 R2
N NH2
R1
NClOC COCl
7
1 equiv.
2 equiv.
5a, 5b, 16a-c
(i)
18: O(CH2)2NH2
19: O(CH2)3NH2
20:
O N
21: O(CH2)2NMe2
22: O(CH2)3NMe2
18-22
R2
Scheme 3.7: (i) TEA, DCM, rt, overnight; then for 18 and 19, TFA/DCM, rt, 1 h.
The N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamides 23-37 were synthesised
as illustrated in Scheme 3.8. One equivalent of the pyridine building blocks 11a-
d, 13 and 15 were reacted with two equivalents of the quinoline building blocks
5a, 5b, 16a-c and 17 to obtain molecules with the desired scaffold. Different
coupling strategies were attempted and it was found that the strategy using
Ghosez’ reagent (1-chloro-N,N,-2-trimethylpropenylamine) was very facile and
gave satisfactory yields. The coupling products could be precipitated from hot
MeCN to yield the desired intermediates or final products. The final compounds
23-25, 27, 28, 31, 32 and 36 were obtained by removing the Boc-protecting
groups with TFA/DCM. All the final compounds were also purified using HPLC
to obtain the pure products, which were used in subsequent biological analyses,
in 53-93% yield.
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28:  OCH2CCH       O(CH2)3NH2
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30:  OMe                 OMe
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Scheme 3.8: (i) 1-chloro-N,N,-2-trimethylpropenylamine, DCM, 2 h; then TEA, 0 ◦C,
1 h; then rt, overnight.
3.3.2 Second generation molecules
In order to introduce further functionalities, a strategy was applied to derivatise
the side chain on the pyridine ring after the scaffold had been assembled. For
that reason, molecules 27 and 28, both containing an alkyne side chain on the
pyridine ring of the scaffold, were used as starting materials. This would allow for
the reaction with azides via a copper-catalysed 1,3-Huisgen cycloaddition using
copper(II) sulfate pentahydrate and sodium ascorbate (’click chemistry’) to easily
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synthesise N,N ′-bis(quinolinyl)pyridine-2,6-di carboxamides with more complex
appendages in just one additional synthetic step. It is precedented in the litera-
ture to use click chemistry to assemble G-quadruplex ligands. [66,101] Compounds
38-46 were prepared using this procedure, which is depicted in Scheme 3.9. This
strategy enabled the introduction of sugar moieties on molecules 42-44. Two
analogues (45 and 46) carrying a derivative of a nucleobase were synthesised by
reacting zidovudine with 27 and 28.
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NH
O
N N
R2 R2
27,28
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27: R1=O(CH2)2NH2
28: R1=O(CH2)3NH2
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N NH
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40:     O(CH2)2NH2       (CH2)3NH2
41:     O(CH2)2NH2
42:     O(CH2)2NH2
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44:     O(CH2)3NH2
45:     O(CH2)2NH2
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Scheme 3.9: (i) copper(II) sulfate pentahydrate, sodium ascorbate, rt, 10 min; RN3,
rt, overnight.
The sugar moieties of molecules 42-44 were chosen as sugars present a high
potential for hydrogen bonding to nucleic acid targets. The thymine on 45 and
46 can also potentially hydrogen-bond with the desired nucleic acid targets. A
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nucleobase is an obvious choice as a side chain of a nucleic acid interacting small
molecule based on the old Latin saying similia similibus solvuntur. The design
of molecules 38 and 39 would allow potential comparisons of the G-quadruplex
interacting effects of the triazole moiety compared with the attached side chains.
The synthesis of the library of N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxami-
des was achieved in reasonably high yields and with high purity in 2-7 steps,
which renders the employed strategy very attractive. It has been demonstrated
how side chain substitution could be achieved before and after the assembly of
the final scaffold.
3.4 G-quadruplex stabilisation
In order to assess the interaction of molecules 18-46 with DNA G-quadruplexes,
a FRET-melting assay was performed on five different quadruplex targets (H-
telo, C-kit1, [148] C-kit2, [149] C-myc, [15,84,86,146] Bcl-2 [150] and K-ras [152,153]) and one
double-stranded DNA sequence for comparison (the sequences can be found in
Chapter 5). The biological data, which will be discussed later, is focussed on the
telomeres and the biophysical discussion will therefore mainly focus on H-telo.
The ∆Tm values at 1 µM ligand obtained by FRET melting experiments can be
found in Table 3.1 for H-telo and ds-DNA and for the promoter G-quadruplexes
studied in Appendix A (Table A.1). All the melting shift profiles can be found
in Appendix A (Figure A.1, Figure A.2 and Figure A.3).
Most of the molecules of this family show very good stabilisation of the telom-
eric quadruplex but no significant stabilisation of ds-DNA at the concentration
range studied. Most of the compounds also stabilise the other G-quadruplex tar-
gets with high ∆Tm values. Ligands 23-26 cause maximal stabilisation for H-telo
at 1 µM ligand. They all have an amine functionality on a two-carbon aliphatic
chain on R1. Compounds 31, 32 and 25, which have a chlorine substituent at
R1, and molecules 43 and 44, which have a sugar functionality at that position,
also exhibit maximal stabilisation of this quadruplex target. Other compounds
with a chlorine or hydrogen substituent at this position also show considerable
changes in the stabilisation temperature ranging from 22±0.9 K (20) to 31.4±0.8
K (19). Ligands with an alkyne functionality on R1 exhibit moderate ∆Tm for
H-telo. The 4-fluorobenzyloxy-substitution on R1 on ligands 36 and 37 resulted
46
3.4 G-quadruplex stabilisation
in a huge drop in ∆Tm values compared to other analogues. Molecules 38-46
which have a 1,2,3-triazole side chain exhibited varying stabilisation potentials.
Whereas molecules 38-42 showed moderate ∆Tm values, the sugar and thymidine
derivatives showed very high values for the quadruplexes studied.
∆Tm (K) ∆Tm (K)
compound H-telo ds-DNA compound H-telo ds-DNA
18 28.4±0.81 0.0±0.1 33 24.3±0.6 0.1±0.1
19 35.7±0.8 0.1±0.2 34 27.9±0.6 0.0±0.1
20 22.0±0.9 0.0±0.1 35 35.9±0.3 0.3±0.2
21 30.0±0.6 0.3±0.2 36 8.8±0.5 0.3±0.1
22 35.5±1.2 0.8±0.3 37 4.3±0.3 0.0±0.2
23 34.8±0.6 0.5±0.2 38 10.1±0.6 0.0±0.1
24 35.1±0.9 0.9±0.2 39 13.2±0.8 0.0±0.1
25 35.5±0.9 0.4±0.1 40 18.8±0.6 0.0±0.1
26 35.5±0.8 0.9±0.2 41 6.3±0.4 0.0±0.1
27 16.0±1.0 0.0±0.1 42 30.0±1.0 0.0±0.2
28 18.3±0.5 0.0±0.1 43 35.5±0.7 0.4±0.1
29 12.5±1.1 1.0±0.3 44 35.5±1.0 0.4±0.1
30 0.5±0.4 0.0±0.2 45 32.0±0.4 0.0±0.1
31 35.5±0.9 0.0±0.0 46 32.2±0.6 0.0±0.0
32 35.5±0.7 0.4±0.0
Table 3.1: ∆Tm at 1 µM ligand in K measured by FRET-melting against H-telo and
ds-DNA for 18-46.
The general trend of decreasing stabilisation for H-telo at the R1 position
is: O(CH2)2NH2 > 2-pyrrolidinoethyloxy > sugar functionalities > Cl > H >
OCH2CCH > OMe > 4-fluorobenzyloxy. Positively charged functionalities and
sugars gave the highest values, which could be due to their potential for electro-
static or hydrogen bonding interactions with the nucleic acid target, possibly the
loops and phosphate backbones of the quadruplexes. Since ligands with chlorine
and hydrogen substitution at R1 also gave very high stabilisation potentials, this
position does not seem to be crucial to ensure good interactions with quadruplex
nucleic acids. However, substitution with uncharged, aromatic or aliphatic side
chains adversely affects the stabilisation potentials of the molecules, which could
1Errors were calculated as standard deviation of three independent experiments.
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be due to repulsion.
The nature of the primary amine side chain at R2 did not greatly affect the
G-quadruplex stabilisation potential of the molecules. There was only a slight
general trend at this position with greater stabilisation observed for NH2 > pyrro-
lidine > NMe2. Comparing ∆Tm values for 18-22, 31-35 and 42-44, which are
three series where R1 is unaltered in each case, shows that a three-carbon side
chain on position R2 gives slightly higher stabilisation potentials than two-carbon
side chains. Compound 30 does not have any amine functionality at either posi-
tion R1 or R2. This eliminated the stabilisation potential for any of the quadru-
plex targets almost entirely.
Figure 3.4: FRET competition results at 1 µM 18-46 for H-telo in the presence of
50 mole equivalents of DNA competitor. Values are expressed as %∆Tm(max), which is
the maximum measurable change in Tm where Tm(max) is 95 ◦C. ∆Tm(max) is therefore
35.5 K for H-telo. Dark blue: ∆Tm(max) in the absence of ds-DNA; cyan: ∆Tm(max) in
the presence of ds-DNA competitor.
In order to further assess the selectivity of these compounds for G-quadruplex
DNA over ds-DNA, I performed a FRET-melting assay on the H-telo quadru-
plex in the presence of an excess of ds-DNA as depicted in Figure 3.4. 50 mole
equivalents of a DNA competitor, which can form an intramolecular hairpin or
inter-molecular duplex, were added. Thus, at least 25 mole equivalents of ds-DNA
were present in these experiments. The melting profiles for the H-telo quadru-
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plex were not affected and the stabilisation temperatures were almost unaltered.
The ∆Tm values determined in the absence and presence of ds-DNA competitor
normalised against ∆Tm(max) are illustrated Figure 3.4.
These results demonstrate that the N,N ′-bis(quinolinyl)pyridine-2,6 dicarbox-
amides are very effective and selective G-quadruplex stabilising ligands in the
presence of an excess of ds-DNA. This also suggests their likely interaction with
telomeric G-quadruplexes in cellulo, validating the design. The data suggests
that these molecules could potentially interact with a variety of G-quadruplex
targets in cells.
3.5 Short-term growth inhibition
Molecules 18-46 were assessed for their ability to inhibit cell growth using a lu-
minescent cell viability assay (CellTiter-Glo
TM
by Promega R©) [185] after 72 h of
exposure of the cells to the compounds at eight different doses. This would allow
an initial indication as to whether these compounds may cause a mechanistic
effect in cells. Growth inhibition was determined for a panel of three human can-
cer cell lines: HeLa [186] (cervical adenocarcinoma), HT-1080 [187] (fibrosarcoma)
and U2OS [188] (osteosarcoma). The growth inhibition of WI-38 cells which is a
non-cancerous, normal and untransformed cell line was also assessed. [189,190] The
luminescent assay determines the average number of viable cells in culture based
on the quantification of ATP present, which signals the presence of metabolically
active cells. The supplied reagent mixture lyses the cells to liberate all the ATP
into solution. As a detection method beetle luciferin is used, which is converted
into luminescent oxyluciferin by the enzyme luciferase (see Scheme 3.10).
N
SHO
S
N COOH
+ ATP + O2
luciferase
N
SO
S
N O
+ AMP + PPi + CO2 + light
Mg2+
Scheme 3.10: Oxidation of luciferin into oxyluciferin by luciferase.
Experiments were performed in triplicate using three independent repeats. GI50
values (i.e. the ligand concentration needed to induce 50% of the signal as com-
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pared to the untreated cells) were determined by plotting the concentration of
ligand against % of cells observed at 72 h compared to the untreated control
(which was set to 100%). A dose-response curve was fitted to the values and an
example is given for compound 23 (pyridostatin) for HT-1080 cells in Figure 3.5.
Figure 3.5: GI50 results for HT-1080 cells treated with different doses of 23
(pyridostatin).a
aErrors were calculated as the SD of triplicates of the experiment.
The GI50 values against the four cell lines of compounds 18-46 are tabulated in
Table 3.2, which shows the selectivity ratios of the cancer cell lines against the
normal cell line. Molecules 18-29 and 31-38 cause growth inhibition at high
nanomolar to low micromolar concentrations against this panel of cell lines. No-
tably, compounds 27-46 which contain a triazole at position R1, generally exhibit
higher GI50 values by a factor of 10 or more compared to analogues 18-29 and
31-37. Ligand 30, as the only molecule without amine functionalities at either
R1 or R2, did not show any significant growth inhibition at the concentrations
used. Compound 25, which carries a 2-aminoethoxy side chain at position R1
and a 2-pyrrolidineoethoxy substituent at R2, causes the lowest GI50 for all the
cell lines ranging from 0.2 to 0.5 µM (Figure 3.6).
Many of the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamides cause growth
inhibition at lower concentrations for the cancer cell lines investigated than the
normal cell line WI-38. Strikingly, 23 (pyridostatin) shows a 18.5-fold selec-
tivity for HT-1080 cells over WI-38 cells. The most selective compounds for
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HeLa (5.2-fold) and U2OS (6.0-fold) over WI-38 cells are 38 and 33, respectively
(Figure 3.6).
GI50 (µM)
Selectivity ratio
Compound HeLa HT-1080 U2OS WI-38 HeLa/HT-1080/U2OS/WI-38
18 1.2±0.31 0.3±0.1 0.7±0.2 1.1±0.3 0.9/3.4/1.7/1.0
19 1.4±0.4 1.1±0.2 1.5±0.3 1.6±0.2 1.1/1.5/1.1/1.0
20 3.0±0.2 0.6±0.1 0.8±0.3 3.1±0.6 1.0/5.5/4.0/1.0
21 2.2±0.3 3.3±0.3 2.3±0.5 2.1±0.4 1.0/0.6/0.9/1.0
22 3.0±0.3 2.6±0.3 2.1±0.3 2.1±0.5 0.7/0.8/1.0/1.0
23 2.5±0.5 0.6±0.1 16.8±1.0 11.1±1.6 4.4/18.5/0.7/1.0
24 13.7±1.0 6.8±0.3 14.1±1.3 10.6±1.6 0.8/1.6/0.8/1.0
25 0.3±0.1 0.2±0.0 0.2±0.1 0.5±0.1 1.4/2.6/2.6/1.0
26 2.3±0.2 2.2±0.2 2.1±0.3 2.1±0.2 0.9/1.0/1.0/1.0
27 5.2±0.4 4.7±0.5 4.9±0.7 4.0±0.5 0.8/0.9/0.8/1.0
28 3.6±0.3 2.6±0.2 2.3±0.2 3.5±0.4 1.0/1.3/1.5/1.0
29 3.9±0.2 1.5±0.2 1.6±0.3 3.9±0.4 1.0/2.6/2.4/1.0
30 >40.0 >40.0 >40.0 >40.0 n.d.2
31 1.5±0.2 1.8±0.2 0.8±0.1 1.6±0.2 1.1/0.9/2.0/1.0
32 0.7±0.1 0.6±0.1 0.3±0.1 0.6±0.1 0.9/1.0/2.0/1.0
33 4.7±0.4 3.4±0.2 2.3±0.3 13.7±1.9 2.9/4.0/6.0/1.0
34 3.2±0.2 2.2±0.1 2.2±0.5 4.0±0.4 1.3/1.8/1.8/1.0
35 1.6±0.2 1.8±0.2 1.8±0.5 3.6±0.7 2.3/2.0/2.0/1.0
36 9.6±0.8 1.6±0.2 5.6±0.8 4.9±1.2 0.5/3.1/0.9/1.0
37 13.0±1.1 8.5±0.3 5.8±0.7 11.4±2.4 0.9/1.3/2.0/1.0
38 7.7±0.7 13.5±1.5 >40.0 39.7±3.7 5.2/3.0/n.d./1.0
39 >40.0 35.2±3.3 >40.0 >40.0 n.d.
40 >40.0 >40.0 >40.0 >40.0 n.d.
41 >40.0 >40.0 >40.0 >40.0 n.d.
42 >40.0 >40.0 >40.0 >40.0 n.d.
43 >40.0 23.5±2.3 24.3±4.3 19.2±2.6 n.d./0.8/0.8//1.0
44 38.2±3.5 23.5±2.7 16.8±2.3 29.7±3.3 0.8/1.3/1.8/1.0
45 >40.0 >40.0 >40.0 >40.0 n.d.
46 38.2±2.1 20.9±1.5 >40.0 >40.0 n.d.
Table 3.2: GI50 in µM after 72 h incubation of the stated cell lines with compounds
18-46. Selectivity given as GI50.WI-38/GI50.cancer cell line.
1Errors were calculated as SD of three independent experiments.
2Value was not determined as the maximum compound concentration used was 40 µM.
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Figure 3.6: Molecular structures of 23 (pyridostatin), 25, 33 and 38. 23 is most
selective for HT-1080 cells, 25 gives the lowest GI50 for all the cell lines, 33 is most
selective for U2OS cells and 38 is most selective for HeLa cells.
Compound 9 has a hydrogen and 22 a chlorine at position R1 and both mo-
lecules have a pyrrolidine-containing side chain at position R2. They are more
selective towards the cancer cell lines than other analogues that carry a hydrogen
or chlorine at position R1. This suggests that the nature of the substitution at
R2 has a considerable effect on growth inhibitory properties. The varying growth
inhibition of different cell lines may be exploited to develop molecules selective
for a particular cancer. Upon incubation of cells with the compounds at their
GI50 values, an elevated level of cell death compared to the untreated control
was not observed (assessed by a Trypan blue nuclear exclusion assay), suggest-
ing that the compounds may cause growth inhibition but are not generally toxic
at these concentrations. Factors such as differential cellular uptake, metabolism
and off-target effects (i.e., targets other than G-quadruplexes) may contribute
to the GI50 values measured. Therefore, I did not try to correlate G-quadruplex
stabilisation to the GI50 values.
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3.6 Long-term growth inhibition
The following studies were performed on HT-1080 cells, the same cell line that
had been used to study the effects on telomeres and shelterin by pyridostatin as
described earlier. [144] I investigated the long-term growth effects on HT-1080 cells
of the following molecules: 18-20, 22, 23, 25, 26, 31-33, 35-38 and 44. The
cells were incubated for up to 30 days with the compounds at their respective
GI50. Cells were counted every third or fourth day and replated at the initial
density. Population doublings (PD) were calculated using the following formula
(3.1):
PD =
ln(n1/n2)
ln2
(3.1)
n1 = initial number of cells, n2 = final number of cells.
As discussed in section 3.5, an increase in cell death was not observed at these
concentrations for any of the compounds, suggesting that these concentrations
are subcytotoxic. These concentrations were used to facilitate a comparison of
the long-term growth effects between different N,N ′-bis(quinolinyl)pyridine-2,6
dicarboxamides. The PDs were plotted against days of treatment for the different
compounds and the graph is illustrated in Figure 3.7. Some of the molecules
caused a strong reduction of PD, indicating a long-term growth arrest of HT-
1080 cells, notably 23, 31 and 33 after 6 days, 25 after 12 days, 26 and 37
after 18 days and 36 and 44 after 24 days of exposure. Compounds 31 and
33 both have a chlorine substitution at position R1 and 23, 25 and 26 have an
amine side chain at that position. Compound 44 has a glucosyl side chain at
R1. Compounds which have a hydrogen at this position (18, 19, 20 and 22) did
not show a decrease in PD over the time period measured. The two compounds
which have a 4-fluorobenzyloxy-substitution at position R1 (36 and 37) also
caused long-term growth arrest. The latter two compounds do not exhibit a
high stabilisation of the telomeric G-quadruplex by FRET-melting (∆Tm of 8.8
and 4.3 K at 1 µM, respectively), whereas 23, 25, 26, 31, 33 and 44 showed
high shifts in melting temperature (all around 35.0 K at 1 µM) as discussed in
section 3.4. This implies that an interaction of the molecules with the telomeric
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G-quadruplex may not be the main contributor or sole cause of the long-term
growth inhibitory effects observed.
Figure 3.7: Long term growth studies of compounds 18-20, 22, 23, 25, 26, 31-33,
35-38 and 44 on HT-1080 cells. CON donates control cells which were not treated with
compound. Measurements were taken at the respective GI50 values of the compounds.
The errors are the SD of three independent experiments.
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3.7 Telomere shortening
It was previously demonstrated that compound 23 (pyridostatin) disrupts shel-
terin by uncapping POT1. [144] The effect of 23 on telomere length was not as-
sessed in that initial study. In order to assess the effect of the N,N ′-bis(quinolinyl)-
pyridine-2,6 dicarboxamides on telomere length, it was chosen to perform a non-
denaturing hybridisation assay [42] to detect the telomeric 3′-G-overhang of HT-
1080 cells treated with a selection of the compounds (see Figure 3.8).
Figure 3.8: Telomere shortening assessed for 23, 25, 26, 31, 33 and 44 for HT-1080
cells by a non-denaturing hybridisation assay. CON represents DNA from cells grown
in the absence of compound. Left: Hybridisation gel radiograph and EBr fluorescent
picture. Right: graph showing the %hybridisation signal against days of treatment.
The radiograph signal was normalised against the fluorescence signal. The errors are
the SD of three different experiments.
The HT-1080 cell line is telomerase-positive and thus maintains the same
telomere length in culture. This assay was performed using a selection of six
compounds (23, 25, 26, 31, 33 and 44). which have shown supportive biophysi-
cal data for telomeric G-quadruplex interaction, short-term growth arrest at high
nanomolar to low micromolar concentrations and long-term growth inhibitory
effects for HT-1080 cells. The DNA of cells incubated with the respective com-
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pounds at their GI50 was extracted after 3 days, 6 days, 9 days and 12 days of
exposure. Cells were split and replated at their initial density with the GI50 of
the respective compound at each time point to avoid increased cell stress due
to confluency. The DNA was hybridised for 16 h with a [γ-32P] ATP-labelled
oligonucleotide of the sequence (5′-(CCCTAA)3CCC-3′), which is complemen-
tary to the 3′-G-overhang. The hybridised DNA was run on an agarose gel which
was subsequently stained with EBr and the resulting radiograph was compared to
the fluorescence intensity. The assay was also performed on a control cell sample
which was treated under the same conditions but in the absence of compound.
The radiographs and fluorescent images are displayed in Figure 3.8. This figure
also shows a graph of the relative %hybridisation signals normalised against the
EBr signal of each sample as an average of three independent experiments. It was
found that the five compounds investigated caused a significant decrease in the
hybridisation signal whereas the control was unaffected. This is further in cellulo
proof that members of the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamide family
can target the telomeres.
3.8 Cellular senescence of HT-1080 cells
Small molecules interacting with telomeric G-quadruplexes can cause shelterin
disruption and telomere shortening. [44,57,72,82,138] As a consequence, certain cells
can undergo replicative cellular senescence. [72] It has been postulated that there
seems to be a minimal or critical mean telomere length necessary to maintain
cell division in cells. [72] It is also established that HT-1080 cells undergo senes-
cence as a consequence of POT1 knockdown. [191] This suggests, that a compound
causing POT1 uncapping from the telomeres would also cause a senescent phe-
notype in this cell line. It was examined if compounds 23, 25, 26, 31, 33 and
44, each of which caused 3′-G-overhang shortening, induce replicative cellular
senescence in HT-1080 cells. Senescent cells usually exhibit an enlarged cell-
size and exhibit a pH-dependent β-galactosidase activity which can be detected
histochemically at pH 6. [192] This enzyme catalyses the cleavage of 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal) to yield galactose and 5-bromo-
4-chloro-3-hydroxyindole; the latter oxidises to the blue dye 5,5′-dibromo-4,4′-
dichloro-indigo which can be observed visually. The reaction scheme for this
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reaction is displayed in Figure 3.9.
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Figure 3.9: Reaction scheme of β-galactosidase catalysed hydrolysis of X-gal.
A senescence β-galactosidase staining assay was performed on cells treated
with the aforementioned compounds to assess replicative cellular senescence. HT-
1080 cells were incubated with the respective compounds at their GI50 for 4 days,
split and replated at the initial density and compound concentration for another
4 days.
Figure 3.10: Cell pictures showing HT-1080 cells incubated with 23, 25, 26, 31, 33
and 44 for 8 d. CON donates cells grown in the absence of compound. Arrows in-
dicate blue staining due to 5,5′-dibromo-4,4′-dichloro-indigo indicating β-galactosidase
activity characteristic of senescent cells.
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Morphological examination of the cells after treatment of compound for 8
days showed an increased proportion of flat giant cells with an over-expression
of β-galactosidase activity, which is characteristic of replicative cellular senes-
cence in cultured cells. [193] Figure 3.10 illustrates blue staining of cells treated
with compounds 23, 25, 26, 31, 33 and 44 and the absence of blue colouring
in the control cells which were not treated with compound. Also, there is an
obvious increase of the cell size, which has been attributed to be a characteristic
of senescent cells. [72,193] This data qualitatively shows that compounds 23, 25,
26, 31, 33 and 44 induce replicative cellular senescence in HT-1080 cells which
is likely to be linked to shelterin disruption and consequently the shortening of
the telomeres.
3.9 Drug development
Some of the compounds were sent to the National Cancer Institute of the United
States (NCI) and Cancer Research Technology R© Ltd. to perform cell-growth and
ADME studies, respectively. The data obtained so far are presented in this
section. I did not not perform the experiments and the data can be found in the
appendix of this thesis.
3.9.1 NCI cell line screen
Six of the synthesised N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamides (20, 22,
23 (pyridostatin), 25, 26 and 31) were sent to the NCI for a developmental
therapeutics program. [194] Other structures were not submitted, as these were the
only compounds synthesised at the time. This screen implemented by the NCI is
designed to identify compounds with promising growth inhibition of cancer cells
and also to assess their general toxicity. Compounds that are promising in these
screens are then taken forward for therapeutic development. These compounds
were tested for growth inhibition in a single dose assay (10 µM) against a panel
of 60 cancer cell lines. Four of the compounds (20, 25, 26 and 31 which are
depicted in Figure 3.11) gave sufficient growth arrest to be selected for the second
round of testing, i.e., a five-point dosing assay. GI50 values were taken after 48 h
incubation of the cells with the compounds.
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Figure 3.11: Molecular structures of 20, 25, 26 and 31 which were selected by the
NCI for further testing.
The summarised data can be found in Appendix B. Generally, these four com-
pounds gave high nanomolar to low micromolar GI50 values for the cancer cell
lines investigated. Strikingly, the GI50 was in most cases two magnitudes lower
than the LC50 (lethal concentration 50, i.e., concentration of drug resulting in
a 50% reduction in the measured protein at the end of the drug treatment as
compared to that at the beginning), which confirmed the earlier observations of
no elevated cell death at the growth inhibitory concentrations as compared to the
control. For example, the LC50 values induced by 25 for the leukemia cell lines
tested were greater than 1.00 × 104 µM, whereas the GI50 values were 2.26-3.08
× 106 µM. The data imply that the compounds target certain cellular pathways.
I propose that these compounds mainly act in a cytostatic and not cytotoxic
manner. This is a very good starting point for potential drug development, but,
perhaps more importantly, for the creation of chemical tools to dissect and study
the biochemical pathways involving G-quadruplexes. The NCI is currently decid-
ing whether to take the compounds forward for further evaluation, which would
involve a hollow fibre cancer model in mice. [194]
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3.9.2 ADME studies
Compounds 20, 21, 22 and 23 (Figure 3.12) were sent to Cancer Research
Technology R© Ltd. for ADME studies which assessed pharmacokinetic param-
eters (as the abbreviation defines: absorption, distribution, metabolism and
excretion). The four compounds were selected from the compounds of the family
which had been synthesised at the time based on the following selection criteria:
1) quantity available and 2) structural diversity in side chains and absence and
presence of the substitution on the pyridine ring.
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Figure 3.12: Molecular structure of compounds 20, 21, 22 and 23 for which ADME
studies were performed.
Drug levels and kinetics of exposure upon drug administration are crucial
parameters to assess potential drug candidates. The studies presented herein ad-
dress some of those parameters. An indication of the performance and potential
pharmacological activity of the compounds is given and the summarised data
can be found in Appendix C. There are certain thresholds for each criterion that
should be fulfilled by a potential drug candidate. These are stated in Table C.1.
Only compounds 20 and 22 show sufficient solubility (according to the ADME
guidelines). The cell permeability is slightly too low for all the compounds in-
vestigated but the eﬄux ratio is sufficient for all the compounds, except for 22.
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None of the compounds causes any inhibition in vitro of the CyP450s studied
(see Appendix C, Table C.1). The cell redox systems are therefore not neces-
sarily directly affected by the N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamides.
Plasma binding of these compounds is high for all the compounds, which may
reduce their effectiveness in reaching their DNA targets they have been designed
for (G-quadruplexes). All the compounds show little microsome turnover in hu-
man cells and mediocre microsome turnover in mouse cells. This suggests that
the compounds are not predicted to be highly metabolised in vivo but may ef-
fectively reach their nucleic acid target without being degraded. The compounds
exhibit minimal hERG binding. This protein is part of the ion channels which
control K+ ion eﬄux. Inhibition of these channels can lead to cardiac and muscle
dysfunctions with concomitant risk of sudden death. [195] Compounds 20, 21, 22
and 23 show considerable muscarinic receptor binding inhibition. Inhibition of
these G protein-coupled acetylcholine receptors renders the compounds potential
neurotoxins. All four compounds possess amine side chains which may bind to
the receptors similarly to the potent inhibitor muscarine (Figure 3.13).
O
N
Figure 3.13: Molecular structure of muscarine.
Muscarinic receptor-binding could potentially be circumvented by changing
primary or tertiary amines to more sterically hindered amines, or cyclic secondary
amines. This may not significantly reduce G-quadruplex interaction as I believe
the interaction of the amine side chains is mainly by electrostatic or hydrogen-
bond interactions.
3.10 Conclusions, future work and outlook
A small family of N,N ′bis(quinolinyl)pyridine-2,6 dicarboxamides was synthesised
based on the scaffold of pyridostatin, [144] a small molecule that had been shown
by our group to interact with G-quadruplexes and cause a shelterin disruption fol-
lowed by a γH2AX response in human HT-1080 cancer cells. A high-yielding and
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efficient synthetic route involving 2-7 steps was employed to obtain these molecu-
les. The compounds were evaluated for their potential to stabilise G-quadruplex
structures in vitro and their effects on cell growth were investigated. Strikingly,
elevated levels of cell death were not observed at their GI50 concentrations even
at long-term exposure of the compounds. It was demonstrated that it is possible
to fine-tune the cellular effects of these compounds by changing the side chains on
the scaffold. A selection of the compounds was shown to induce long-term growth
arrest which was linked to their interaction with telomeric G-quadruplexes lead-
ing to G-overhang shortening and replicative cellular senescence. Some of the
compounds were sent to the NCI and some of these have been selected for further
evaluation in their implemented anti-cancer screening assays. The data suggest
that the compounds have cytostatic growth inhibitory properties. The initial
ADME studies have shown that the compounds fulfill some but not all the cri-
teria usually desired for a drug. However, simple changes on the ligand such as
side chain nature and position and introduction of asymmetry could be applied
to develop the pharmacokinetic properties of the molecule. The data obtained
suggests that N,N ′-bis(quinolinyl)pyridine-2,6 dicarboxamides are potential drug
candidates.
The data demonstrate that molecules of this type have promising anti-cancer
properties which we propose to be linked to their interaction with G-quadruplexes.
This makes them very good tools to further study the underlying biology involv-
ing these nucleic acid targets in cells. The results indicate that the compounds
act mainly in a cytostatic and not cytotoxic manner and it would be of immediate
interest to investigate their cytostatic effects using FACS and cell-cycle markers.
Furthermore, pyridostatin [144] triggered a DDR at telomeres and other genomic
regions, as assessed by immunofluorescent staining of γH2AX. We are currently
investigating in our laboratory the exact mechanisms of DNA damage caused
by compounds of this type. Interestingly, recent evidence suggests that the 5′-
UTR of TRF2 mRNA has a G-quadruplex which can be targeted by small mo-
lecules to down-regulate translational activity. [141] N,N ′-Bis(quinolinyl)pyridine-
2,6 dicarboxamides including pyridostatin have been shown to target RNA G-
quadruplexes in the 5′-UTR of another gene, [36] which makes it likely that these
compounds also affect translational levels of TRF2. This would have a profound
effect on shelterin.
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The next chapter describes a small molecule based on the N,N ′-bis(quinoli-
nyl)pyridine-2,6 dicarboxamide that can selectively recognise and pull down G-
quadruplex DNA with the final goal to isolate from cells and directly analyse
G-quadruplex forming-sequences in the human genome.
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Chapter 4
Small molecule-mediated
G-quadruplex isolation from
human cells
4.1 Background
For the purpose of target discovery and validation, natural products and their re-
lated affinity matrices have been used for the isolation of cellular proteins. [196] The
recent development of massively parallel Illumina sequencing [197] has enabled the
genome-wide analysis of transcription factor binding loci using ChIP-seq, [198,199]
a methodology that involves the immunoprecipitation of chromatin-transcription
factor complexes followed by sequencing of the associated DNA fragments. Such
an approach requires the use of an antibody against the transcription factor of
interest to identify the captured nucleic acids. To the best of my knowledge,
no small organic molecules have yet been reported that can be used to isolate a
particular nucleic acid motif in a structure-dependent manner. Although the exis-
tence of G-quadruplexes in vitro is beyond reasonable doubt and they are believed
to play a role in telomere maintenance, [28] gene expression [67,84] and replication
stalling, [112] their actual formation in human cells remains elusive and unproven.
Until now, scientists have heavily relied on bioinformatic studies about G-
quadruplex loci and their prevalence in the genome. [35,37] It would be advanta-
geous to develop chemical tools which can recognise and ultimately isolate these
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nucleic acid motifs. Yet, no such technology is available. A chemical probe which
could perform the aforementioned task could potentially be used to perform ex-
periments analogous to Chip-seq, [198,199] by isolating and ultimately sequencing
G-quadruplex nucleic acids. This could lead to the the identification of the actual
G-quadruplex forming sequences in cells and would constitute further evidence
for their formation in vivo.
4.2 Objectives
The aim of this work was to develop, synthesise and evaluate small molecule G-
quadruplex probes that can be used to isolate G-quadruplex forming nucleic acid
sequences from solution. The design of the probes was based on the scaffold of
the small molecules presented in Chapter 3. It was intended to synthesise a small
library of G-quadruplex probes with an affinity tag and evaluate them for their
potential to stabilise G-quadruplexes. These probes were intended to be used to
design and optimise an in vitro assay for G-quadruplex isolation. The final aim
was to apply such an approach to isolate these non-canonical DNA structures
from human cells in order to validate this novel method. This approach could
ultimately be used to isolate G-quadruplex forming nucleic acid sequences from
human cells and such a methodology could potentially identify possible druggable
and biologically relevant G-quadruplexes.
4.3 Small molecule probes
4.3.1 Design and synthesis
A G-quadruplex affinity probe would have to possess several structural and func-
tional features: 1) the ability to recognise various G-quadruplex structures with
a high level of specificity over ds-DNA; 2) an affinity tag to allow the pull-down
of DNA fragments; 3) the capacity to release the DNA fragments intact for sub-
sequent analysis and 4) a detectable biological activity that can be related to its
interaction with G-quadruplexes. Depending on the strength of the interaction
between the probe and G-quadruplex targets, reversible covalent cross-linking
may also be required. When using ChIP-seq, [198,199] proteins of interest are com-
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monly cross-linked with formaldehyde. A small library of probes was designed
based on the N,N ′-bis(quinolinyl)pyridine-2,6-dicarboxamide scaffold which was
described in Chapter 3. As was demonstrated in section 3.4 (Chapter 3), many
compounds with this scaffold show good stabilisation of various G-quadruplexes,
suggesting a broad selectivity towards G-quadruplex DNA. That makes this plat-
form an ideal candidate to base a G-quadruplex affinity probe on. As an affinity
tag it was decided to introduce a biotin moiety, which allows pull-down with
streptavidin matrices. [200] The small library consists of the seven molecules 47-
53 (Figure 4.1).
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Figure 4.1: Molecular structures of biotinylated probes 47-53.
The scaffold was kept unaltered and the biotin moiety was attached via a
linker at position R1. Attaching the tag at this position retains the symmetry of
the molecule and is thus synthetically more facile than attaching it on one of the
quinolines. I also attached two alternative side chains at position R2. Primary
amines would potentially allow for formaldehyde cross-linking of the probe with
the exocyclic primary amines of the guanines of G-quadruplexes. However, this
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procedure is novel and would require the amines of the probe and the target
to be in close proximity to each other. Therefore, compounds 47 and 48 were
synthesised to potentially explore that strategy. Since we did not know anything
about the exact molecular spacing required between an affinity tag and a potential
probe to successfully isolate the resulting complex with streptavidin, I varied the
length and nature of the spacer that connects the biotin tag to the scaffold.
Molecules 47-49 were synthesised as illustrated in Scheme 4.1.
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Scheme 4.1: (i) 1-chloro-N,N,-2-trimethylpropenylamine, DCM, rt, 2 h; then TEA,
0 ◦C, 1 h; then rt., overnight; (ii) Pd/C, H2, λ, 1 h; for 47 and 48 (+)-biotin N -
hydroxysuccinimide ester, TEA, DCM, rt, 2 h, for 49 (+)-biotinamidohexanoic acid
N -hydroxysuccinimide ester, TEA, rt, 2 h; then DCM/TFA, rt, 2 h.
One equivalent of the pyridine building block 54 was reacted with two equiva-
lents of the quinoline building block 5a using 1-chloro-N,N,-2-trimethylpropenyl-
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amine and TEA, analogous to the procedure described in Chapter 3, section 3.3.
The resulting product was purified by precipitation from hot MeCN. The Cbz-
protecting group was removed by hydrogenation using H2, Pd/C under microwave
conditions. Strong reaction conditions were necessary as intermediates 55 and
56 are very insoluble in a variety of organic solvents. The subsequent reactions
with the respective hydrosuccinamide biotin esters was achieved at rt using TEA
to afford the final compounds in 90-93% yield. Compounds 50-53 were prepared
using the procedures as displayed in Scheme 4.2.
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Scheme 4.2: (i) 50 (+)-biotin N -hydroxysuccinimide ester, TEA, DCM, rt, 2 h, or 51
(+)-biotinamidohexanoic acid N -hydroxysuccinimide ester, TEA, rt, 2 h, or 52 (+)-
biotinamidohexanoyl-6-aminohexanoic acid N-hydroxysuccinimide ester, TEA, rt, 2 h,
for 53 (+)-biotin polyetheleneoxide iodoacetamide, TEA, 100◦, 2 h.
Compound 25, a N,N ′-bis(quinolinyl)pyridine-2,6-dicarboxamide described in
Chapter 3, section 3.3, was used as starting material. This compound has two
pyrrolidine side chains on the quinoline moieties and a primary amine side chain
at R1. Coupling with the respective hydrosuccinamide biotin esters was achieved
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using TEA at rt in 90-99% yield. The reaction with (+)-biotin polyetheleneoxide
iodoacetamide to afford compound 53 required a large excess of TEA, i.e., very
basic conditions, and heating to 100 ◦C. A much lower yield of 47% was reported
for this reaction.
4.3.2 Biophysical evaluation
The biotinylated molecules 47-53 were evaluated for their potential to stabilise
the G-quadruplexes H-telo, C-kit1, C-kit2 and C-myc and double-stranded DNA
using a FRET-melting assay (The sequences can be found in Chapter 5). The
∆Tm values at 1 µM ligand are displayed in Table 4.1.
∆Tm (K)
Compound H-telo C-kit1 C-kit2 C-myc ds-DNA
47 34.8±0.51 39.1±0.7 14.7±0.7 16.9±0.7 2.0±0.3
48 30.5±0.6 38.6±0.5 9.7±0.5 13.2±0.5 1.0±0.2
49 21.5±0.7 13.1±0.5 19.5±0.6 7.3±0.4 1.5±0.2
50 27.0±0.9 23.5±0.9 8.7±0.8 9.9±0.7 0.0±0.0
51 20.0±0.5 19.0±0.7 7.1±0.9 8.8±0.6 0.0±0.0
52 15.0±0.7 20.5±0.5 5.4±0.3 9.1±0.5 0.0±0.1
53 30.1±0.6 12.6±1.0 15.6±0.6 8.1±0.4 0.3±0.0
Table 4.1: ∆Tm at 1 µM ligand in K measured by FRET-melting against H-telo,
C-kit1, C-kit2, C-myc and ds-DNA for 47-53.
The data demonstrates that compounds 47-53 stabilise all the G-quadruplex
targets evaluated. Molecule 47 shows very high stabilisation temperatures for
the quadruplex targets and causes the highest stabilisation for H-telo, C-kit1 and
C-myc out of the series of ligands. Compounds 49 and 53 have higher ∆Tm
values for C-kit2. It is striking that the compounds with the pyrrolidine side
chains do not exhibit any stabilisation of ds-DNA whereas some stabilisation of
double-stranded DNA was detected for 47-49, which have a primary amine at
this position. This might be due to additional hydrogen bonding interactions
with the free lone pairs of the DNA bases. According to this data, compound 47,
with its very high stabilisation potentials for the various G-quadruplex targets,
1Errors were calculated as SD of three independent experiments.
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could be the best candidate for the G-quadruplex isolation studies. However,
since this compound shows some stabilisation for ds-DNA, compounds 50-53 are
more selective and hence might be more suitable.
4.3.3 Short-term growth inhibition
The biotinylated compounds were evaluated for their potential to inhibit the
growth of four different cell lines, analogous to the study on the other N,N ′-
bis(quinolinyl)pyridine-2,6-dicarboxamides presented in Chapter 3, section 3.5.
The data are summarised in Table 4.2.
GI50 (µM)
Compound HeLa HT-1080 U2OS WI-38
47 18.0±1.31 16.4±1.7 >40.0 32.1±2.3
48 >40.0 21.6±2.0 >40.0 >40.0
49 25.7±3.7 30.2±2.3 >40.0 16.2±1.8
50 25.4±2.3 8.4±1.5 29.8±2.0 27.4±3.0
51 25.3±1.9 22.6±2.3 34.2±2.9 22.0±1.9
52 >40.0 38.8±3.7 >40.0 >40.0
53 7.9±1.2 13.4±1.2 8.8±0.9 10.6±1.1
Table 4.2: GI50 in µM after 72 h incubation of the stated cell-lines with compounds
47-53.
The GI50 values for the biotinylated compounds were observed to be on aver-
age about one order of magnitude higher than of most of the N,N ′-bis(quinolinyl)-
pyridine-2,6-dicarboxamides presented earlier but similar to those induced by the
derivatives with a triazole attached to the side chain of the pyridine ring (see
Table 3.2). The higher GI50 values could be attributed to differential uptake into
the cells, lower solubility or different metabolism of the compounds in the cells.
Compounds 47-49 and 52 showed values higher than 40.0 µM for one or more
cell-lines. Ligand 53 showed low micromolar GI50 values and is the most potent of
the seven candidates, suggesting it to be the most suitable compound for further
studies, providing the biological mechanism of action is analogous to that of the
non-biotinylated molecules.
1Errors were calculated as SD of three independent experiments.
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4.3.4 G-quadruplex isolation
A pull-down assay was developed to isolate G-quadruplex DNA from solution us-
ing the biotinylated molecules developed and magnetic beads coated with strep-
tavidin. The assay consists of the following steps:
(1) Using the biotinylated probe to incubate a solution containing nucleic acids
folded into G-quadruplexes and non-G-quadruplex nucleic acids.
(2) Incubation of that solution with streptavidin-coated magnetic beads.
(3) Isolation of the G-quadruplex bound biotinylated probe by magnetic separa-
tion.
(4) Recovery of the G-quadruplex nucleic acids from the beads in a new buffer-
containing solution.
A picture of that assay is depicted in Figure 4.2.
m
ag
ne
t
= small molecule probe
= G-quadruplex nucleic acid
= magnetic streptavidin-
   coated beads
= non-quadruplex
   nucleic acid
pull-down
supernatant
recovery
supernatant
sequencing
Figure 4.2: Schematic drawing of G-quadruplex isolation with a small molecule.
Firstly, it was investigated whether the compounds can selectively isolate G-
quadruplex DNA from solution. Three G-quadruplex targets, C-kit1, C-kit2 and
C-myc (these G-quadruplexes were discussed in the previous chapters and the
sequences can be found in Table 4.4), and one ds-DNA control of the sequence
5′-CAA TCG GAT CGA ATT CGA TCC GAT TG-3′ were chosen for this inves-
tigation. Annealed DNA samples were incubated with various concentrations of
compounds 47-53. This resulting solution was then incubated with streptavidin-
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coated magnetic beads and subsequently the supernatant isolated after incubation
for 15 min. The resulting solution was analysed by UV and the absorbance values
at 260 nm were recorded. A starting concentration of 2 µM DNA was used for
each experiment and the concentrations of oligonucleotide of the supernatants
after pull-down were determined using the Beer-Lambert law (equation 4.1).
A = l × × c (4.1)
A = absorbance; l = pathlength in cm;  = molar extinction coefficient in M−1
cm−1, c = concentration in M.
The G-quadruplex DNA concentration of the solutions decreased using in-
creasing amounts of biotinylated probe. On the contrary, the concentration of
ds-DNA was unaltered. By plotting 1/[ligand] against [DNA] (that remained in
solution), it was established that the relationship was inversely proportional for
the concentration range used, as a straight line could be fitted on the graph. The
gradient of those graphs gives values of nM DNA/µM compound. The values
for each target corresponding to the different compounds were compared in or-
der to establish if there was a difference in pull-down between molecules 47-53.
These values were termed pull-down constants and all the values obtained are
tabulated in Table 4.3. Figure 4.3 portrays the graph obtained for molecule 53
as an example.
Figure 4.3: Plot of 1/[DNA] against [53] for C-kit1, C-kit2, C-myc and ds-DNA. The
gradients of the graphs donate the pull-down constants.
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The pull-down constants displayed in Table 4.3 suggest that molecules 49
and 53 can mediate G-quadruplex isolation most efficiently from solution. It is
striking that all the compounds very selectively facilitate G-quadruplex DNA pull-
down with constants ranging from 22.8±0.7 to 110.9±5.5 nMcompound/µMDNA and
that they do not mediate the isolation of ds-DNA. However, the compounds with
the primary amine side chains (47-49) also pull down a small amount of ds-DNA
(between 0.4 and 1.0 nMcompound/µMDNA). These accumulated data suggest that
molecule 53 is the most suitable probe for this in vitro pull-down study out of
the series synthesised.
Compound C-kit1 C-kit2 C-myc ds-DNA
47 43.9±1.81 26.1±0.8 28.5±0.9 0.4±0.0
48 31.1±0.9 22.8±0.7 33.8±0.9 0.6±0.5
49 110.9±5.5 61.6±3.1 129.6±7.8 1.0±0.2
50 41.1±2.5 9.9±0.4 26.8±0.8 0.0±0.0
51 42.6±2.6 24.1±1.4 25.2±0.8 0.0±0.0
52 21.7±1.1 39.4±1.2 41.1±1.6 0.1±0.0
53 88.6±4.4 72.5±2.2 109.9±3.3 0.0±0.0
Table 4.3: Pull-down constants in nMcompound/µMDNA for 47-53 for C-kit1, C-kit2,
C-myc and ds-DNA.
4.3.5 Selection of a competent probe
A small library of seven biotinylated small molecules based on the N,N ′-bis(quino-
linyl)pyridine-2,6-dicarboxamide scaffold has been synthesised. The compounds
very selectively stabilise G-quadruplex DNA as shown by FRET-melting experi-
ments. These compounds also induced short-term growth inhibition of four cell
lines and can be used to isolate small synthetic G-quadruplex oligonucleotides
from solution. The FRET-melting data suggest that 50-53 are most selective
for G-quadruplex DNA over ds-DNA. It was also found that only compounds
47, 48 and 53 were very soluble in water. From the short-term growth assays it
was concluded that 53 is the most suitable probe for cellular investigations. The
preliminary pull-down studies presented in section 4.3.4 suggested that 49 and
1Errors were calculated as SD of three independent experiments.
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53 are the most efficient molecules for G-quadruplex isolation. Based on these
results, 53 (Figure 4.4) was chosen as a small molecule probe to further inves-
tigate its aptitude to mediate G-quadruplex DNA pull-down on more complex
systems in vitro and also on human genomic DNA isolated from cells, which will
be presented hereafter.
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Figure 4.4: Molecular structure of 53, the molecule chosen to perform more detailed
pull-down studies.
The G-quadruplex forming sequences presented in this chapter have all been
established in the literature to form G-quadruplexes under the experimental con-
ditions used, and thus constitute good systems to study the structure-dependency
of the pull-down experiments.
4.4 G-quadruplex isolation and recovery
Further studies on the pull-down properties of 53 were performed on a variety
of G-quadruplex and ds-DNA targets. Magnetic streptavidin beads different to
those used for the previous studies were employed. They are more costly but
more efficient in isolating biotinylated molecules from solution, as their loading
capacity and purity is higher. It was therefore concluded to be beneficial to switch
to that system for more detailed studies. These beads produce different pull-down
efficiencies compared to the beads used for the preliminary studies presented in
section 4.3.4.
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4.4.1 FRET-melting with ds-DNA competition
Good selectivity of 53 for G-quadruplex DNA over ds-DNA is an essential fea-
ture a G-quadruplex affinity probe has to possess. Therefore, I evaluated the
G-quadruplex stabilisation properties of compound 53 in the presence of an ex-
cess of ds-DNA. A FRET-melting assay was performed for H-telo, C-kit1, C-kit2
and C-myc in the presence of 200 mole equivalents of unlabelled ds-DNA com-
petitor oligonucleotide. The sequence (5′-CAA TCG GAT CGA ATT CGA TCC
GAT TG-3′) can form a hairpin and is self-complementary, i.e., two strands can
hybridise to form a double helix, and therefore at least 100 mole equivalents of
ds-DNA were present in these experiments. The results of these experiments are
depicted in Figure 4.5.
Figure 4.5: Left: Thermal shift profile induced by molecule 53 in presence and
absence of ds-DNA competitor. Right: Bar chart of ∆Tm values at 1 µM 53. (•)
H-telo; (•) H-telo + ds-DNA; (•) C-myc; (•) C-myc + ds-DNA; (•) C-kit1; (•) C-kit1
+ ds-DNA; (•) C-kit2; (•) C kit2 + ds-DNA.
The effect of the double stranded DNA on the ∆Tm induced by 53 was small,
as can be seen by the thermal shift profiles illustrated in Figure 4.5. The figure
also shows (on the right) that the ∆Tm at 1 µM 53 only dropped slightly, which
is consistent with a good selectivity of the compound for G-quadruplex over ds-
DNA. The results imply that this biotinylated probe can very selectively recognise
and stabilise G-quadruplex DNA in the presence of a large excess of ds-DNA.
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4.4.2 Short sequence isolation and recovery
In order to further investigate the aptitude of molecule 53 to mediate the iso-
lation of small G-quadruplex forming oligonucleotides, further experiments were
conducted. The work presented in this section was carried out with the help
of Dr. Raphae¨l Rodriguez and Dr. Sunita Kumari. An initial oligonucleotide
concentration of 5 µM was used and a pull-down assay was performed on the
following G-quadruplexes: H-telo, C-kit1, C-kit2, C-myc1 (these G-quadruplexes
were discussed in the previous chapters and the sequences can be found in Ta-
ble 4.4) and also on ds-DNA. The UV titration results are displayed in Figure 4.6.
As the figure shows, six different concentrations of compound 53 were used in
this assay, which had been prepared in serial dilution: 0.0 µM, 3.0 µM, 4.5 µM,
6.5 µM, 10.0 µM and 15 µM. The amplitude of the graph of the pull-down su-
pernatant decreases for G-quadruplex forming DNA (H-telo, C-kit1, C-kit2 and
Pu22) using increasing amounts of the small molecule. The amplitude of the
graph corresponding to the respective recovery supernatants increases, respec-
tively. This indicates that an increasing amount of compound 53 has been used
to isolate an increasing amount of DNA that can fold into G-quadruplexes. The
UV signal corresponding to the double stranded DNA (ds-DNA) was untouched
using increasing amounts of the probe, for both, the supernatants of pull-down
and recovery. This suggests that the probe selectively mediates G-quadruplex
DNA isolation but no ds-DNA pull-down at these concentrations.
It was found that the oligonucleotides pulled-down could only be recovered
from the magnetic beads using denaturing conditions such as 8 M LiCl and heat
or 8 M urea. It has been shown before that urea has a destabilising effect on
G-quadruplex structures. [201] Li+ ions have been proposed not to destabilise G-
quadruplexes, [202] but adding a high molarity of LiCl might displace the K+ ions
from the G-quadruplex structures, lowering their thermal stability. This would
rationalise, why heating was required in conjunction with 8 M LiCl to recover
the G-quadruplexes under investigation. Washing or heating in the presence of
buffer-containing solution did not release any DNA.
This demonstrates that the complex formed between G-quadruplex DNA and
1We used a mutated sequence of the C-myc quadruplex established in the literature, which
only forms a single conformation, making subsequent gel analyses easier. [15] This mutated C-
myc G-quadruplex is also termed Pu22.
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53 is very strong. Therefore, it was concluded that for these experiments cross-
linking of the small molecules with the oligonucleotide targets would not be es-
sential as initially proposed and commonly used in Chip-seq protocols. [198,199]
Figure 4.6: UV traces of pull-down experiments with DNA-targets with increasing
amounts of probe 53: (•) 0.0 µM; (•) 3.0 µM; (•) 4.5 µM; (•) 6.5 µM; (•) 10.0 µM;
(•) 15.0 µM.
In order to assess the integrity of the recovered oligonucleotide and investigate
if G-quadruplex DNA can be isolated from solution in the presence of ds-DNA
using the developed methodology, we performed the same experiment with 2.5 µM
G-quadruplex DNA and 2.5 µM ds-DNA and analysed the resulting supernatant
and recovery solutions by PAGE. The oligonucleotides were recovered from beads
using 8 M urea and purified prior to PAGE analysis using G-25 (GE-Healthcare R©)
columns. The results are displayed in Figure 4.7. As the gels in this figure
illustrate, the bands corresponding to G-quadruplex DNA (H-telo, C-kit1, C-kit2
and Pu22) in the pull-down supernatants decrease in intensity upon an increase
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of 53 used. This demonstrates that larger molarities of 53 isolate more of G-
quadruplex DNA. The intensities of the bands corresponding to ds-DNA do not
change. The amount of G-quadruplex DNA recovered from the beads increases as
more of the compound is used in the assay, whereas there is a complete absence of
bands corresponding to ds-DNA in all the gels. This is consistent with an increase
of isolated G-quadruplex DNA but not ds-DNA when using greater amounts of
the small molecule. Furthermore, these results show that the oligonucleotides are
intact after pull-down and also that the assay is selective for G-quadruplex DNA
for a 1:1 solution of G-quadruplex DNA:ds-DNA.
Figure 4.7: PAGE results showing pull-down of four different G-quadruplex DNAs
form a 1:1 mixture with ds-DNA. Only G-quadruplex DNA is isolated and not ds-DNA.
It was next explored whether this assay could also be employed to isolate RNA
G-quadruplexes formed by synthetic RNA oligonucleotides. As a G-quadruplex
target, the one situated in the 5′-UTR of the mRNA of the gene N-ras [34] was
chosen and as a control the assay was performed on a RNA sequence that can
adopt a hairpin as secondary structure (for the sequences see Table 4.4). The
experiments were analysed by UV and the results are displayed in Figure 4.8. The
figure shows a strong decrease in the amplitudes of the UV spectra corresponding
to the N-ras G-quadruplex upon larger amounts of 53 used. The amplitudes
of the recovery solutions increase in a dose-dependent manner, indicating more
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nucleic acid being isolated. The results presented in Figure 4.8 show that there
was very little pull-down of the control hairpin sequence using 15 µM 53 and
negligible changes in amplitude using smaller amounts of the compound. It is
noteworthy that the recovery of RNA from beads could not be achieved with 8
M LiCl as this was found to degrade the RNA (a disappearance of the band shift
was observed using PAGE and the UV signal at 260 nm disappeared after the
oligonucleotide had been incubated for 10 min with 8 M LiCl). However, recovery
of the oligonucleotide from beads was successfully achieved using 8 M urea.
Figure 4.8: UV traces of pull-down experiments with RNA-targets with increasing
amounts of probe 53: (•) 0.0 µM; (•) 3.0 µM; (•) 4.5 µM; (•) 6.5 µM; (•) 10.0 µM;
(•) 15.0 µM.
These results suggest that the methodology can also be applied to isolate RNA
G-quadruplexes as the N-ras G-quadruplex is pulled down and the RNA hairpin is
almost untouched. This further demonstrates that the assay works in a structure-
dependent manner. However, it was decided to focus the studies and methodology
development presented hereafter on DNA targets.
4.4.3 Long sequence isolation and recovery
Classical Chip-Seq experiments [198,199] implement shearing or micrococcal diges-
tion of genomic DNA isolated from cells in order to obtain DNA fragments bound
to the protein target of interest, which are sequenced subsequently. If this tech-
nology is to be applied to fragments of genomic DNA to isolate G-quadruplex-
forming sequences, it would be necessary to 1) isolate longer fragments (normally
shearing of genomic DNA yields fragments of the size of approximately 100-500
bp) and 2) isolate these fragments in the presence of the complementary DNA
strand. I applied this in vitro pull-down methodology on a variety of longer
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oligonucleotide sequences to investigate the applicability of the methodology. It
was evaluated if compound 53 could mediate the isolation of longer strands of the
telomeric sequence (5′-TTAGGG-3′)n from solution and the assay was performed
on a 50-mer and 100-mer oligonucleotide. The experiments on long oligonu-
cleotides were performed on a 5 µM starting concentration for the 50-mer and
and a 1 µM concentration for the 100-mer. The lower concentration for the
longer oligonucleotide was chosen for practical reasons, i.e., the large amount of
DNA required for the experiment. Furthermore, the molar extinction coefficient
for longer sequences is higher and thus measuring the UV spectra at lower con-
centrations of longer sequences is more facile than for shorter sequences. The
aptitude of 53 to mediate pull-down was investigated at three concentrations
corresponding to 0, 1 and 3 mole equivalents of the DNA concentration used.
The results of these experiments are highlighted in Figure 4.9.
Figure 4.9: Isolation of a H-telo 50-mer and 100-mer with 53 and recovery from 53.
Left: UV spectra of pull-down and recovery solutions. Right: PAGE analyses of the
solutions. (•) 0 equivalents 53, (•) 1 equivalent 53 and (•) 3 equivalents 53.
This experiment revealed the possibility to isolate single stranded sequences of the
single-stranded telomeric G-overhang from solution. The UV graphs in Figure 4.9
show that the DNA is isolated in a dose-dependent manner using 53. The PAGE
presented in Figure 4.9 illustrate that the DNA is intact after recovery from beads.
It is noteworthy that this sequence can form multiple G-quadruplexes which may
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favour the pull-down of these oligonucleotides.
These encouraging results prompted me to explore this assay on a longer
oligonucleotide with a single G-quadruplex forming sequence. I chose to perform
studies on the wild-type C-myc sequence and selected a 51-mer oligonucleotide
(C-myc(51)) with the G-quadruplex forming sequence positioned in the middle
of the sequence. The natural genomic DNA sequence was used for these exper-
iments. In order to investigate if the probe could isolate G-quadruplex forming
sequences in the presence of the complementary strand, pull-down experiments
were also performed with 53 on the complementary sequence (comp. C-myc(51))
and on both strands annealed together in solution. The sequences are depicted
in Figure 4.10. The G-quadruplex forming sequence is highlighted in red.
Figure 4.10: C-myc(51) and comp. C-myc(51) sequences with the C-myc G-
quadruplex forming sequence highlighted in red.
The results of these experiments are displayed in Figure 4.11. The UV graphs
in the figure demonstrate that DNA could only be isolated if the G-quadruplex
forming strand was present. Strikingly, the assay could also isolate this sequence if
the complementary strand was present. It is noteworthy that the DNA recovered
in the presence of the complementary strand, as depicted on the bottom right gel
in Figure 4.11, shows a larger proportion of the single stranded DNA containing
the G-quadruplex forming sequence. These results imply that is is possible to
isolate 51-mer C-myc DNA of the G-quadruplex forming sequence in the absence
and presence of the complementary strand. This provides further evidence that
the probe 53 acts in a structure-dependent manner and targets G-quadruplexes
selectively.
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Figure 4.11: Isolation of C-myc(51) with 53 and recovery from 53 in the absence and
presence of the complementary strand. Pull-down and recovery of comp. C-myc(51) is
also displayed. Left: UV spectra of pull-down and recovery solutions. Right: PAGE
analyses of the solutions. (•) 0 equivalents 53, (•) 1 equivalent 53 and (•) 3 equivalents
53.
The assay was also performed on a 101-mer oligonucleotide, which was de-
signed on the same principles as its shorter counterpart as depicted in Figure 4.12.
The G-quadruplex forming sequence is again highlighted in red.
Figure 4.12: C-myc(101) and comp. C-myc(101) sequences with the C-myc G-
quadruplex forming sequence in red.
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It was found that it is possible to isolate C-myc(101) with and without its comple-
mentary strand but the pull-down was weaker than for C-myc(51) as can be seen
in Figure 4.13. The results suggest that this assay can be used to isolate oligonu-
cleotides from solution of up to at least 101 bp in length, if the oligonucleotide
contains a G-quadruplex forming sequence.
Figure 4.13: Isolation of C-myc(101) with 53 and recovery from 53 in the absence and
presence of the complementary strand. Pull-down and recovery of comp. C-myc(101) is
also displayed. Left: UV spectra of pull-down and recovery solutions. Right: PAGE
analyses of the solutions. (•) 0 equivalents 53, (•) 1 equivalent 53 and (•) 3 equivalents
53.
The stabilisation of G-quadruplexes by 53 as has been demonstrated by
FRET-melting experiments presented in sections 4.3.2 and 4.4.1, suggesting that
the compound induces the formation of G-quadruplexes by driving the equilib-
rium towards their formation. This would, in fact, be expected for any small
molecule interacting with G-quadruplexes. However, if the small molecule can
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drive the population in one direction, it is implied that the G-quadruplex pop-
ulation already exists. The data therefore imply that G-quadruplexes may form
in the presence of their complementary DNA strand. The formation of these
structures might be favoured by annealing the DNA in 60 mM KCl. However,
the experiments clearly show that it is possible to isolate G-quadruplex forming
DNA from more complex systems using our methodology. The results and the
dose-dependency on the small molecule suggest that the C-myc quadruplex is
in dynamic equilibrium with double-stranded DNA. The PAGE show that the
the complementary strand is also being isolated if the experiment is performed
in the presence of the G-quadruplex forming strand. This is expected since the
base pairs of the quadruplex flanking sequences pair with the complementary
DNA-strand.
4.4.4 Quadruplex mutations abrogate pull-down
Following this, it was explored if a mutated sequence of the C-myc G-quadruplex
containing sequences, which does not allow for the formation of this secondary
structure, would have an effect on the pull-down mediated by 53. A mutated C-
myc sequence (mut. C-myc(51)) was used (depicted in Figure 4.14). Each G-tract
was mutated to ensure that the sequence could not form a G-quadruplex. [37]
Figure 4.14: Mut. C-myc(51) and comp. mut. C-myc(51) sequences. Mutations are
highlighted in blue.
The results of the experiments using the mutated 51-mer and its complementary
strand are illustrated in Figure 4.15. Neither the sequences including the mu-
tated quadruplex, nor its complementary strand could be isolated as the figure
shows. Furthermore, DNA was also not isolated if both sequences were present
as demonstrated by the UV graphs and PAGE presented in Figure 4.15. These
results demonstrate that a G-quadruplex forming sequence is required to isolate
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DNA and they also constitute further evidence that ds-DNA pull-down is not
mediated by 53.
Figure 4.15: Isolation of mut. C-myc(51) with 53 and recovery from 53 in the absence
and presence of the complementary strand. Pull-down and recovery of comp. mut. C-
myc(51) is also displayed. Left: UV spectra of pull-down and recovery solutions.
Right: PAGE analyses of the solutions. (•) 0 equivalents 53, (•) 1 equivalent 53 and
(•) 3 equivalents 53.
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Analogous experiments were performed using a 101-mer and its complementary
strand as displayed in Figure 4.16. The results of the experiments are shown in
Figure 4.17.
Figure 4.16: Mut. C-myc(101) and comp. mut. C-myc(101) sequences. Mutations are
highlighted in blue.
Figure 4.17: Pull-down of mut. C-myc(101) with 53 and recovery from 53 in the
absence and presence of the complementary strand. Pull-down and recovery of comp.
mut. C-myc(101) is also displayed. Left: UV spectra of pull-down and recovery solu-
tions. Right: PAGE analyses of the solutions. (•) 0 equivalents 53, (•) 1 equivalent
53 and (•) 3 equivalents 53.
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Analogous to the results preformed on the mutated 51mer, DNA could not be
isolated using 53. The UV graphs and PAGE results illustrated in Figure 4.17
display that pull-down was completely abrogated compared to the wild type se-
quence used in the experiments presented in Figure 4.13. These experiments
also served as a ds-DNA control since the mutated sequences are expected to
exclusively form a double-stranded DNA-helix upon hybridisation in solution. It
was observed that the pull-down was completely abrogated due to the mutations,
further giving evidence to our hypothesis that the assay can be applied to isolate
G-quadruplexes and is structure-dependent.
A summary of all the sequences studied and the outcome of the pull-down
experiments can be found in Table 4.4. The table shows how quadruplex-forming
sequences are a requirement for pull-down to occur. It has to be noted that
there is a window of specificity for this assay. I observed some pull-down of all
the sequences when the assay was performed with very high equivalents of small
molecule compared to the DNA. This might be because 53 carries three positive
charges at pH 7.4 and some interaction with the negatively charged phosphate
groups of any nucleic acid molecule would be expected at high concentrations
of the biotinylated ligand. Therefore, a low ratio of small molecule equivalents
to DNA1 was maintained to ensure specificity towards G-quadruplexes. It is
also noteworthy that various sequences presented here are G-rich without a G-
quadruplex forming motif and were not pulled down. This suggests that the pull-
down is not due to the G-richness of the sequence but rather to the formation of
G-quadruplexes, i.e., is structure-dependent.
1At least one order of magnitude below concentrations where any traces of pull-down of
sequences without a G-quadruplex forming sequence could be seen.
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Table 4.4: Oligonucleotide sequences studied in nucleic acid isolation experiments.
 
 
Name (mer)
# 
 
 
Sequence (5´ to 3´)
† 
 
 
PQS
‡ 
 
 
Pull-down
¶ 
 
1 H-telo(21) -  GGG TTA GGG TTA GGG TTA GGG- + + 
2 C-kit1(21) -  GGG AGG GCG CTG GGA GGA GGG- + + 
3 C-kit2(20) -  GGG CGG GCG CGA GGG AGG GG- + + 
4 Pu22(22)  -      TGA GGG TGG GTA GGG TGG GTA A- + + 
5 C-myc(27) -  TGG GGA GGG TGG GGA GGG TGG GGA AGG- + + 
6 ds-DNA(26) -  CAA TCG GAT CGA ATT CGA TCC GAT TG- ! ! 
7 N-ras(18) -  GGG AGG GGC GGG UCU GGG- + + 
8 RNA hairpin(24) -  CUA CAG UAC AGA UCU GUA CUG UAG- ! ! 
9 H-telo(50) 
-  TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG 
   TT- 
+ + 
10 C-myc(51) 
-  GAG GGG CGC TTA TGG GGA GGG TGG GGA GGG TGG GGA AGG TGG GGA GGA 
   GAC- 
+ + 
11 comp. C-myc(51) 
-  GTC TCC TCC CCA CCT TCC CCA CCC TCC CCA CCC TCC CCA TAA GCG CCC 
   CTC- 
! ! 
12 
C-myc(51) / 
comp. C-myc(51) 
-  GAG GGG CGC TTA TGG GGA GGG TGG GGA GGG TGG GGA AGG TGG GGA GGA 
   GAC- 
-  GTC TCC TCC CCA CCT TCC CCA CCC TCC CCA CCC TCC CCA TAA GCG CCC 
   CTC- 
+ + 
13 mut. C-myc(51) 
-  GAG GGG CGC TTA TGC TTA CGC TCT TGA ATC TCA TGA AGG TGG GGA GGA 
   GAC- 
! ! 
14 comp. mut. C-myc(51) 
-  GTC TCC TCC CCA CCT TCA TGA GAT TCA AGA GCG TAA GCA TAA GCG CCC 
   CTC- 
! ! 
15 
mut. C-myc(51) / 
comp. mut. C-myc(51) 
-  GAG GGG CGC TTA TGC TTA CGC TCT TGA ATC TCA TGA AGG TGG GGA GGA 
   GAC- 
-  GTC TCC TCC CCA CCT TCA TGA GAT TCA AGA GCG TAA GCA TAA GCG CCC 
   CTC- 
! ! 
16 H-telo(100) 
-  TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG 
   TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG 
   TTA G- 
+ + 
17 C-myc(101) 
-C ACG CCC TCT GCT TTG GGA ACC CGG GAG GGG CGC TTA TGG GGA GGG TGG 
   GGA GGG TGG GGA AGG TGG GGA GGA GAC TCA GCC GGG CAG CCG AGC ACT 
   CTA G- 
+ + 
18 comp. C-myc(101) 
-C TAG AGT GCT CGG CTG CCC GGC TGA GTC TCC TCC CCA CCT TCC CCA CCC 
   TCC CCA CCC TCC CCA TAA GCG CCC CTC CCG GGT TCC CAA AGC AGA GGG 
   CGT G- 
! ! 
19 
C-myc(101) / 
 
comp. C-myc(101) 
-C ACG CCC TCT GCT TTG GGA ACC CGG GAG GGG CGC TTA TGG GGA GGG TGG 
   GGA GGG TGG GGA AGG TGG GGA GGA GAC TCA GCC GGG CAG CCG AGC ACT 
   CTA G- 
-C TAG AGT GCT CGG CTG CCC GGC TGA GTC TCC TCC CCA CCT TCC CCA CCC 
   TCC CCA CCC TCC CCA TAA GCG CCC CTC CCG GGT TCC CAA AGC AGA GGG 
   CGT G- 
+ + 
20 mut. C-myc(101) 
-C ACG CCC TCT GCT TTG GGA ACC CGG GAG GGG CGC TTA TGC TTA CGC TCT 
   TGA ATC TCA TGA AGG TGG GGA GGA GAC TCA GCC GGG CAG CCG AGC ACT 
   CTA G- 
! ! 
21 comp. mut. C-myc(101) 
-C TAG AGT GCT CGG CTG CCC GGC TGA GTC TCC TCC CCA CCT TCA TGA GAT 
   TCA AGA GCG TAA GCA TAA GCG CCC CTC CCG GGT TCC CAA AGC AGA GGG 
   CGT G- 
! ! 
22 
mut. C-myc(101) / 
 
comp. mut. C-myc(101) 
-C ACG CCC TCT GCT TTG GGA ACC CGG GAG GGG CGC TTA TGC TTA CGC TCT 
   TGA ATC TCA TGA AGG TGG GGA GGA GAC TCA GCC GGG CAG CCG AGC ACT 
   CTA G- 
-C TAG AGT GCT CGG CTG CCC GGC TGA GTC TCC TCC CCA CCT TCA TGA GAT 
   TCA AGA GCG TAA GCA TAA GCG CCC CTC CCG GGT TCC CAA AGC AGA GGG 
   CGT G- 
! ! 
 
#: the symbol / defines a 1:1 mixture of the oligonucleotide and its complementary strand.
†: oligonucleotides highlighted in red correspond to the wild type C-myc sequences, mutations are highlighted in blue.
‡: + indicates motifs that contain a PQS and - indicates motifs that do not contain a PQS.
¶: + indicate motifs pulled down by 53 and symbols - indicates motifs that remained in the supernatant after a pull-down
experiment.
4.4.5 Pull-down enhancement with pyridostatin
The pull-down assay was performed in the presence of pyridostatin (23). In-
terestingly, it was observed that the addition of 23 to the DNA prior to isolation
studies enhances the pull-down efficiency of 53. As a control experiment, com-
pound 23 does not mediate any isolation in the absence of 53. The results of the
experiment are displayed in Figure 4.18.
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Figure 4.18: Top left: Pull-down supernatant using (•) 0.0 µM, (•) 10.0 µM and (•)
20.0 µM 23. Top second from left: Pull-down supernatant using (•) 0.0 µM, (•) 5.0
µM and (•) 15.0 µM 53. Top second from right: Pull-down supernatant using (•) 0.0
µM 53/10.0 µM 23, (•) 5.0 µM 53/10.0 µM 23 and (•) 15.0 µM 53/10.0 µM 23. Top
right: Pull-down supernatant using (•) 0.0 µM 53/20.0 µM 23, (•) 5.0 µM 53/20.0
µM 23 and (•) 15.0 µM 53/20.0 µM 23. Bottom row: Corresponding recoveries
of the top row. Red arrows mark increase in DNA pull-down by decreasing the DNA
concentrations in the pull-down supernatant and increasing the DNA concentrations of
the recovery solutions.
Figure 4.18 shows that the amplitude of the UV signal corresponding to the
DNA in the supernatant decreases if the assay is performed with an equimolar
concentration of 53 but increasing amounts of pyridostatin (23), indicative of
an increased pull-down efficiency. Complementary to these results, the ampli-
tudes of the UV signals in the recovery solutions get bigger if more pyridostatin
(23) is added to the assay, indicative of more G-quadruplex DNA isolated. This
result can be rationalised by the fact that DNA prone to fold into G-quadruplex
motifs is in dynamic equilibrium with its single coiled counterpart. The equilib-
rium can be driven by the presence of a G-quadruplex stabilising small molecule.
Pyridostatin (23) may act co-operatively with molecule 53 by driving the DNA
towards G-quadruplex folding in solution prior to pull-down with the biotinylated
probe.
Although we could relate the apparent phenotype of HT-1080 cells caused
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by 53 with that induced by pyridostatin (23), the latter compound was much
more active in cells and also at lower concentrations. Also, the long term growth
effect was more pronounced for the lead molecule. Furthermore, pyridostatin
(23) showed a greater aptitude to stabilise G-quadruplexes as assessed by FRET-
melting studies. [144] The observed co-operative effect between the compounds for
the pull-down could be exploited to isolate genomic G-quadruplex forming DNA.
One could incubate cells with pyridostatin (23) and then isolate the DNA.
The pull-down could then be conducted in vitro using 53. We are currently
investigating the feasibility of such an approach in our laboratory.
4.4.6 Cellular effects of the probe
It was demonstrated that it is possible to pull down G-quadruplex forming oligonu-
cleotides in vitro using the biotinylated probe 53. The major objective of this
project was to utilise this small molecule to recognise and isolate G-quadruplexes
from cells. Such an approach could help identify druggable G-quadruplexes. A
preliminary characterisation of the cellular effects of 53 was performed and they
were compared to those of the lead molecule pyridostatin (23), which had been
identified to interact with the telomeric G-quadruplex. [144] All the studies pre-
sented here were performed at the GI50 of the compounds. It was initially ob-
served that incubation of HT-1080 cells with compounds 23 and 53 caused phe-
notypic changes not seen in the untreated control cells. Upon incubation with
the compounds the cells enlarged with an obvious increase of the cytoplasmic to
nucleoplasmic ratio (see Figure 4.19).
Figure 4.19: Pictures of cells after 12 d. Left: Untreated control HT-1080 cells.
Center: HT-1080 cells incubated with 23. Right: HT-1080 cells incubated with 53.
An increase of this ratio is characteristic of senescent cells [193] and implies a
90
4.4 G-quadruplex isolation and recovery
cytostatic effect of the compounds. Cells were split and replated at the ap-
propriate compound concentration every 4th day. I also performed experiments
on HT-1080 cells, analogous to those presented in Chapter 3, for other N,N ′-
bis(quinolinyl)pyridine-2,6-dicarboxamides. It was investigated if 53 causes long-
term growth inhibition and G-overhang attrition leading to replicative senescence.
The results of these experiments are summarised in Figure 4.20.
Figure 4.20: Top left: Long-term growth curves of HT-1080 cells treated with 23, 53
and control (CON) cells without ligand treatment. Top center: G-overhang shorten-
ing shown for DNA isolated from HT-1080 cells treated with 53 over 12 d. Top right:
Histogram showing average hybridisation signal of four independent experiments for
DNA isolated from HT-1080 cells treated with (•) 23 and (•) 53. Bottom left: Senes-
cence β-galactosidase assay performed on control cells and bottom right: Performed
on cells treated with 53 for 8 d. Arrows indicate blue staining due to 5,5′-dibromo-
4,4′-dichloro-indigo indicating β-galactosidase activity characteristic of senescent cells.
(For results for 23 see Chapter 3).
The data obtained suggest that 53 has cellular effects on HT-1080 cells anal-
ogous to those induced by pyridostatin (23), exemplified by the fact that both
compounds cause telomere shortening, replicative cellular senescence and induce
the same apparent cellular phenotype upon exposure. The data suggests that
53 may be a G-quadruplex interacting small molecule, which can recognise these
structures in cells. This makes this probe a suitable candidate to mediate the
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pull-down of G-quadruplexes from human cells. It should therefore be possible
to isolate biologically relevant and/or druggable DNA and RNA G-quadruplexes
from human cells using this probe and the methodology that was presented earlier
in this chapter.
4.4.7 Genomic DNA pull-down
Currently, we are exploring the aptitude of the pull-down assay to isolate G-
quadruplexes from human cells in our laboratory. It is an ongoing project and
preliminary results are discussed in this section. The initial experiments were
performed on genomic, non-chromatinised DNA. Although, this system is still
removed from the natural state of DNA, it is a good choice to study the method-
ology in a more complex environment than the one used for the in vitro studies
presented earlier in this chapter.
Figure 4.21: Pull-down and recovery from genomic DNA. Left: PA gel showing:
lane 1) DNA ladder; lane 2) recovery from beads after pull-down with 0.0 µM 53; lane
3) recovery from beads after pull-down with 1.0 µM 53; 4) supernatant of pull-down
before the experiment. Center: pull-down of genomic DNA with 53. Right: Recovery
of genomic DNA from 53. (•) 0.0 µM, (•) 0.5 µM, (•) 1.0 µM, (•) 2.0 µM , (•) 4.0
µM 53.
Genomic DNA was isolated from HT-1080 cells and associated proteins and
RNA were removed by using protease K and RNase A, respectively. The DNA was
sheared by sonication; a procedure which yields DNA fragments of approximately
100-500 bp in length. Each sample contains DNA of approximately 6 × 106 cells.
Since shearing nicks the DNA at random foci, any single PQS will be within
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varying DNA sizes in the range of these fragments. It was possible to isolate DNA
using our established methodology and the results are displayed in Figure 4.21.
The genomic DNA concentration was calculated from the average fragment size.
For the pull-down experiments displayed in Figure 4.21, a DNA concentration
of 0.52 µM was used; a concentration in relation to that of 53 well within the
window of specificity seen in the earlier experiments.
These preliminary results were very encouraging. However, the experiments
do not give any insight into the composition of the DNA isolated. We thought of
three practical ways to assess the content of the DNA pull-down: 1) sequencing
of the fragments, 2) nucleobase digestion and investigation of the G-content of
the pull-down and 3) specific qPCR on selected sequences like the telomeric one
or the promoter region of c-myc which are suspected to form G-quadruplexes.
Option 1) is the ultimate goal, but is very resource consuming and it would
be better to have a simpler way to investigate if there is a PQS enrichment in
the recovered DNA from beads before performing DNA-sequencing. Option 2)
would only give a very crude way of assessing G-richness. Option 3) would give a
very good overview on the feasibility of the assay and can easily be applied to a
selection of targets. We are currently investigating the composition of the genomic
DNA fragments isolated by qPCR in our laboratory, which will be presented in
the next section.
4.4.8 Isolation of the telomeric G-quadruplex
The work presented in this section has been carried out in collaboration with Dr.
Sunita Kumari and Dr. Raphae¨l Rodriguez. For this study we decided to assess
the DNA composition of the supernatant after pull-down mediated by increasing
amounts of 53. The genomic DNA was sonicated and a final concentration of 0.52
µM DNA (using an average fragment size of 300 bp as suggested by the gel shown
in Figure 4.21) was used for the studies. We performed the pull-down assay using
0, 2.6, 5.2 and 10.4 µM 53. Subsequently, we performed qPCR experiments
on the telomeric sequence and on the sequence of a control gene 36B4 using
the supernatants after pull-down. The 36B4 gene, which does not contain a G-
quadruplex forming sequence, is located on chromosome 12 and encodes for the
acidic ribosomal phosphoprotein PO. The qPCR conditions for these sequences,
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including the primers used, are established in the literature. [203] The results of
these experiments are illustrated in Figure 4.22. This methodology allowed us
to compare the Cp values of the amplification reactions and directly relate them
to the control reaction (no compound). The experiments showed that increasing
amounts of 53 reduced the amount of telomeric sequence in the supernatant in
a dose-dependent manner, whereas the quantity of control gene 36B4 remained
unaffected (Figure 4.22 on the left). It is noteworthy that we did not relate the
absolute amplifications of the telomeric sequence and 36B4. Despite the fact
that the primer efficiencies were comparable, the copy numbers of the sequences
are different. Thus, we only performed an intrinsic comparison of each target
with its control PCR reaction of the pull-down experiment performed using no
compound. Specific qPCR amplification performed on the DNA recovered form
beads further demonstrated the presence of telomeric DNA in the pull-down
extracts as seen in Figure 4.22 on the right. The primers used gave a major
amplification product of 76 bp but also longer fragments as visualised by the
gel. These results indicate that compound 53 is capable of selectively mediating
G-quadruplex DNA isolation from cells. It is possible that nucleic acid fragments
comprising similar sequences found elsewhere in the genome than telomeres may
also have been isolated.
Figure 4.22: Results of the qPCR experiments performed on H-telo and 36B4. Left:
Bar chart showing the relative percentage of remaining telomeric sequence and 36B4
control gene in supernatants after pull-down performed on 0.52 µM genomic DNA
(n=5). Right: Agarose gel showing the PCR amplification products of telomeric
sequences after DNA recovery from 53. SD: ? p ≤ 0.05, ? ? p ≤ 0.01, ? ? ? p ≤ 0.0001.
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The outcome of the experiments presented in sections 4.4.3 and 4.4.4 suggested
that the pull-down assay may be applied to G-quadruplexes in the presence of
their complementary strand. We have now started investigating G-quadruplex
targets other than the telomeric one and are currently examining the feasibility to
selectively isolate genomic DNA sequences containing promoter G-quadruplexes
from genes such as c-kit and c-Myc, using qPCR as detection method.
4.5 Conclusions, future work and outlook
The successful design and synthesis of biotinylated G-quadruplex stabilising small
molecules has been demonstrated. The molecules showed good stabilisation of
a variety of G-quadruplex targets as assessed by FRET-melting experiments.
Based on these molecules, an in vitro assay was developed that can isolate DNA
fragments containing G-quadruplexes from solution selectively over ds-DNA. One
of the probes was shown to cause phenotypic cellular effects analogous to those
of the established G-quadruplex ligand pyridostatin. [144] The results suggest
that the assay can be used to isolate G-quadruplexes from genomic DNA, as
demonstrated by the successful isolation of the telomeric G-quadruplex forming
sequence from genomic DNA of human HT-1080 cells. This platform provides a
starting point to map all G-quadruplex forming sequences in the human genome.
Thus, this approach could be used to identify all G-quadruplex forming sequences
in a genome and this information might ultimately supersede the bioinformatic
studies on the prevalence of G-quadruplexes in the genome. [37] Such an outcome
may help steer and focus the research efforts in the G-quadruplex field.
Indubitably, there is a limitation to this approach. A molecule may induce the
formation of G-quadruplexes and identified targets may therefore be wrongly at-
tributed to be of biological significance. However, this is the case for other studies
involving small molecules. Also, a small molecule can only drive an equilibrium
towards the formation of one population. Therefore any identified G-quadruplex
by this method would form in the absence of the small molecule, even though its
population in the equilibrium might be small.
Thus I conclude that our methodology offers a good approach to identify possi-
ble biologically relevant and/or druggable G-quadruplexes in the human genome.
The new methodology presented in this chapter can also be applied to isolate
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RNA G-quadruplexes, as the results of the experiments presented in section 4.4.2
imply. However, RNA sequencing is far from trivial due to the various extremely
stable secondary structures RNA can adopt.
It has been demonstrated that 53 targets telomeres in cells. This evidence
suggests that the compound 1) penetrates into the cells and 2) interacts with
DNA at telomeres. This suggests that it might be possible to incubate the cells
with compound 53 and isolate G-quadruplexes from the cells. This route is very
challenging as the probe will have to fulfill a plethora of properties which have
not yet been fully assessed:
1) It would have to stay intact and not be metabolised.
2) The detection of the isolated DNA has to be sensitive enough to detect a
potentially very small amount of DNA.
3) The interactions of the G-quadruplexes with the probe have to be strong
enough to survive all the isolation steps. With the current system in place, there
is no covalent interaction between the probe and the target. It may be necessary
to explore the potential of formaldehyde or glutaraldehyde cross-linking, which
may require the usage of the probes with primary amines as presented earlier in
the chapter.
Furthermore, the experiments performed in section 4.4.5 suggest that an al-
ternative approach is feasible: the isolation of G-quadruplexes with 53 in vitro
from DNA isolated from cells treated with 23.
Ultimately, the DNA isolated using one of those approaches will have to be
sequenced to identify the G-quadruplex sequences isolated. This part would have
to be addressed using methodologies such as Illumina [197] sequencing technology.
Despite these challenges lying ahead, the system and methodology developed is
functional as shown extensively in vitro in this chapter and by the successful
isolation the telomeric G-quadruplex forming sequence.
Since, we have shown that human telomeric DNA is a molecular target for
53, it provides further evidence for the formation of G-quadruplexes at human
telomeres.
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Chapter 5
Experimental
5.1 Synthesis
5.1.1 General experimental
All solvents and reagents were purified by standard techniques reported in Ar-
marego, W.L.F., Chai, C.L.L., Purification of Laboratory Chemicals, 5th edition,
Elsevier, 2003; or used as supplied from commercial sources (Sigma-Aldrich R© or
Alfa-Aesar R©). NMR spectra were acquired on Bruker DRX-400, Bruker DPX-
400 and DRX-500 instruments using deuterated solvents as detailed and at am-
bient probe temperature (300 K). Notation for the 1H-NMR spectral splitting
patterns includes: singlet (s), doublet (d), triplet (t), broad (br) and multi-
plet/overlapping peaks (m). Signals are quoted as δ values in ppm, coupling
constants (J ) are quoted in Hz and rounded to the nearest 0.5 Hz. Proton as-
signments are supported by 1H-COSY, 1H-13C HMBC and 1H-13C HMQC where
necessary. Data analysis for NMR was performed using TopSpin R© software. Mass
spectra were recorded on Micromass Q-Tof (ESI) spectrometer. TLC was per-
formed on Merck Kieselgel 60 F254 plates, and spots were visualised under UV
light. Flash chromatography (FC) was performed using Merck Kieselgel 60 at rt
under a positive pressure of N2 or Ar using previously distilled solvents. Melting
points were recorded using a Griffin R© melting point apparatus and were recorded
for crystalline compounds only and not for salts or precipitates. HPLC purifica-
tion was carried out using a Varian R© Pursuit
TM
C18, 5 µ column (250.0 × 21.2
mm) and a gradient elution with H2O/MeCN containing 0.1% TFA at a flow
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rate of 12.0 ml/min or a Varian R© Pursuit
TM
C18, 5 µ column (250.0 × 10.0 mm)
and a gradient elution with H2O/MeCN containing 0.1% TFA at a flow rate of
4.6 ml/min. [α]20D values were recorded on a Perkin Elmer
R© 241 polarimeter.
All labelled DNA oligonucleotides were purchased from Eurogentec R© Ltd. and
all unlabelled oligonucleotides were purchased from IBA R© GmbH. Reagents for
cell-based studies were purchased from GIBCO R© unless stated otherwise. Lumi-
nescence was recorded on a Berthold Detection Services R© Orion II Microplate
Luminometer. Fluorescent readings for FRET experiments were performed using
a Roche R© LightCycler
TM
480 System RT-PCR. A NanoDrop
TM
1000 spectrome-
ter (Thermo Scientific R©) was used to record UV spectra and quantify DNA. Gel
imaging was performed using a UVP R© Bio Doc-it
TM
imaging system. Cell imag-
ing was performed with an Olympus R© microscope fitted with a colour camera.
Final data analysis was performed using the Microsoft Office
TM
package unless
stated otherwise.
5.1.2 Procedures
This section describes general procedures for the synthesis of some of the com-
pounds. Structures and analytical data are presented in section 5.1.3.
Procedure for 1a-3b
G1: Two equivalents of 5a (for 1a, 2a and 3a) or 5b (for 1b, 2b and 3b) were
dissolved in dry chloroform (2 ml) and one equivalent of 1,3-diisocyanatobenzene
6a (for 1a and 1b), 2,4-toluene diisocyanate 6b (for 2a and 2b) or 2,6-toluene
diisocyanate 6c (for 3a and 3b) was added. The mixture was heated to 50 ◦C
and allowed to stir overnight. The solvent was removed in vacuo and the mixture
redissolved in DCM (3 ml) and TFA (1 ml). The mixture was allowed to stir for 1
h and then the solvent removed in vacuo to yield a pale yellow solid. Compounds
were purified by HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 100%
MeCN, 0.1% TFA over 30 min, Rt=13.0-16.0 min) to yield the TFA salts of the
products as white powders.
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Procedure for 18-22
G2: One mole equivalent of 2,6-pyridine dicarboxyldichloride (7) was dissolved
in DCM and cooled to 0 ◦C under argon. TEA was added dropwise and the solu-
tion allowed to warm to rt and stirred for 30 min. Typically, 2.2 mole equivalents
of 5a, 5b or 16a-16c was added and the solution allowed to stir overnight under
argon. The solvent was removed in vacuo. The intermediate for 18 and 19 was
precipitated from hot MeCN, filtered, dried using MgSO4 and deprotected using a
1:2 mixture of TFA/DCM (10-100 ml). The final compounds were purified using
HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA
over 30 min, Rt=12.0-13.5 min) to yield the TFA salt of the product.
Procedure for 23-37
G3: One mole equivalent of 11a-d, 13 or 15 were dissolved in DCM and 1-chloro-
N,N,-2-trimethylpropenylamine was added slowly and the reaction allowed to stir
at rt for 2 h. The solution was then cooled to 0 ◦C. TEA was added dropwise
and the solution was allowed to warm to rt and stirred for 1 h. Typically, 2.2
mole equivalents of 5a, 5b or 16a-16c was added and the solution stirred under
argon at rt overnight. The solvent was removed in vacuo. The intermediate for
23-25, 27, 28, 31, 32 and 36 was precipitated from hot MeCN, filtered, dried
and deprotected using TFA/DCM (1:2). The final compounds were purified using
HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA
over 30 min, Rt=12.0-13.5 min) to yield the TFA salt of the product.
Procedure for 38-46
G4: 27 or 28 was dissolved in a 1:2 mixture of tBuOH/H2O (1-3 ml). Copper(II)
sulfate pentahydrate and sodium ascorbate were added and the solution left to
stir for 10 min. The respective azide was added and the solution was allowed to
stir overnight under argon. The solvent was removed in vacuo and the product
purified by HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA to 100% MeCN,
0.1% TFA over 30 min, Rt=13.0-14.5 min) to yield the TFA salt of the product.
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5.1.3 Synthesised molecules
For each compound synthesised the molecular structure is depicted. Some protons
are numbered on a few of the molecules for clarity. Additional abbreviations used
int he annotations: al = aliphatic, ar = aromatic, T = thymidinyl.
1,3-[Di(4-{2-amino-ethoxy}quinolin-2-yl)diureido]benzene (1a)
N
H
N
H
HN
O O
NH
N N
OO NH2H2N
Following procedure G1, 5a (133 mg, 0.440 mmol) was reacted with 1,3- pheny-
lene diisocyanate (6a, 35 mg, 0.220 mmol) to afford the TFA salt of the title
compound (1a·2CF3CO2H, 154 mg, 0.190 mmol, 86%). 1H-NMR (500 MHz,
D2O) δH 8.31 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.78 (2H, dd, J 8.0, 1.0 Hz, CH
(ar)), 7.69 (2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 7.60 (1H, s, CH (ar)), 7.48
(2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 7.35 (2H, d, J 8.0 Hz, CH (ar)), 7.20
(1H, t, J 8.0 Hz, CH (ar)), 6.69 (2H, s, CH (ar)), 4.59 (4H, t, J 5.0 Hz, OCH2),
3.61 (4H, t, J 5.0 Hz, OCH2CH2);
13C-NMR (125 MHz, D2O) δC 163.0, 162.5,
154.1, 153.9, 139.8, 134.2, 130.7, 127.5, 127.4, 124.1, 118.9, 116.1, 111.0, 93.1,
68.0, 39.7; HRMS (ES) calculated for C30H31N8O4 ([M+H]
+) m/z: 567.2463,
found 567.2456.
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1,3-[Di(4-{2-pyrrolidinyl-ethoxy}quinolin-2-yl)diureido]benzene (1b)
N
H
N
H
HN
O O
NH
N N
OO NN
Following procedure G1, 5b (56 mg, 0.220 mmol) was reacted with 1,3 phenylene
diisocyanate (6a, 18 mg, 0.110 mmol) to afford the TFA salt of the title com-
pound (1b·2CF3CO2H, 90 mg, 0.1 mmol, 91%). 1H-NMR (500 MHz, D2O) δH
8.23 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 8.05-8.01 (1H, m, CH (ar)), 7.90 (2H, dd, J
8.5, 1.0 Hz, CH (ar)), 7.77 (2H, ddd, J 8.5, 7.0, 1.0 Hz, CH (ar)), 7.47 (2H, ddd,
J 8.0, 7.0, 1.0 Hz, CH (ar)), 7.40-7.38 (2H, m, CH (ar)), 7.36-7.32 (1H, m, CH
(ar)), 6.94 (2H, s, CH (ar)), 4.55 (4H, t, J 4.0 Hz, OCH2), 3.81 (4H, t, J 4.0 Hz,
OCH2CH2), 3.76-3.66 (4H, m, NCH2CH2CH2), 3.31-3.19 (4H, m, NCH2(CH2)2),
2.14-2.03 (4H, m, NCH2CH2CH2), 1.97-1.86 (4H, m, NCH2CH2CH2);
13C-NMR
(125 MHz, D2O) δC 161.7, 153.6, 152.2, 139.5, 131.2, 129.7, 125.5, 124.3, 122.3,
117.9, 117.4, 115.1, 112.7, 94.9, 65.0, 54.2, 53.9, 23.0; HRMS (ES) calculated
for C38H43N8O4 ([M+H]
+) m/z: 675.3407, found 675.3411.
2,4-[Di(4-{2-amino-ethoxy}quinolin-2-yl)diureido]toluene (2a)
N
H
N
H
HN
O O
NH
N N
OO NH2H2N
Following procedure G1, 5a (118 mg, 0.4 mmol) was reacted with 2,4-toluene
diisocyanate (6b, 34 mg, 0.2 mmol) to afford the TFA salt of the title compound
(2a·2CF3CO2H, 150 mg, 0.180 mmol, 90%). 1H-NMR (500 MHz, D2O) δH 8.28
(1H, dd, J 8.5, 1.0 Hz, CH (ar)), 8.24 (1H, dd, J 8.5, 1.0 Hz, CH (ar)), 8.20 (1H, s,
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CH (ar)), 7.75-7.70 (2H, m, CH (ar)), 7.70-7.62 (2H, m, CH (ar)), 7.50-7.45 (1H,
m, CH (ar)), 7.45-7.40 (1H, m, CH (ar)), 7.13-7.09 (1H, m, CH (ar)), 7.00-6.96
(1H, m, CH (ar)), 6.75-6.70 (2H, m, CH (ar)), 4.60-4.50 (4H, m, OCH2), 3.61-
3.53 (4H, m, OCH2CH2), 2.19 (3H, s, CH3);
13C-NMR (125 MHz, D2O) δC
163.2, 162.9, 162.6, 162.3, 154.3, 153.89 153.8, 137.3, 134.5, 134.0, 131.8, 127.4,
126.9, 126.8, 124.3, 124.0, 122.0, 119.6, 119.5, 118.9, 118.7, 117.2, 116.6, 114.0,
93.3, 93.1, 67.9, 67.6, 39.7, 39.6, 18.2; HRMS (ES) calculated for C31H33N8O4
([M+H]+) m/z: 581.2619, found 581.2637.
2,4-[Di(4-{2-pyrrolidinyl-ethoxy}quinolin-2-yl)diureido]toluene (2b)
N
H
N
H
HN
O O
NH
N N
OO NN
Following procedure G1, 5b (49 mg, 0.2 mmol) was reacted with 2,4-toluene
diisocyanate (6b, 17 mg, 0.1 mmol) to afford the TFA salt of the title com-
pound (2b·2CF3CO2H, 85 mg, 0.090 mmol, 90%). 1H-NMR (500 MHz, D2O)
δH 8.42 (1H, s, CH (ar)), 8.22 (2H, br d, J 8.5 Hz, CH (ar)), 7.80 (1H, d, J
8.0 Hz, CH (ar)), 7.84 (1H, d, J 8.0 Hz, CH (ar)), 7.78-7.74 (2H, m, CH (ar)),
7.49-7.43 (3H, m, CH (ar)), 7.27-7.23 (1H, m, CH (ar)), 7.00 (1H, s, CH (ar)),
6.81 (1H, s, CH (ar)), 4.60-4.50 (4H, m, OCH2), 3.85-3.78 (4H, m, OCH2CH2),
3.75-3.66 (4H, m, NCH2(CH2)2), 3.30-3.20 (4H, m, NCH2(CH2)2), 2.57 (3H, s,
CH3), 2.13-2.04 (4H, m, NCH2CH2CH2), 1.97-1.87 (4H, m, NCH2CH2CH2);
13C-
NMR (125 MHz, D2O) 161.6, 161.4, 153.8, 153.5, 152.5, 152.2, 146.0, 137.7,
137.1, 131.2, 131.1, 130.6, 130.5, 125.6, 125.5, 124.2, 124.1, 122.4, 122.3, 121.4,
119.7, 117.9, 117.8, 115.1, 113.7, 111.2, 92.8, 92.7, 64.4, 64.3, 54.2, 52.7, 22.7,
22.4, 18.3; HRMS (ES) calculated for C39H45N8O4 ([M+H]
+) m/z: 689.3564,
found 689.3569.
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2,6-[Di(4-{2-amino-ethoxy}quinolin-2-yl)diureido]toluene (3a)
N
H
N
H
HN
O O
NH
N N
OO NH2H2N
Following procedure G1, 5a (97 mg, 0.320 mmol) was reacted with 2,6-toluene
diisocyanate (6c, 28 mg, 0.160 mmol) to afford the TFA salt of the title compound
(3a·2CF3CO2H, 117 mg, 0.140 mmol, 88%). 1H-NMR (500 MHz, D2O) δH 8.26
(2H, dd, J 8.5, 1.0 Hz, CH (ar)), 7.88 (2H, dd, J 8.5, 1.0 Hz, CH (ar)), 7.84 (2H,
ddd, J 8.5, 6.5, 1.0 Hz, CH (ar)), 7.64 (2H, ddd, J 8.5, 6.5, 1.0 Hz, CH (ar)),
7.41 (2H, d, J 8.0 Hz, CH (ar)), 7.35 (1H, d, J 8.0 Hz, CH (ar)), 6.74 (2H, s, CH
(ar)), 4.65 (4H, t, J 5.0 Hz, OCH2), 3.62 (4H, t, J 5.0 Hz, OCH2CH2), 2.40 (3H,
s, CH3);
13C-NMR (125 MHz, D2O) δC 162.1, 161.8, 154.9, 154.2, 137.1, 134.7,
127.6, 127.4, 124.4, 123.3, 119.0, 118.8, 116.5, 93.3, 68.0, 39.6, 13.3; HRMS (ES)
calculated for C31H33N8O4 ([M+H]
+) m/z: 581.2619, found 581.2637.
2,6-[Di(4-{2-pyrrolidinyl-ethoxy}quinolin-2-yl)diureido]toluene (3b)
N
H
N
H
HN
O O
NH
N N
OO NN
Following procedure G1, 5b (62 mg, 0.220 mmol) was reacted with 2,6-toluene
diisocyanate (6c, 21 mg, 0.120 mmol) to afford the TFA salt of the title com-
pound (3b·2CF3CO2H, 103 mg, 0.110 mmol, 92%); 1H-NMR (500 MHz, D2O)
δH 8.23 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.88 (2H, dd, J 8.0, 1.0 Hz, CH (ar)),
7.79 (2H, d, J 8.0 Hz, CH (ar)), 7.76 (2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)),
7.48 (2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 7.23 (1H, t, J 8.0 Hz, CH (ar)), 6.87
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(2H, s, CH (ar)), 4.55-4.52 (4H, m, OCH2), 3.86-3.79 (4H, m, OCH2CH2), 3.76-
3.65 (4H, m, NCH2(CH2)2), 3.30-3.20 (4H, m, NCH2(CH2)2), 3.56 (3H, s, CH3),
2.13-2.04 (4H, m, NCH2CH2CH2), 1.96-1.88 (4H, m, NCH2CH2CH2);
13C-NMR
(125 MHz, D2O) 161.8, 153.6, 152.6, 145.0, 137.4, 131.2, 126.0, 125.2, 124.1,
122.4, 119.8, 117.9, 117.2, 114.7, 112.5, 92.7, 64.4, 54.1, 52.7, 22.7, 13.6; HRMS
(ES) calculated for C39H45N8O4 ([M+H]
+) m/z: 689.3564, found 689.3574.
4-(2-tert-Butoxycarbonylamino-ethoxy)-quinolin-2-ylamine (5a)
N NH2
O NHBoc
2-Aminoquinolin-4(1H )-one (4, 1.0 g, 6.2 mmol), N -Boc-ethanolamine (1.5 g,
9.3 mmol) and triphenylphosphine (3.3 g, 12.6 mmol) were dissolved in freshly
distilled THF (100 ml) and cooled to 0 ◦C. DIAD (1.8 ml, 9.4 mmol) was added
dropwise under argon. The mixture was allowed to warm to rt and stirred for 3
d. The solvent was removed in vacuo and the product purified by column chro-
matography (90% EtOAc, 10% MeOH) to obtain the title compound as a white
powder (1.2 g, 4.0 mmol, 65%). 1H-NMR (500 MHz, CDCl3) δH 7.97 (1H, dd, J
8.0, 1.0 Hz, CH (ar)), 7.59 (1H, dd, J 8.5, 1.0 Hz, CH (ar)), 7.54 (1H, ddd, J 8.5,
7.0, 1.0 Hz, CH (ar)), 7.23 (1H, ddd, J 8.0, 7.0, 1.0 Hz, CH (ar)), 6.02 (1H, s, CH
(ar)), 5.00 (1H, br s, NHBoc), 4.71-4.69 (2H, m, OCH2), 4.17-4.13 (2H, m, NH2),
3.69-3.66 (2H, m, OCH2CH2), 1.47 (9H, s, CH3);
13C-NMR (125 MHz, CDCl3)
δC 162.3, 158.0, 155.9, 148.5, 130.3, 125.7, 122.0, 121.6, 117.5, 90.1, 79.8, 67.5,
39.8, 28.4; HRMS (ES) calculated for C16H22N3O3 ([M+H]
+) m/z: 304.1650,
found 304.1668.
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4-(2-Pyrrolidinyl-ethoxy)-quinolin-2-ylamine (5b)
N NH2
O N
2-Aminoquinolin-4(1H )-one (4, 1.5 g, 9.4 mmol), N -(2-hydroxyethyl)-pyrrolidine
(1.7 g, 14.5 mmol) and triphenylphosphine (4.9 g, 18.6 mmol) were dissolved in
freshly distilled THF (100 ml) and cooled to 0 ◦C. DIAD (2.7 g, 14.1 mmol)
was added dropwise under argon. The mixture was allowed to warm to rt and
stirred for 3 d. The solvent was removed in vacuo and the product purified by
column chromatography (87% EtOAc, 10% MeOH, 3% TEA) to obtain the ti-
tle compound as a pale yellow powder (1.3 g, 5.0 mmol, 53%). 1H-NMR (400
MHz, CD3OD) δH 8.00 (1H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.53 (1H, dd, J 8.0, 1.5
Hz, CH (ar)), 7.48 (1H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 7.20 (1H, ddd, J 8.0,
6.5, 1.5 Hz, CH (ar)), 6.28 (1H, s, CH (ar)), 4.33 (2H, t, J 5.5 Hz, OCH2), 3.10
(2H, t, J 5.5 Hz, OCH2CH2), 2.81-2.73 (4H, m, NCH2(CH2)2), 1.94-1.82 (4H, m,
NCH2CH2CH2);
13C-NMR (100 MHz, CD3OD) δC 163.0, 160.3, 148.0, 130.2,
124.1, 121.9, 121.6, 110.8, 90.4, 67.6, 54.8, 54.6, 23.3; HRMS (ES) calculated
for C15H20N3O ([M+H]
+) m/z: 258.1606, found 258.1611.
Chelidamic acid dimethyl ester (9)
N
H
COOMe
O
MeOOC
MeOH (100 ml) was cooled to -10 ◦C. SOCl2 (40 ml) was added slowly and drop-
wise under stirring. Chelidamic acid (8, 10.0 g, 54.6 mmol) was added and the
resulting mixture stirred at rt overnight. The solvent was removed in vacuo. The
product was dissolved in H2O (100 ml). The crude product crashed out, was
filtered and recrystallised from hot EtOH to obtain the title compound as white
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crystals (9.1 g, 43.2 mmol, 85%). M.p. 168.5-169.0 ◦C; 1H-NMR (400 MHz,
CD3OD) δH 7.39 (2H, br s, CH), 3.92 (6H, s, CH3). The spectroscopic data were
in agreement with the literature. [184]
4-(2-((tert-Butoxycarbonyl)amino)ethoxy)pyridine-2,6 dicarboxylate
(11a)
N COOH
O
HOOC
NHBoc
Compound 9 (1.5 g, 7.1 mmol), N -Boc-ethanolamine (1.7 g, 10.5 mmol) and
triphenylphosphine (3.7 g, 14.1 mmol) were dissolved in freshly distilled THF (50
ml) and cooled to 0 ◦C. DIAD (1.9 ml, 9.9 mmol) was added dropwise under
argon. The mixture was allowed to warm to rt and stirred for 3 d. The solvent
was removed in vacuo and the product purified by column chromatography (50%
EtOAc, 50% petroleum ether) to obtain the dimethyl ester of the title compound
as a white powder. This compound was dissolved in MeOH (50 ml) and depro-
tected by slowly adding a solution of NaOH (0.4 g, 10.6 mmol) in H2O (50 ml).
The solvent was evaporated in vacuo and the remaining solid dissolved in H2O.
The solution was acidified with 5% HCOOH (aq.) and extracted with EtOAc.
The organic layer was dried over MgSO4, filtered, and the solvent removed in
vacuo to obtain the title compound as a white powder (1.5 g, 4.6 mmol, 64%).
1H-NMR (500 MHz, CD3OD) δH 7.86 (2H, s, CH (ar)), 4.26 (2H, t, J 5.0 Hz,
OCH2), 3.49 (2H, t, J 5.0 Hz, OCH2CH2), 1.42 (9H, s, CH3);
13C-NMR (125
MHz, CD3OD) δC 169.4, 167.0, 158.4, 150.3, 115.2, 80.5, 69.6, 40.7, 28.6; HRMS
(ES) calculated for C14H17N2O7 ([M-H]
−) m/z: 325.1041, found 325.1046.
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4-(2-(Pyrrolidin-1-yl)ethoxy)pyridine-2,6 dicarboxylate (11b)
N COOH
O
HOOC
N
Compound 9 (1.0 g, 4.7 mmol), N -hydroxyethyl-pyrrolidine (0.8 ml, 9.4 mmol)
and triphenylphosphine (2.5 g, 9.4 mmol) were dissolved in freshly distilled THF
(50 ml) and cooled to 0 ◦C. DIAD (1.8 ml, 9.4 mmol) was added dropwise under
argon. The mixture was allowed to warm to rt and stirred for 3 d. The solvent
was removed in vacuo and the product purified by column chromatography (50%
EtOAc, 49% petroleum ether, 1% TEA) to obtain the dimethyl ester of the title
compound as a white powder. This compound was dissolved in MeOH (50 ml)
and deprotected by slowly adding a solution of NaOH (0.4 g, 10.3 mmol) in H2O
(50 ml). The solvent was evaporated in vacuo and the remaining solid dissolved in
H2O. The product was purified by HPLC (gradient: 10% MeCN/90% H2O, 0.1%
TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=7.0-7.5 min) to obtain the TFA
salt of the title compound (11b·CF3CO2H, 1.3 g, 3.1 mmol, 66%). 1H-NMR
(400 MHz, D2O) δH 7.39 (2H, s, CH (ar)), 4.21 (2H, t, J 5.5 Hz, OCH2), 2.94
(2H, t, J 5.5 Hz, OCH2CH2), 2.71-2.59 (4H, m, NCH2(CH2)2), 1.75-1.62 (4H, m,
NCH2CH2CH2);
13C-NMR (100 MHz, D2O) δC 173.2, 166.8, 155.3, 111.7, 66.6,
54.1, 53.9, 23.1; HRMS (ES) calculated for C13H16N2NaO5 ([M+Na]
+) m/z:
303.0951, found 303.0962.
4-(Prop-2-yn-1-yloxy)pyridine-2,6 dicarboxylate (11c)
N COOH
O
HOOC
Compound 9 (0.8 g, 3.5 mmol), propargyl alcohol (0.3 ml, 4.6 mmol) and triph-
enylphosphine polymer bound (1.6 g, 3.0 mmol loading/ g) were added to freshly
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distilled THF (50 ml) and cooled to 0 ◦C. DIAD (0.9 ml, 4.9 mmol) was added
dropwise under argon. The mixture was allowed to warm to rt and stirred for 3 d.
The solution was filtered and the solvent was removed in vacuo and the product
purified by column chromatography (50% EtOAc, 50% petroleum ether) to obtain
the dimethyl ester of the title compound as a white powder. This compound was
dissolved in MeOH (50 ml) and deprotected by slowly adding a solution of NaOH
(0.3 g, 7.7 mmol) in H2O (50 ml). The solvent was evaporated in vacuo and the
remaining solid dissolved in H2O. The solution was acidified with 5% HCOOH
(aq.) and extracted with EtOAc. The organic layer was dried over MgSO4, fil-
tered, and the solvent removed in vacuo to obtain the title compound as a white
powder (0.6 g, 2.7 mmol, 77%). 1H-NMR (400 MHz, CD3OD) δH 7.95 (2H, s,
CH (ar)), 5.04 (2H, d, J 2.5 Hz, OCH2), 3.16 (1H, t, J 2.5 Hz, CH);
13C-NMR
(100 MHz, CD3OD) δC 167.1, 165.9, 149.5, 114.4, 78.8, 76.8, 56.5; HRMS (ES)
calculated for C10H8NO5 ([M+H]
+) m/z: 222.0402, found 222.0398.
4-(4-Fluoro-benzyloxy)-pyridine-2,6 dicarboxylate (11d)
N COOH
O
HOOC
F
Compound 9 (0.7 g, 3.5 mmol), (4-fluorophenyl)methanol (0.6 g, 4.6 mmol) and
triphenylphosphine (1.8 g, 7.0 mmol) were dissolved in freshly distilled THF (50
ml) and cooled to 0 ◦C. DIAD (1.0 ml, 5.0 mmol) was added dropwise under
argon. The mixture was allowed to warm to rt and stirred for 3 d. The solvent
was removed in vacuo and the product purified by column chromatography (50%
EtOAc, 50% petroleum ether) to obtain the dimethyl ester of the title compound
as a white powder. This compound was dissolved in MeOH (50 ml) and depro-
tected by slowly adding a solution of NaOH (0.3 g, 7.7 mmol) in H2O (50 ml).
The solvent was evaporated in vacuo and the remaining solid dissolved in H2O.
The solution was acidified with 5% HCOOH (aq.) and extracted with EtOAc.
The organic layer was dried over MgSO4, filtered, and the solvent removed in
vacuo to obtain the title compound as a white powder (0.7 g, 2.0 mmol, 57%).
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1H-NMR (400 MHz, CDCl3) δH 7.88 (2H, s, CH (ar)), 7.45-7.40 (2H, m, CH
(ar)), 7.14-7.07 (2H, m, CH (ar)), 5.20 (2H, s, OCH2), 4.01;
13C-NMR (100
MHz, CDCl3) δC 166.5, 165.8, 162.9 (d, J 246 Hz), 149.9, 130.5, 122.7 (d, J 8
Hz), 115.8 (d, J 22 Hz), 114.7, 70.1; HRMS (ES) calculated for C16H11FNO5
([M+H]+) m/z: 292.0621, found 292.0632.
Dimethyl 4-chloropyridine-2,6 dicarboxylate (12)
N COOMe
Cl
MeOOC
Chelidamic acid (8, 10.0 g, 54.6 mmol) was dissolved in SOCl2 (100 ml) and
refluxed overnight. The solvent was removed in vacuo and a yellow solid was
obtained, which was quenched with freshly distilled MeOH (100 ml) at 0 ◦C. The
excess solvent was then removed in vacuo. The crude product was dissolved in
sat. aq. NaHCO3 solution (200 ml) and extracted with EtOAc (100 ml) to afford
the title compound as a white powder (3.5 g, 16.1 mmol, 28%). 1H-NMR (500
MHz, CDCl3) δH 8.28 (2H, s, CH (ar)), 4.02 (6H, s, CH3);
13C-NMR (125
MHz, CDCl3) δC 164.1, 149.4, 146.8, 128.3, 53.5; HRMS (ES) calculated for
C9H9ClNO4 ([M+H]
+) m/z: 230.0215, found 230.0206.
4-Chloropyridine-2,6 dicarboxylate (13)
N COOH
Cl
HOOC
Compound 12 (1.0 g, 4.3 mmol) was dissolved in MeOH (100 ml) and deprotected
by slowly adding a solution of NaOH (0.4 g, 9.5 mmol) in H2O (100 ml). The
solvent was evaporated in vacuo and the remaining solid dissolved in H2O. The
solution was acidified with 5% HCOOH (aq.) and extracted with EtOAc. The
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organic layer was dried over MgSO4, filtered, and the solvent removed in vacuo to
obtain the title compound as a white powder (0.9 g, 4.3 mmol, 99%). 1H-NMR
(500 MHz, CD3OD) δH 8.34 (2H, s, CH (ar));
13C-NMR (125 MHz, CDCl3) δC
166.1, 150.6, 148.5, 129.0; HRMS (ES) calculated for C7H5ClNO4 ([M+H]
+)
m/z: 201.9901, found 201.9894.
Dimethyl 4-methoxypyridine-2,6 dicarboxylate (14).
N COOMe
OMe
MeOOC
Chelidamic acid (8, 0.2 g, 1.1 mmol) was dissolved in a 3:2 mixture of PhMe:MeOH
(50 ml). Me3SiCHN2 (2 M, 1.8 ml, 3.5 mmol) was added dropwise and the re-
action left to stir for 30 min at rt. The solvent was removed in vacuo and the
crude product dissolved in sat. aq. NaHCO3 solution. The aqueous layer was
extracted with EtOAc and the organic layer dried over MgSO4, filtered, and the
solvent removed in vacuo to obtain the product as a white powder (0.2 g, 0.9
mmol, 90%). 1H-NMR (400 MHz, DMSO-d6) δH 7.60 (2H, s, CH (ar)), 3.84
(3H, s, OCH3), 3.77 (6H, s, COOCH3);
13C-NMR (100 MHz, DMSO-d6) δC
167.6, 165.2, 149.9, 114.3, 56.7, 53.0; HRMS (ES) calculated for C10H12NO5
([M+H]+) m/z: 226.0715, found 226.0721.
4-Methoxypyridine-2,6 dicarboxylate (15).
N COOH
OMe
HOOC
Compound 14 (0.2 g, 0.9 mmol) was dissolved in MeOH (50 ml) and deprotected
by slowly adding a solution of NaOH (0.1 g, 1.9 mmol) in H2O (50 ml). The
solvent was evaporated in vacuo and the remaining solid dissolved in H2O. The
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solution was acidified with 5% HCOOH (aq.) and extracted with EtOAc. The
organic layer was dried over MgSO4, filtered, and the solvent removed in vacuo to
obtain the title compound as a white powder (0.2 g, 0.9 mmol, 99%). 1H-NMR
(400 MHz, CD3OD) δH 7.58 (2H, s, CH (ar)), 3.84 (3H, s, CH3);
13C-NMR
(125 MHz, CDCl3) δC 168.0, 165.7, 150.2, 113.7, 56.6; HRMS (ES) calculated
for C8H6NO5 ([M-H]
−) m/z: 196.0246, found 196.0237.
4-(2-tert-Butoxycarbonylamino-propoxy)-quinolin-2-ylamine (16a)
N NH2
O NHBoc
2-Aminoquinolin-4(1H )-one (4, 1.0 g, 6.2 mmol), N -Boc-propanolamine (1.6 g,
9.1 mmol) and triphenylphosphine (3.3 g, 12.6 mmol) were dissolved in freshly
distilled THF (10 ml) and cooled to 0 ◦C. DIAD (1.8 ml, 9.4 mmol) was added
dropwise under argon. The mixture was allowed to warm to rt and stirred for 3
d. The solvent was removed in vacuo and the product purified by column chro-
matography (90% EtOAc, 10% MeOH) to obtain the title compound as a white
powder (1.4 g, 4.4 mmol, 71%). 1H-NMR (400 MHz, CD3OD) δH 7.98 (1H, dd,
J 8.0, 1.0 Hz, CH (ar)), 7.55-7.45 (2H, m, CH (ar)), 7.19 (1H, ddd, J 8.0, 6.5, 1.0
Hz, CH (ar)), 6.42 (1H, s, CH (ar)); 4.21 (2H, t, J 6.0 Hz, OCH2), 3.40-3.30 (2H,
m, OCH2CH2), 2.15-2.04 (2H, m, O(CH2)2CH2), 1.43 (9H, s, CH3);
13C-NMR
(100 MHz, CD3OD) δC 163.0, 160.2, 157.6, 148.0, 130.2, 124.1, 122.0, 121.5,
117.7, 90.3, 79.0, 66.3, 37.5, 29.7, 27.8; HRMS (ES) calculated for C17H24N3O3
([M+H]+) m/z: 318.1812, found 318.1824.
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4-(2-(Dimethylamino)ethoxy)quinolin-2-amine (16b)
N NH2
O N
2-Aminoquinolin-4(1H )-one (4, 1.0 g, 6.3 mmol), 3-dimethylaminoethanol (0.7 g,
7.8 mmol) and triphenylphosphine (3.3 g, 12.6 mmol) were dissolved in freshly
distilled THF (100 ml) and cooled to 0 ◦C. DIAD (1.2 g, 5.9 mmol) was added
dropwise under argon. The mixture was allowed to warm to rt and stirred for 3
d. The solvent was removed in vacuo and the product purified by column chro-
matography (87% EtOAc, 10% MeOH, 3% TEA) to obtain the title compound as
a pale yellow powder (1.0 g, 4.3 mmol, 68%). 1H-NMR (400 MHz, CD3OD) δH
8.01 (1H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.55-7.43 (2H, m, CH (ar)), 7.20 (1H, ddd,
J 8.0, 6.5, 1.0, CH (ar)), 6.27 (1H, s, CH (ar)); 4.31 (2H, t, J 5.5 Hz, OCH2),
2.95 (2H, t, J 5.5 Hz, OCH2CH2), 2.43 (6H, s, CH3);
13C-NMR (100 MHz,
CD3OD) δC 162.8, 160.0, 148.0, 130.3, 123.9, 122.0, 121.7, 117.6, 90.5, 66.5, 57.7,
45.1; HRMS (ES) calculated for C13H18N3O ([M+H]
+) m/z: 232.1444, found
232.1449.
4-(3-Dimethylaminopropoxy)quinolin-2-amine (16c)
N NH2
O N
2-Aminoquinolin-4(1H )-one (4, 1.0 g, 6.3 mmol), 3-dimethylamino-1-propanol
(0.8 g, 7.8 mmol) and triphenylphosphine (3.3 g, 12.6 mmol) were dissolved in
of freshly distilled THF (100 ml) and cooled to 0 ◦C. DIAD (1.2 g, 5.9 mmol)
was added dropwise under argon. The mixture was allowed to warm to rt and
stirred for 3 d. The solvent was removed in vacuo and the product purified by
column chromatography (87% EtOAc, 10% MeOH, 3% TEA) to obtain the title
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compound as a pale yellow powder (1.0 g, 4.1 mmol, 65%). 1H-NMR (400 MHz,
CD3OD) δH 7.95 (1H, dd, J 8.0, 1.5 Hz, CH (ar)), 7.55-7.45 (2H, m, CH (ar)),
7.20 (1H, ddd, J 8.0, 6.5, 1.5 Hz, CH (ar)), 6.25 (1H, s, CH (ar)); 4.22 (2H, t, J
5.5 Hz, OCH2), 2.65-2.60 (2H, m, OCH2CH2), 2.34 (6H, s, CH3), 2.18-2.10 (2H,
m, O(CH2)2CH2);
13C-NMR (100 MHz, CD3OD) δC 162.9, 160.0, 147.9, 130.2,
123.9, 121.7, 121.6, 117.6, 90.4, 66.7, 56.3, 44.5, 26.9; HRMS (ES) calculated
for C14H20N3O ([M+H]
+) m/z: 246.1600, found 246.1601.
4-Methoxyquinolin-2-ylamine (17)
N NH2
OMe
2-Aminoquinolin-4(1H )-one (4, 0.3 g, 1.9 mmol) was dissolved in a solution of
PhMe:MeOH (50 ml). Me3SiCHN2 (2 M, 2.0 ml, 4.0 mmol) was added dropwise
and the reaction left to stir for 30 min at rt. The solvent was removed in vacuo
and the crude product dissolved in aq. NaOH (0.1 M) solution. The aq. layer
was extracted with EtOAc and the organic layer dried over MgSO4, filtered, and
the solvent removed in vacuo to obtain the product as a white powder (0.2 g,
1.1 mmol, 55%). 1H-NMR (400 MHz, CD3OD) δH 7.93 (1H, br d, J 8.5 Hz,
CH (ar)), 7.53-7.44 (2H, m, CH (ar)); 7.21-7.15 (1H, m, CH (ar)), 6.26 (1H, s,
CH (ar)), 3.23 (3H, s, CH3);
13C-NMR (100 MHz, CD3OD) δC 163.8, 160.5,
148.1, 130.1, 124.1, 122.7, 121.6, 118.7, 89.8, 89.8; HRMS (ES) calculated for
C10H11N2O ([M+H]
+) m/z: 175.0871, found 175.0861.
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N 2,N 6-bis(4-(2-Aminoethoxy)quinolin-2-yl)pyridine-
2,6 dicarboxamide (18)
NO O
HNNH
N N
O O NH2H2N
Following procedure G2, 7 (50 mg, 0.245 mmol), 5a (150 mg, 0.495 mmol) and
TEA (75 µl, 0.539 mmol) were reacted to afford the TFA salt of the title com-
pound as a white powder (18·2CF3CO2H, 120 mg, 0.151 mmol, 62%). 1H-NMR
(400 MHz, CD3OD) δH 8.70 (2H, d, J 8.0 Hz, CH (ar)), 8.56 (2H, dd, J 8.0, 1.0
Hz, CH (ar)), 8.46 (1H, t, J 8.0 Hz, CH (ar)), 8.20 (2H, s, CH (ar)), 8.14 (2H,
br d, J 8.5 Hz, CH (ar)), 8.02 (2H, ddd, J 8.5, 7.0, 1.0 Hz, CH (ar)), 7.76 (2H,
ddd, J 8.0, 7.0, 1.0 Hz, CH (ar)), 4.83 (4H, t, J 5.0 Hz, OCH2), 3.72 (4H, t, J 5.0
Hz, OCH2CH2);
13C-NMR (100 MHz, CD3OD) δC 166.5, 164.3, 151.4, 147.9,
141.2, 141.0, 134.9, 127.5, 127.0, 123.3, 122.5, 119.0, 94.3, 66.9, 38.8; HRMS
(ES) calculated for C29H28N7O4 ([M+H]
+) m/z: 538.2197, found 538.2183.
N 2,N 6-bis(4-(3-Aminopropoxy)quinolin-2-yl)pyridine-
2,6 dicarboxamide (19)
NO O
HNNH
N N
O OH2N NH2
Following procedure G2, 7 (50 mg, 0.245 mmol), 16a (150 mg, 0.473 mmol)
and TEA (75 µl, 0.539 mmol) were reacted to afford the TFA salt of the title
compound as a white powder (19·2CF3CO2H, 150 mg, 0.891 mmol, 77%). 1H-
NMR (400 MHz, CD3OD) δH 8.69 (2H, d, J 8.0 Hz, CH (ar)), 8.48 (1H, t,
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J 8.0 Hz, CH (ar)), 8.39 (2H, br d, J 8.5 Hz, CH (ar)), 8.16-8.11 (4H, m, CH
(ar)), 8.05-8.00 (2H, m, CH (ar)), 7.78-7.73 (2H, m, CH (ar)), 4.74-4.68 (4H,
m, OCH2), 3.40-3.34 (4H, m, OCH2CH2), 2.52-2.44 (4H, m, O(CH2)2CH2);
13C-
NMR (100 MHz, CD3OD) δC 167.4, 163.7, 151.3, 147.8, 141.1, 140.2, 133.8,
127.6, 127.1, 123.0, 121.9, 119.1, 94.3, 67.9, 37.1, 27.0; HRMS (ES) calculated
for C31H32N7O4 ([M+H]
+) m/z: 566.2510, found 566.2498.
N 2,N 6bis(4-(2-(Pyrrolidin-1-yl)ethoxy)quinolin-2-yl)pyridine-
2,6 dicarboxamide (20)
NO O
HNNH
N N
O O NN
Following procedure G2, 7 (50 mg, 0.245 mmol), 5b (151 mg, 0.587 mmol) and
TEA (75 µl, 0.539 mmol) were reacted to afford the TFA salt of the title com-
pound as a pale yellow powder (20·2CF3CO2H, 175 mg, 0.200 mmol, 82%). 1H-
NMR (400 MHz, CD3OD) δH 8.46 (2H, d, J 8.0 Hz, CH (ar)), 8.38 (1H, t, J 8.0
Hz, CH (ar)), 8.33 (2H, br d, J 8.0 Hz, CH (ar)), 8.19 (2H, s, CH (ar)), 7.98 (2H,
br d, J 8.5 Hz, CH (ar)), 7.83 (2H, ddd, J 8.5, 7.0, 1.0 Hz, CH (ar)), 7.57 (2H, ddd,
J 8.0, 7.0, 1.0 Hz, CH (ar)), 4.66 (4H, t, J 4.0 Hz, OCH2), 3.85 (4H, t, J 4.0 Hz,
OCH2CH2), 3.81-3.69 (4H, m, NCH2(CH2)2), 3.38-3.28 (4H, m, NCH2(CH2)2),
2.17-2.04 (4H, m, NCH2CH2CH2), 2.04-1.88 (4H, m, NCH2CH2CH2);
13C-NMR
(100 MHz, CD3OD) δC 163.8, 162.1, 158.9, 158.5, 152.8 147.2, 131.1, 127.0,
126.5, 125.1, 122.5, 119.0, 95.6, 64.8, 54.6, 53.1, 23.0; HRMS (ES) calculated
for C37H40N7O4 ([M+H]
+) m/z: 646.3142, found 646.3168.
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N 2,N 6-bis(4-(2-(Dimethylamino)ethoxy)quinolin-2-yl)pyridine-
2,6 dicarboxamide (21)
NO O
HNNH
N N
O O NN
Following procedure G2, 7 (50 mg, 0.245 mmol), 16b (113 mg, 0.489 mmol) and
TEA (75 µl, 0.539 mmol) were reacted to afford the TFA salt of the title com-
pound as a white powder (21·2CF3CO2H, 138 mg, 0.168 mmol, 68%). 1H-NMR
(400 MHz, CD3OD) δH 8.70 (2H, d, J 8.0 Hz, CH (ar)), 8.50-8.48 (3H, m, CH
(ar)), 8.24 (2H, s, CH (ar)), 8.14 (2H, br d, J 8.0 Hz, CH (ar)), 8.03-7.98 (2H, m,
CH (ar)), 7.76-7.72 (2H, m, CH (ar)), 4.98-4.92 (4H, m, OCH2), 3.98-3.93 (4H, m,
OCH2CH2), 3.16 (12H, s, CH3);
13C-NMR (100 MHz, CD3OD) δC 165.6, 163.5,
151.5, 147.9, 142.1, 141.0, 133.5, 127.4, 126.9, 123.2, 119.1, 118.1, 94.6, 64.7, 56.2,
43.2; HRMS (ES) calculated for C33H36N7O4 ([M+H]
+) m/z: 594.2829, found
594.2825.
N 2,N 6-bis(4-(3-(Dimethylamino)propoxy)quinolin-2-yl)pyridine-
2,6 dicarboxamide (22)
NO O
HNNH
N N
O ON N
Following procedure G2, 7 (50 mg, 0.245 mmol), 16c (120 mg, 0.489 mmol) and
TEA (75 µl, 0.539 mmol) were reacted to afford the TFA salt of the title com-
pound as a white powder (22·2CF3CO2H, 148 mg, 0.174 mmol, 71%). 1H-NMR
(400 MHz, CD3OD) δH 8.66 (2H, d, J 8.0 Hz, CH (ar)), 8.45 (1H, t, J 8.0 Hz, CH
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(ar)), 8.41 (2H, br d, J 8.0 Hz, CH (ar)), 8.16-8.05 (4H, m, CH (ar)), 8.04-8.00
(2H, m, CH (ar)), 7.78-7.73 (2H, m, CH (ar)), 4.72-4.66 (4H, m, OCH2), 3.60-
3.51 (4H, m, OCH2CH2), 3.04 (12H, s, CH3), 2.62-2.50 (4H, m, O(CH2)2CH2);
13C-NMR (100 MHz, CD3OD) δC 167.5, 163.7, 151.2, 147.7, 141.0, 140.0, 133.8,
127.6, 127.2, 123.3, 121.7, 119.0, 94.3, 67.7, 55.1, 42.6, 24.5; HRMS (ES) calcu-
lated for C35H40N7O4 ([M+H]
+) m/z: 622.3123, found 622.3119.
4-(2-Aminoethoxy)-N 2,N 6-bis(4-(2-aminoethoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (23, pyridostatin)
NO O
HNNH
N N
O O NH2H2N
O NH2
3
4
1
2
Following procedure G3, 11a (110 mg, 0.337 mmol), 5a (205 mg, 0.675 mmol),
TEA (103 µl, 0.742 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (98 µl,
0.742 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (23·3CF3CO2H, 210 mg, 0.224 mmol, 66%). 1H-NMR (400 MHz,
CD3OD) δH 8.43 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 8.16 (2H, s, CH (ar)), 8.16
(2H, s, CH (ar)), 7.98 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.83 (2H, ddd, J 8.0, 7.0,
1.0 Hz, CH (ar)), 7.61 (2H, ddd, J 8.5, 7.0, 1.0 Hz, CH (ar)), 4.68 (4H, t, J 5.5
Hz, OCH2 (3)), 4.57 (2H, t, J 5.0 Hz, OCH2 (1)), 3.63 (4H, t, J 5.5 Hz, OCH2CH2
(4)), 3.51 (2H, t, J 5.0 Hz, OCH2CH2 (2));
13C-NMR (125 MHz, CD3OD) δC
169.0, 165.0, 164.0, 152.9, 151.9, 146.7, 132.9, 126.8, 126.8, 123.6, 120.5, 113.7,
95.7, 66.9, 66.7, 39.9, 39.9; HRMS (ES) calculated for C31H33N8O5 ([M+H]
+)
m/z: 597.2574, found 597.2550.
117
5.1 Synthesis
4-(2-Aminoethoxy)-N 2,N 6-bis(4-(3-aminopropoxy)quinolin-2-yl)-
pyridine-2,6 dicarboxamide (24)
NO O
HNNH
N N
O O
O NH2
H2N NH2
Following procedure G3, 11a (76 mg, 0.223 mmol), 16a (150 mg, 0.473 mmol),
TEA (71 µl, 0.413 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (68 µl,
0.413 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (24·3CF3CO2H, 178 mg, 0.184 mmol, 79%). 1H-NMR (400 MHz,
CD3OD) δH 8.37 (2H, br d, J 8.0 Hz, CH (ar)), 8.23 (2H, s, CH (ar)), 8.19 (2H,
s, CH (ar)), 8.10 (2H, br d, J 8.0 Hz, CH (ar)), 8.02-7.95 (2H, m, CH (ar)), 7.76-
7.69 (2H, m, CH (ar)), 4.73-4.61 (6H, m, OCH2), 3.59-3.49 (2H, m, OCH2CH2N),
3.41-3.35 (4H, m, OCH2CH2CH2), 2.52-2.42 (4H, m, O(CH2)2CH2);
13C-NMR
(100 MHz, CD3OD) δC 162.7, 157.9, 151.1, 149.9, 143.0, 132.7, 130.2, 128.1,
126.2, 123.1, 122.3, 118.9, 112.7, 93.9, 69.1, 66.9, 36.8, 26.7; HRMS (ES) calcu-
lated for C33H37N8O5 ([M+H]
+) m/z: 625.2887, found 625.2865.
4-(2-Aminoethoxy)-N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)
quinolin-2-yl)-pyridine-2,6 dicarboxamide (25)
NO O
HNNH
N N
O O NN
O NH2
Following procedure G3, 11a (230 mg, 0.705 mmol), 5b (360 mg, 1.399 mmol),
TEA (216 µl, 1.552 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (205
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µl, 1.552 mmol) were reacted to afford the TFA salt of the title compound
as a white powder (25·3CF3CO2H, 550 mg, 0.525 mmol, 74%). 1H-NMR
(400 MHz, CD3OD) δH 8.48 (2H, br d, J 8.0 Hz, CH (ar)), 8.21 (2H, s, CH
(ar)), 8.17 (2H, s, CH (ar)), 8.12 (2H, br d, J 8.0 Hz, CH (ar)), 8.01 (2H,
ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 7.75 (2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)),
4.98-4.93 (4H, m, OCH2CH2NCH2), 4.69-4.63 (2H, m, OCH2CH2NH2), 4.07-3.99
(4H, m, OCH2CH2NCH2), 3.97-3.85 (4H, m, NCH2(CH2)2), 3.61-3.53 (2H, m,
OCH2CH2NH2), 3.48-3.34 (4H, m, NCH2(CH2)2), 2.36-2.08 (8H, m, NCH2CH2-
CH2);
13C-NMR (100 MHz, CD3OD) δC 168.2, 167.2, 163.7, 151.0, 149.7 139.5,
134.4, 127.6, 123.5, 121.3, 118.8, 113.9, 94.7, 66.4, 65.7, 55.2, 53.6, 39.1, 23.1;
HRMS (ES) calculated for C39H45N8O5 ([M+H]
+) m/z: 705.3501,
found 705.3510.
4-(2-(Pyrrolidin-1-yl)ethoxy)-N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)
quinolin-2-yl)pyridine-2,6 dicarboxamide (26)
NO O
HNNH
N N
O O NN
O N
5
6
1
2 3
4
7
8
Following procedure G3, the TFA salt of 11b (52 mg, 0.132 mmol), 5b (70
mg, 0.271 mmol), TEA (40 µl, 0.290 mmol) and 1-chloro-N,N,2-trimethylpro-
penyl-amine (38 µl, 0.290 mmol) were reacted to afford the TFA salt of the title
compound as a white powder (26·3CF3CO2H, 88 mg, 0.080 mmol, 61%). 1H-
NMR (400 MHz, CD3OD) δH 8.47 (2H, br d, J 8.5 Hz, CH (ar)), 8.22 (2H, s,
CH (ar)), 8.20 (2H, s, CH (ar)), 8.12 (2H, br d, J 8.5 Hz, CH (ar)), 8.02-7.96
(2H, m, CH (ar)), 7.75-7.70 (2H, m, CH (ar)), 4.95-4.90 (4H, m, OCH2 (5)), 4.78-
4.74 (2H, m, OCH2 (1)), 4.05-3.76 (12H, m, NCH2(CH2)2, (3,7)), 3.50-3.35 (6H,
m, OCH2CH2 (2,6)), 2.34-2.07 (12H, m, NCH2CH2CH2 (4,8));
13C-NMR (100
MHz, CD3OD) δC 165.9, 163.1, 151.3, 150.1, 142.0, 133.3, 126.8, 123.1, 119.1,
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118.5, 115.5, 113.4, 94.4, 65.8, 64.7, 55.1, 55.0, 54.9, 53.6, 23.0, 22.9; HRMS
(ES) calculated for C43H51N8O5 ([M+H]
+) m/z: 759.3977, found 759.3980.
N 2,N 6-bis(4-(2-Aminoethoxy)quinolin-2-yl)-4-(prop-2-yn-1-yloxy)
pyridine-2,6 dicarboxamide (27)
NO O
HNNH
N N
O O NH2H2N
O
Following procedure G3, 11c (115 mg, 0.520 mmol), 5a (315 mg, 1.040 mmol),
TEA (160 µl, 1.145 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (151 µl,
1.145 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (27·2CF3CO2H, 395 mg, 0.482 mmol, 93%). 1H-NMR (400 MHz,
CD3OD) δH 8.57 (2H, br d, J 8.0 Hz, CH (ar)), 8.27-8.24 (4H, m, CH (ar)), 8.16
(2H, br d, J 8.0 Hz, CH (ar)), 8.08-8.02 (2H, m, CH (ar)), 7.82-7.76 (2H, m, CH
(ar)), 5.20-5.17 (2H, m, OCH2C), 4.89-4.85 (4H, m, OCH2), 3.76-3.70 (4H, m,
OCH2CH2), 3.26-3.25 (1H, m, CH);
13C-NMR (100 MHz, CD3OD) δC 167.7,
167.2, 163.9, 151.3, 149.5, 139.1, 134.1, 127.5, 123.6, 121.4, 118.8, 114.2, 94.6,
78.6, 76.4, 67.4, 56.8, 38.6; HRMS (ES) calculated for C33H30N7O5 ([M+H]
+)
m/z: 592.2284, found 592.2297.
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N 2,N 6-bis(4-(3-Aminopropoxy)quinolin-2-yl)-4-(prop-2-yn-1-yloxy)
pyridine-2,6 dicarboxamide (28)
NO O
HNNH
N N
O O
O
H2N NH2
Following procedure G3, 11c (115 mg, 0.520 mmol), 16a (360 mg, 1.078 mmol),
TEA (160 µl, 1.145 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (151 µl,
1.145 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (28·2CF3CO2H, 350 mg, 0.413 mmol, 79%). 1H-NMR (400 MHz,
CD3OD) δH 8.38 (2H, br d, J 8.0 Hz, CH (ar)), 8.24 (2H, s, CH (ar)), 8.15-8.11
(4H, m, CH (ar)), 8.04-7.99 (2H, m, CH (ar)), 7.78-7.72 (2H, m, CH (ar)), 5.18-
5.16 (2H, m, OCH2C), 4.72-4.67 (4H, m, OCH2), 3.39-3.35 (4H, m, OCH2CH2),
3.26-3.24 (1H, m, CH), 2.52-2.44 (4H, m, O(CH2)2CH2);
13C-NMR (100 MHz,
CD3OD) δC 168.1, 167.0, 163.3, 151.4, 149.9, 140.9, 133.5, 127.3, 123.2, 122.5,
119.1, 113.7, 94.3, 78.2, 76.6, 67.8, 57.0, 37.2, 27.0; HRMS (ES) calculated for
C34H34N7O5 ([M+H]
+) m/z: 620.2621, found 620.2612.
4-Methoxy-N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (29)
NO O
HNNH
N N
O O NN
OMe
Following procedure G3, 15 (50 mg, 0.255 mmol), 5b (132 mg, 0.510 mmol),
TEA (76 µl, 0.546 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (72 µl,
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0.546 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (29·2CF3CO2H, 140 mg, 0.207 mmol, 81%). 1H-NMR (400 MHz,
CD3OD) δH 8.33 (2H, br d, J 8.5 Hz, CH (ar)), 8.17 (2H, s, CH (ar)), 7.97 (4H,
m, CH (ar)), 7.82 (2H, ddd, J 8.5, 7.0, 1.0 Hz, CH (ar)), 7.58 (2H, ddd, J 8.5, 7.0,
1.0 Hz, CH (ar)), 4.07 (3H, s, CH3), 3.87-3.62 (8H, m, OCH2, OCH2CH2), 3.32-
3.20 (4H, m, NCH2(CH2)2), 2.61-2.51 (4H, m, NCH2(CH2)2), 2.17-1.88 (8H, m,
NCH2CH2CH2);
13C-NMR (100 MHz, CD3OD) δC 166.1, 162.7, 151.6, 149.7,
148.9, 142.7, 134.0, 128.1, 126.8, 123.4, 119.3, 115.6, 94.6, 66.1, 54.1, 53.5, 45.8,
23.6; HRMS (ES) calculated for C38H42N7O5 ([M+H]
+) m/z: 676.3245, found
676.3241.
4-Methoxy-N 2,N 6-bis(4-methoxyquinolin-2-yl)
pyridine-2,6 dicarboxamide (30)
NO O
HNNH
N N
MeO OMe
OMe
1
2
Following procedure G3, 15 (100 mg, 0.510 mmol), 17 (178 mg, 1.020 mmol),
TEA (152 µl, 1.091 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (144 µl,
1.091 mmol) were reacted to afford the title compound as a white powder (137
mg, 0.270 mmol, 53%). 1H-NMR (400 MHz, CD3OD) δH 8.42 (2H, br d, J 8.0
Hz, CH (ar)), 8.22 (2H, s, CH (ar)), 8.13 (2H, s, CH (ar)), 8.06 (2H, br d, J 8.0
Hz, CH (ar)), 7.94-7.90 (2H, m, CH (ar)), 7.70-7.65 (2H, m, CH (ar)), 4.87 (6H,
s, OCH3 (2)), 4.15 (3H, s, OCH3 (1));
13C-NMR (100 MHz, CD3OD) δC 162.8,
162.1, 152.6, 151.0, 147.4, 146.8, 131.2, 127.3, 126.4, 125.2, 122.6, 119.5, 95.4,
54.3, 53.2; HRMS (ES) calculated for C28H23N5O5 ([M+H]
+) m/z: 510.1777,
found 510.1787.
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4-Chloro-N 2,N 6-bis(4-(2-aminoethoxy)quinolin-2-yl)-pyridine-2,6
dicarboxamide (31)
NO O
HNNH
N N
O O
Cl
NH2H2N
Following procedure G3, 13 (100 mg, 0.496 mmol), 5a (300 mg, 0.989 mmol),
TEA (152 µl, 1.091 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (144 µl,
1.091 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (31·2CF3CO2H, 250 mg, 0.312 mmol, 63%). 1H-NMR (400 MHz,
CD3OD) δH 8.64 (2H, s, CH (ar)), 8.52 (2H, br d, J 8.5 Hz, CH (ar)), 8.15 (2H,
s, CH (ar)), 8.10 (2H, br d, J 8.5 Hz, CH (ar)), 7.97 (2H, m, CH (ar)), 7.72 (2H,
m, CH (ar)), 4.80 (4H, t, J 5.0 Hz, OCH2), 4.71 (4H, t, J 5.0 Hz, OCH2CH2);
13C-NMR (100 MHz, CD3OD) δC 166.1, 162.5, 151.4, 149.7, 148.8, 142.4, 133.2,
127.3, 126.6, 123.4, 119.4, 115.1, 94.7, 66.5, 38.8; HRMS (ES) calculated for
C29H27ClN7O4 ([M+H]
+) m/z: 572.1813, found 572.1824.
4-Chloro-N 2,N 6-bis(4-(3-aminopropoxy)quinolin-2-yl)-pyridine-2,6
dicarboxamide (32)
NO O
HNNH
N N
O O
Cl
H2N NH2
Following procedure G3, 13 (50 mg, 0.248 mmol), 16a (157 mg, 0.495 mmol),
TEA (76 µl, 0.546 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (72 µl,
0.546 mmol) were reacted to afford the TFA salt of the title compound as a
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white powder (32·2CF3CO2H, 164 mg, 0.198 mmol, 80%). 1H-NMR (400 MHz,
CD3OD) δH 8.59 (2H, s, CH (ar)), 8.35-8.31 (2H, m, CH (ar)), 8.10-8.04 (4H,
m, CH (ar)), 8.00-7.93 (2H, m, CH (ar)), 7.74-7.68 (2H, m, CH (ar)), 4.70-4.62
(4H, m, OCH2), 3.40-3.34 (4H, m, OCH2CH2), 2.53-2.43 (4H, m, O(CH2)2CH2);
13C-NMR (100 MHz, CD3OD) δC 166.9, 162.4, 151.2, 149.5, 141.1, 133.7, 127.3,
126.8, 123.0, 122.5, 119.2, 115.4, 94.2, 67.9, 37.0, 27.1; HRMS (ES) calculated
for C31H30ClN7NaO4 ([M+Na]
+) m/z: 601.3145, found 601.3155.
4-Chloro-N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (33)
NO O
HNNH
N N
O O
Cl
NN
Following procedure G3, 13 (100 mg, 0.496 mmol), 5b (295 mg, 0.991 mmol),
TEA (152 µl, 1.091 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (144 µl,
1.091 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (33·2CF3CO2H, 330 mg, 0.363 mmol, 73%). 1H-NMR (400 MHz,
CD3OD) δH 8.62 (2H, s, CH (ar)), 8.39 (2H, dd, J 8.5, 1.0 Hz, CH (ar)), 8.20
(2H, s, CH (ar)), 8.01 (2H, dd, J 8.5, 1.0 Hz, CH (ar)), 7.87 (2H, ddd, J 8.5, 6.5,
1.0 Hz, CH (ar)), 7.64 (2H, ddd, J 8.5, 6.5, 1.0 Hz, CH (ar)), 4.84 (4H, t, J 5.5
Hz, OCH2), 3.98 (4H, t, J 5.5 Hz, OCH2CH2), 3.95-3.81 (4H, m, NCH2(CH2)2),
3.48-3.36 (4H, m, NCH2(CH2)2), 2.35-2.04 (8H, m, NCH2CH2CH2);
13C-NMR
(100 MHz, CD3OD) δC 170.5, 163.7, 152.0, 150.4, 145.9, 142.4, 140.4, 131.8,
126.6, 126.1, 125.8, 122.3, 94.9, 64.9, 55.3, 53.8, 23.1; HRMS (ES) calculated
for C37H39ClN7O4 ([M+H]
+) m/z: 680.2747, found 680.2730.
124
5.1 Synthesis
4-Chloro-N 2,N 6-bis(4-(2-(dimethylamino)ethoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (34)
NO O
HNNH
N N
O O
Cl
NN
Following procedure G3, 13 (50 mg, 0.248 mmol), 16b (115 mg, 0.498 mmol),
TEA (76 µl, 0.546 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (72 µl,
0.546 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (34·2CF3CO2H, 165 mg, 0.193 mmol, 78%). 1H-NMR (400 MHz,
CD3OD) δH 8.46 (2H, s, CH (ar)), 8.35 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 8.16
(2H, s, CH (ar)), 7.98 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.82 (2H, ddd, J 8.0, 6.5,
1.0 Hz, CH (ar)), 7.57 (2H, ddd, J 8.0, 6.5, 1.0 Hz, CH (ar)), 4.72-4.68 (4H, m,
OCH2), 3.81-3.73 (4H, m, OCH2CH2), 3.00 (12H, s, CH3);
13C-NMR (100 MHz,
CD3OD) δC 162.5, 161.7, 152.3, 150.7, 147.2, 146.4, 131.1, 127.1, 126.1, 124.9,
122.2, 119.2, 95.4, 63.2, 55.4, 42.9; HRMS (ES) calculated for C33H35ClN7O4
([M+H]+) m/z: 628.2439, found 628.2441.
4-Chloro-N 2,N 6-bis(4-(3-(dimethylamino)propoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (35)
NO O
HNNH
N N
O O
Cl
N N
Following procedure G3, 13 (50 mg, 0.248 mmol), 16c (122 mg, 0.498 mmol),
TEA (76 µl, 0.546 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (72 µl,
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0.546 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (35·2CF3CO2H, 158 mg, 0.178 mmol, 72%). 1H-NMR (400 MHz,
CD3OD) δH 8.57 (2H, s, CH (ar)), 8.37 (2H, br d, J 8.0 Hz, CH (ar)), 8.10 (2H, br
d, J 8.0 Hz, CH (ar)), 8.01 (2H, s, CH (ar)), 8.00-7.96 (2H, m, CH (ar)), 7.76-7.71
(2H, m, CH (ar)), 4.68-4.64 (4H, m, OCH2), 3.59-3.52 (4H, m, OCH2CH2), 3.05
(12H, s, CH3), 2.60-2.51 (4H, m, O(CH2)2CH2 );
13C-NMR (100 MHz, CD3OD)
δC 167.2, 162.8, 150.9, 149.3, 140.2, 133.9, 127.6, 127.2, 123.1, 121.9, 118.9, 115.4,
94.5, 67.7, 55.2, 42.6, 24.5; HRMS (ES) calculated for C35H39ClN7O4 ([M+H]
+)
m/z: 656.2736, found 656.2747.
4-(4-Fluorobenzyloxy)-N 2,N 6-bis(4-(2-aminoethoxy)quinolin-2-yl)
pyridine-2,6 dicarboxamide (36)
NO O
HNNH
N N
O O
O
NH2H2N
F
1
Following procedure G3, 11d (8 mg, 0.024 mmol), 5a (13 mg, 0.049 mmol),
TEA (7 µl, 0.053 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (7 µl,
0.053 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (36·2CF3CO2H, 15 mg, 0.059 mmol, 61%). 1H-NMR (500 MHz,
CD3OD) δH 8.46 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 8.19 (2H, s, CH (ar)), 8.17
(2H, s, CH (ar)), 8.05 (2H, dd, J 8.0, 1.0 Hz, CH (ar)), 7.93 (2H, d, J 8.5 Hz, CH
(ar)), 7.68 (2H, d, J 8.5 Hz, CH (ar)), 7.61-7.57 (2H, m, CH (ar)), 7.20-7.14 (2H,
m, CH (ar)), 5.44 (2H, s, OCH2 (1)), 4.77 (4H, t, J 4.0 Hz, OCH2CH2), 3.68 (4H,
t, J 4.0 Hz, OCH2CH2);
13C-NMR (125 MHz, CD3OD) δC 169.8, 166.7, 164.3
(d, J 245 Hz), 164.2, 152.5, 151.0, 143.7, 134.1, 132.8, 131.2 (d, J 8 Hz), 127.6,
124.5, 124.1, 120.2, 116.5 (d, J 22 Hz), 114.5, 95.3, 71.7, 67.6, 39.8; HRMS (ES)
calculated for C36H33FN7O5 ([M+H]
+) m/z: 662.2521, found 662.2501.
126
5.1 Synthesis
4-(4-Fluorobenzyloxy)-N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)
quinolin-2-yl)pyridine-2,6 dicarboxamide (37)
NO O
HNNH
N N
O O
O
NN
F
1
Following procedure G3, 11d (12 mg, 0.041 mmol), 5b (23 mg, 0.089 mmol),
TEA (13 µl, 0.091 mmol) and 1-chloro-N,N,-2-trimethylpropenyl-amine (12 µl,
0.091 mmol) were reacted to afford the TFA salt of the title compound as a
white powder (37·2CF3CO2H, 26 mg, 0.026 mmol, 63%). 1H-NMR (400 MHz,
CD3OD) δH 8.42 (2H, br d, J 8.0 Hz, CH (ar)), 8.20 (2H, s, CH (ar)), 8.18 (2H,
s, CH (ar)), 8.07 (2H, br d, J 8.0 Hz, CH (ar)), 7.97-7.91 (2H, m, CH (ar)),
7.71-7.66 (2H, m, CH (ar)), 7.63-7.57 (2H, m, CH (ar)), 7.23-7.16 (2H, m, CH
(ar)), 5.46 (2H, s, OCH2 (1)), 4.94-4.87 (4H, m, OCH2CH2), 4.04-3.82 (8H, m,
NCH2(CH2)2), 3.48-3.36 (4H, m, OCH2CH2), 2.34-2.04 (8H, m, NCH2CH2CH2);
13C-NMR (100 MHz, CD3OD) δC 169.0, 165.4 (d, J 245.0 Hz), 163.3, 151.5,
150.1, 143.3, 133.0, 130.5 (d, J 8.0 Hz), 126.7, 124.0, 123.5, 122.8, 199.4, 115.9
(d, J 20.0 Hz), 115.3, 113.3, 94.5, 70.5, 65.6, 55.1, 53.9, 22.9; HRMS (ES) cal-
culated for C44H45N7O5F1 ([M+H]
+) m/z: 770.3461, found 770.3450.
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4-((1H-1,2,3-Triazol-4-yl)methoxy)-N 2,N 6-bis(4-(2-aminoethoxy)
quinolin-2-yl)pyridine-2,6 dicarboxamide (38)
NO O
HNNH
N N
O O
O
NH2H2N
NHN
N
Following procedure G4, 27 (20 mg, 0.024 mmol), copper(II) sulfate pentahy-
drate (1.5 mg, 0.006 mmol), sodium ascorbate (5.3 mg, 0.027 mmol) and sodium
azide (1.7 mg, 0.027 mmol) were reacted to afford the TFA salt of the title com-
pound as a pale white solid (38·3CF3CO2H, 12 mg, 0.014 mmol, 57%). 1H-NMR
(400 MHz, CD3OD) δH 8.53 (2H, br d, J 8.0 Hz, CH (ar)), 8.26 (2H, s, CH (ar)),
8.15 (2H, s, CH (ar)), 8.12 (2H, br d, J 8.0 Hz, CH (ar)), 8.08 (1H, s, CH (ar)),
8.00 (2H, m, CH (ar)), 7.74 (2H, m, CH (ar)), 5.64 (2H, s, CH2C), 4.83 (4H,
t, J 5.0 Hz, OCH2CH2), 3.72 (4H, t, J 5.0 Hz, OCH2CH2);
13C-NMR (100
MHz, CD3OD) δC 168.6, 166.6, 163.6, 151.4, 149.8, 141.2, 133.9, 133.3, 127.1,
123.5, 122.6, 119.0, 113.8, 94.2, 66.9, 62.6, 60.5, 38.8; HRMS (ES) calculated
for C32H31N10O5 ([M+H]
+) m/z: 635.2479, found 635.2480.
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4-((1H-1,2,3-Triazol-4-yl)methoxy)-N 2,N 6-bis(4-(3-aminopropoxy)
quinolin-2-yl)pyridine-2,6 dicarboxamide (39)
NO O
HNNH
N N
O O
O
NHN
N
H2N NH2
Following procedure G4, 28 (20 mg, 0.024 mmol), copper(II) sulfate pentahy-
drate (1.5 mg, 0.006 mmol), sodium ascorbate (5.3 mg, 0.027 mmol) and sodium
azide (1.7 mg, 0.027 mmol) were reacted to afford the TFA salt of the title
compound as a pale yellow solid (39·3CF3CO2H, 14 mg, 0.016 mmol, 67%). 1H-
NMR (400 MHz, CD3OD) δH 8.37 (2H, br d, J 8.0 Hz, CH (ar)), 8.26 (2H,
s, CH (ar)), 8.14 (2H, s, CH (ar)), 8.14-8.06 (3H, m, CH (ar)), 8.04-7.96 (2H,
m, CH (ar)), 7.78-7.70 (2H, m, CH (ar)), 5.64 (2H, s, CH2C), 4.71-4.65 (4H,
m, OCH2CH2), 3.40-3.33 (4H, m, OCH2CH2), 2.52-2.43 (4H, m, O(CH2)2CH2);
13C-NMR (100 MHz, CD3OD) δC 168.6, 166.8, 163.5, 151.5, 149.8, 141.2, 133.5,
133.1, 127.5, 123.6, 122.6, 119.2, 113.7, 94.1, 67.5, 62.4, 56.2, 36.9, 27.1; HRMS
(ES) calculated for C34H35N10O5 ([M+H]
+) m/z: 663.2792, found 663.2797.
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5.1 Synthesis
4-((1H-1,2,3-Triazol-4-yl)methoxy)-N 2,N 6-bis(4-(2-aminoethoxy)
quinolin-2-yl)pyridine-2,6 dicarboxamide (40)
NO O
HNNH
N N
O O
O
NH2H2N
NN
N
NH2
Following procedure G4, 27 (22 mg, 0.027 mmol), copper(II) sulfate pentahy-
drate (0.9 mg, 0.004 mmol), sodium ascorbate (8.1 mg, 0.041 mmol) and 3-
azidopropan-1-amine (4.1 mg, 0.041 mmol) were reacted to afford the TFA salt
of the title compound as a pale yellow solid (40·3CF3CO2H, 6 mg, 0.006 mmol,
22%). 1H-NMR (500 MHz, CD3OD) δH 8.47 (2H, br d, J 8.5 Hz, CH (ar)), 8.25
(1H, s, CH (ar)), 8.21 (2H, s, CH (ar)), 8.15 (2H, s, CH (ar)), 8.04 (2H, br d, J 8.5
Hz, CH (ar)), 7.93-7.89 (2H, m, CH (ar)), 7.68-7.63 (2H, m, CH (ar)), 5.55 (2H,
s, OCH2C), 4.74 (4H, t, J 5.0 Hz, OCH2CH2), 4.61-4.55 (2H, m, NCH2CH2CH2),
3.66 (4H, t, J 5.0 Hz, OCH2CH2), 3.04-2.97 (2H, m, N(CH2)2CH2), 2.33-2.25 (2H,
m, NCH2CH2CH2);
13C-NMR (125 MHz, CD3OD) δC 169.4, 166.5, 164.2, 152.5,
151.2, 144.0, 143.5, 134.0, 127.5, 126.3, 124.8, 124.1, 120.2, 114.3, 95.3, 67.5, 63.5,
54.8, 39.8, 38.1, 29.1; HRMS (ES) calculated for C35H38N11O5 ([M+H]
+) m/z:
692.3057, found 692.3051.
130
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4-((1-(Meth-4-ylbenzoate)-1,2,3-triazol-4-yl)methoxy)-N 2,N 6-bis
(4-(2-aminoethoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide (41)
NO O
HNNH
N N
O O
O
NH2H2N
NN
N
COOH
1
Following procedure G4, 27 (19 mg, 0.023 mmol), copper(II) sulfate pentahy-
drate (0.8 mg, 0.003 mmol), sodium ascorbate (7.1 mg, 0.035 mmol) and 4-
(azidomethyl)benzoic acid (6.3 mg, 0.036 mmol) were reacted to afford the TFA
salt of the title compound as a pale yellow solid (41·2CF3CO2H, 10 mg, 0.010
mmol, 43%). 1H-NMR (400 MHz, CD3OD) δH 8.49 (2H, br d, J 8.5 Hz, CH
(ar)), 8.30 (1H, s, CH (ar)), 8.18 (2H, s, CH (ar)), 8.13 (2H, s, CH (ar)), 8.07-7.98
(4H, m, CH (ar)), 7.97-7.90 (2H, m, CH (ar)), 7.71-7.64 (2H, m, CH (ar)), 7.42
(2H, br d, J 8.5 Hz, CH (ar)), 5.76 (2H, s, CH2 (1)), 5.59 (2H, s, OCH2C), 4.79
(4H, t, J 5.0 Hz, OCH2CH2), 3.72 (4H, t, J 5.0 Hz, OCH2CH2);
13C-NMR (100
MHz, CD3OD) δC 168.4, 168.0, 166.0, 163.2, 151.3, 149.9, 143.9, 143.3, 142.6,
142.2, 140.8, 133.2, 130.3, 128.0, 126.3, 125.4, 123.2, 119.2, 113.7, 94.2, 66.8, 62.6,
53.4, 38.8; HRMS (ES) calculated for C40H37N10O7 ([M+H]
+) m/z: 769.2826,
found 769.2841.
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4-((1-(Glucos-2-yl)-1,2,3-triazol-4-yl)methoxy)-N 2,N 6-bis
(4-(3-aminoethoxy)quinolin-2-yl)-pyridine-2,6 dicarboxamide (42)
NO O
HNNH
N N
O O
O
NH2H2N
NN
N
O
HO OH
OH
1 2
3
45
OH
Following procedure G4, 27 (20 mg, 0.024 mmol), copper(II) sulfate pentahy-
drate (0.9 mg, 0.003 mmol), sodium ascorbate (7.4 mg, 0.037 mmol) and 1-azido-
1-deoxy-β-D-glucopyranoside (7.7 mg, 0.038 mmol) were reacted to afford the
TFA salt of the title compound as a pale yellow solid (42·2CF3CO2H, 10 mg,
0.010 mmol, 40%). 1H-NMR (500 MHz, CD3OD) δH 8.44-8.42 (3H, m, CH
(ar)), 8.21 (2H, s, CH (ar)), 8.16 (2H, s, CH (ar)), 8.00 (2H, br d, J 8.5 Hz,
CH (ar)), 7.89-7.86 (2H, m, CH (ar)), 7.64-7.61 (2H, m, CH (ar)), 5.65-5.63 (1H,
m, H (1)), 5.56 (2H, s, OCH2C), 4.71-4.70 (4H, m, OCH2CH2), 3.91-3.84 (2H,
m, HOCH2), 4.15-3.55 (4H, m, H (2-5)), 3.43-3.37 (4H, m, OCH2CH2);
13C-
NMR (125 MHz, CD3OD) δC 165.9, 164.1, 152.1, 151.3, 145.0, 142.2, 133.6,
127.2, 125.5, 125.4, 123.9, 120.3, 114.3, 95.4, 89.7, 81.2, 78.5, 74.1, 70.9, 67.2,
63.4, 62.4, 54.8, 39.8; [α]20D =21.0
◦ (c 100 µM, H2O); HRMS (ES) calculated for
C38H41N10O10 ([M+H]
+) m/z: 797.3038, found 797.3001.
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4-((1-(Glucos-2-yl)-1,2,3-triazol-4-yl)methoxy)-N 2,N 6-bis(4-(3-
aminopropoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide
(43)
NO O
HNNH
N N
O O
O
NN
N
O
HO OH
OH
NH2H2N
1 2
3
45
OH
Following procedure G4, 28 (28 mg, 0.033 mmol), copper(II) sulfate pentahy-
drate (2.1 mg, 0.008 mmol), sodium ascorbate (7.2 mg, 0.036 mmol) and 1-azido-
1-deoxy-β-D-glucopyranoside (7.3 mg, 0.036 mmol) were reacted to afford the
TFA salt of the title compound as a pale white solid (43·2CF3CO2H, 21 mg,
0.020 mmol, 60%). 1H-NMR (500 MHz, CD3OD) δH 8.47 (1H, s, CH (ar)),
8.28 (2H, br d, J 8.5 Hz, CH (ar)), 8.20 (2H, s, CH (ar)), 8.10 (2H, s, CH (ar)),
8.04 (2H, br d, J 8.5 Hz, CH (ar)), 7.96-7.91 (2H, m, CH (ar)), 7.71-7.65 (2H,
m, CH (ar)), 5.71-5.65 (1H, m, H (1)), 5.58 (2H, s, OCH2C), 4.67-4.59 (4H, m,
OCH2CH2), 4.20-4.15 (1H, m, H (2)), 3.98-3.92 (1H, m, HOCH2), 3.90-3.86 (1H,
m, HOCH2), 3.74-3.68 (1H, m, H (5)), 3.62-3.56 (1H, m, H (4)), 3.53-3.49 (1H,
m, H (3)), 3.35-3.31 (4H, m, OCH2CH2), 2.47-2.41 (4H, m, O(CH2)2CH2);
13C-
NMR (125 MHz, CD3OD) δC 167.9, 166.5, 162.8, 150.6, 149.2, 141.7, 140.2,
133.0, 126.5, 124.1, 122.4, 121.7, 118.5, 113.3, 93.6, 88.1, 79.8, 77.0, 72.6, 69.3,
67.2, 62.0, 60.8, 36.6, 26.5; [α]20D =+20.1
◦ (c 100 µM, H2O); HRMS (ES) calcu-
lated for C40H45N10O10 ([M+H]
+) m/z: 825.3320, found 825.3335.
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4-((1-(Galactos-2-yl)-1,2,3-triazol-4-yl)methoxy)-N 2,N 6-bis(4-(3-
aminopropoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide
(44)
NO O
HNNH
N N
O O
O
NN
N
O
HO OH
OH
NH2H2N
1 2
3
45
OH
Following procedure G4, 28 (18 mg, 0.021 mmol), copper(II) sulfate pentahy-
drate (1.5 mg, 0.005 mmol), sodium ascorbate (4.6 mg, 0.023 mmol) and 1-azido-
1-deoxy-β-D-galactopyranoside (4.7 mg, 0.023 mmol) were reacted to afford the
TFA salt of the title compound as a pale white solid (44·2CF3CO2H, 14 mg,
0.013 mmol, 63%). 1H-NMR (500 MHz, CD3OD) δH 8.49 (1H, s, CH (ar)),
8.20 (2H, br d, J 8.5 Hz, CH (ar)), 8.23 (2H, s, CH (ar)), 8.17-8.06 (4H, m, CH
(ar)), 7.98-7.93 (2H, m, CH (ar)), 7.72-7.67 (2H, m, CH (ar)), 5.65-5.62 (1H, m,
H (1)), 5.60 (2H, s, OCH2C), 4.69-4.61 (4H, m, OCH2CH2), 4.22-4.16 (1H, m, H
(2)), 4.01-3.97 (1H, m, HOCH2), 3.88-3.83 (1H, m, HOCH2), 3.78-3.55 (3H, m,
H (3-5)), 3.36-3.32 (4H, m, OCH2CH2), 2.48-2.39 (4H, m, O(CH2)2CH2);
13C-
NMR (125 MHz, CD3OD) δC 167.9, 166.5, 162.8, 150.6, 149.2, 141.8, 140.2,
133.0, 126.4, 124.1, 122.4, 121.9, 118.5, 113.3, 93.6, 88.2, 79.8, 76.9, 72.7, 69.5,
67.3, 61.9, 60.8, 36.7, 26.5; [α]20D =+19.0
◦ (c 100 µM, H2O); HRMS (ES) calcu-
lated for C40H45N10O10 ([M+H]
+) m/z: 825.3320, found 825.3353.
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4-((1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H )-yl)tetrahydrofuran-3-yl)-1,2,3-triazol-4-
yl)methoxy)-N 2,N 6-bis(4-(2-aminoethoxy)quinolin-2-yl)pyridine-2,6
dicarboxamide (45)
NO O
HNNH
N N
O O
O
NH2H2N
NN
N
O
HO
N NH
O
O
1
23
4
Following procedure G4, 28 (30 mg, 0.037 mmol), copper(II) sulfate pentahy-
drate (3.0 mg, 0.012 mmol), sodium ascorbate (8.0 mg, 0.040 mmol) and zi-
dovudine (12.0 mg, 0.045 mmol) were reacted to afford the TFA salt of the title
compound as a pale white solid (45·2CF3CO2H, 29 mg, 0.027 mmol, 73%). 1H-
NMR (400 MHz, CD3OD) δH 8.52 (2H, br d, J 8.5 Hz, CH (ar)), 8.44 (1H,
s, CH (ar)), 8.22 (2H, s, CH (ar)), 8.12-8.05 (4H, m, CH (ar)), 8.00-7.93 (2H,
m, CH (ar)), 7.91 (1H, s, CH (T )), 7.74-7.67 (2H, m, CH (ar)), 5.62 (2H, s,
OCH2C), 4.87-4.80 (4H, m, OCH2CH2), 4.44-4.39 (1H, m, H (1)), 4.00 (2H, m,
H (2)), 3.95-3.89 (1H, m, HOCH2), 3.87-3.80 (1H, m, HOCH2), 3.77-3.71 (4H,
m, OCH2CH2), 2.97-2.88 (1H, m, H (4)), 2.82-2.71 (1H, m, H (3)), 1.89 (3H,
s, CH3);
13C-NMR (100 MHz, CD3OD) δC 166.8, 165.3, 163.5, 151.4, 151.1,
149.6, 140.3, 137.0, 133.9, 127.1, 125.2, 123.4, 121.8, 118.8, 114.1, 110.9, 94.2,
85.7, 85.5, 85.0, 67.2, 62.6, 61.4, 60.6, 54.2, 38.7, 38.2, 37.3; [α]20D =+22.0
◦ (c 100
µM, H2O); HRMS (ES) calculated for C42H43N12O9 ([M+H]
+) m/z: 859.3294,
found 859.3294.
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4-((1-((2S,3S,5R)-2-(Hydroxymethyl)-5-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)tetrahydrofuran-3-yl)-1,2,3-triazol-4-
yl)methoxy)N 2,N 6-bis(4-(3-aminopropoxy)quinolin-2-yl)pyridine-2,6
dicarboxamide (46)
NO O
HNNH
N N
O O
O
NN
N
NH2H2N
O
HO
N NH
O
O
1
23
4
Following procedure G4, 28 (33 mg, 0.039 mmol), copper(II) sulfate pentahy-
drate (3.0 mg, 0.012 mmol), sodium ascorbate (8.0 mg, 0.040 mmol) and zi-
dovudine (13.0 mg, 0.049 mmol) were reacted to afford the TFA salt of the title
compound as a pale white solid (46·2CF3CO2H, 21 mg, 0.019 mmol, 48%). 1H-
NMR (400 MHz, CD3OD) δH 8.42 (1H, s, CH (ar)), 8.34 (2H, br d, J 8.0
Hz, CH (ar)), 8.25 (2H, s, CH (ar)), 8.14-8.04 (4H, m, CH (ar)), 8.03-7.96 (2H,
m, CH (ar)), 7.92 (1H, s, CH (T )), 7.77-7.70 (2H, m, CH (ar)), 5.62 (2H, s,
OCH2C), 4.73-4.66 (4H, m, OCH2CH2), 4.45-4.40 (1H, m, H (1)), 4.00 (2H, m,
H (2)), 3.96-3.89 (1H, m, HOCH2), 3.86-3.78 (1H, m, HOCH2), 3.39-3.34 (4H,
m, OCH2CH2), 2.98-2.88 (1H, m, H (4)), 2.82-2.71 (1H, m, H (3)), 2.52-2.41
(4H, m, O(CH2)2CH2), 1.91 (3H, s, CH3);
13C-NMR (100 MHz, CD3OD) δC
168.5, 167.3, 163.7, 151.5, 151.2, 149.7, 140.0, 137.0, 133.8, 127.1, 125.1, 122.9,
121.9, 119.0, 114.0, 113.4, 110.7, 94.2, 85.8, 85.5, 68.0, 62.6, 61.4, 60.8, 54.3, 38.1,
37.1, 26.9, 11.5; [α]20D =+23.0
◦ (c 100 µM, H2O); HRMS (ES) calculated for
C44H47N12O9 ([M+H]
+) m/z: 887.3589, found 887.3554.
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5.1 Synthesis
4-(2-((+)biotinylamido)ethoxy)N 2,N 6-bis(4-(2-aminoethoxy)quinolin-
2-yl)pyridine-2,6 dicarboxamide
(47)
NO O
HNNH
N N
O O NH2H2N
O
NH
O S
NHHN
O
H
H1
2 34
Compound 55 (50 mg, 0.054 mmol) was dissolved in 5 ml MeOH and 5% Pd/C
was added. The mixture was stirred under microwave irradiation for 1 h. The
mixture was filtered through celite and the solvent removed in vacuo. Some of
the Cbz-deprotected product was used without further purification for the next
step. This compound (47·2CF3CO2H, 13 mg, 0.016 mmol) and TEA (8 µl, 0.054
mmol) were dissolved in 1 ml DCM and (+)biotin N -hydroxysuccinimide ester
(6 mg, 0.018 mmol) was added. The solution was stirred for 2 h at rt. The
solvent was removed in vacuo and the product purified by HPLC (gradient: 10%
MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=14.5-
15.0 min) to yield the TFA salt of the product as a white solid (16 mg, 0.015
mmol, 93%). 1H-NMR (500 MHz, D2O) δH 8.49 (2H, br d, J 8.0 Hz, CH
(ar)), 8.19 (2H, s, CH (ar)), 8.13 (2H, s, CH (ar)), 8.07 (2H, br d, J 8.0 Hz,
CH (ar)), 7.96-7.92 (2H, m, CH (ar)), 7.70-7.66 (2H, m, CH (ar)), 4.79-4.69 (4H,
m, OCH2CH2NH2), 4.46-4.40 (2H, m, OCH2CH2NH), 4.38-4.33 (1H, m, H (1)),
4.24-4.19 (1H, m, H (2)), 3.72-3.63 (6H, m, OCH2CH2NH2, OCH2CH2NH), 3.17-
3.08 (1H, m, H (4)), 2.88-2.80 (1H, m, H (3)), 2.65-2.56 (1H, m, H (3)), 2.27-2.19
(2H, m, COCH2), 1.74-1.47 (4H, m, COCH2CH2, CO(CH2)3CH2), 1.44-1.29 (2H,
m, CO(CH2)2CH2);
13C-NMR (125 MHz, D2O) δC 176.7, 170.0, 164.4, 152.5,
151.1, 149.8, 144.3, 133.9, 127.4, 124.9, 124.1, 120.1, 116.7, 114.3, 95.5, 67.5, 63.5,
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61.5, 56.9, 53.9, 41.2, 39.8, 39.6, 36.7, 29.7, 29.6, 26.9; [α]20D =+57.1
◦ (c 100 µM,
H2O); HRMS (ES) calculated for C41H47N10O7 ([M+H]
+) m/z: 823.3350, found
823.3314.
4-(2-((+)Biotinylamido)ethoxy)-N 2,N 6-bis(4-(3-
aminopropoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide
(48)
NO O
HNNH
N N
O O
O
NH
O S
NHHN
O
H
H
H2N NH2
1
2 34
Compound 56 (70 mg, 0.073 mmol) was dissolved in MeOH (5 ml) and 5% Pd/C
was added. The mixture was stirred under microwave irradiation for 1 h. The
mixture was filtered through celite and the solvent removed in vacuo. Some of the
Cbz-deprotected product was used without further purification for the next step.
This compound (20 mg, 0.024 mmol) and TEA (11 µl, 0.079 mmol) were dissolved
in DCM (1 ml) and (+)-biotin N -hydroxysuccinimide ester (9 mg, 0.026 mmol)
was added. The solution was stirred for 2 h at rt. The solvent was removed in
vacuo and the product purified by HPLC (gradient: 10% MeCN/90% H2O, 0.1%
TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=14.5-15.0 min) to yield the TFA
salt of the product as a white solid (48·2CF3CO2H, 23 mg, 0.022 mmol, 92%).
1H-NMR (500 MHz, CD3OD) δH 8.39 (2H, br d, J 8.0 Hz, CH (ar)), 8.18-8.09
(6H, m, CH (ar)), 8.06-7.98 (2H, m, CH (ar)), 7.79-7.72 (2H, m, CH (ar)), 4.75-
4.66 (4H, m, OCH2(CH2)2), 4.50-4.41 (3H, m, OCH2CH2NH, (1)), 4.29-4.23 (1H,
m, H (2)), 3.76-3.67 (2H, m, OCH2CH2NH), 3.41-3.35 (4H, m, OCH2CH2CH2),
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3.21-3.13 (1H, m, H (4)), 2.92-2.83 (1H, m, H (3)), 2.65-2.58 (1H, m, H (3)),
2.53-2.44 (4H, m, O(CH2)2CH2), 2.32-2.23 (2H, m, COCH2), 1.76-1.38 (6H, m,
COCH2(CH2)3);
13C-NMR (125 MHz, CD3OD) δC 175.6, 167.4, 163.5, 151.2,
149.8, 147.4, 140.2, 133.8, 127.2, 123.1, 121.8, 119.0, 116.1, 113.6, 94.3, 68.3, 67.8,
62.3, 60.7, 55.9, 40.0, 38.6, 37.1, 35.9, 30.1, 28.5, 27.1, 25.9; [α]20D =+52.8
◦ (c 100
µM, H2O); HRMS (ES) calculated for C43H51N10O7 ([M+H]
+) m/z: 851.3663,
found 851.3692.
4-(2-(6-((+)Biotinylamido)hexanamido)ethoxy)-N 2,N 6-bis(4-(3-
aminopropoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide
(49)
NO O
HNNH
N N
O O
O
NH
O
H2N NH2
N
H
O
S
NH
HN OH
H1
2
3
4
Compound 56 (70 mg, 0.073 mmol) was dissolved in MeOH (5 ml) and 5% Pd/C
was added. The mixture was stirred under microwave irradiation for 1 h. The
mixture was filtered through celite and the solvent removed in vacuo. Some of the
Cbz-deprotected product was used as a crude for the next step. This compound
(20 mg, 0.024 mmol) and TEA (11 µl, 0.053 mmol) were dissolved in DCM (1
ml) and (+)-biotinamidohexanoic acid N -hydroxysuccinimide ester (12 mg, 0.026
mmol) was added. The solution was stirred for 2 h at rt. The solvent was removed
in vacuo and the product purified by HPLC (gradient: 10% MeCN/90% H2O,
0.1% TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=14.5-15.0 min) to yield
the TFA salt of the product as a white solid (49·2CF3CO2H, 26 mg, 0.022 mmol,
90%). 1H-NMR (500 MHz, CD3OD) δH 8.45-3.38 (2H, m, CH (ar)), 8.21-8.12
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(4H, m, CH (ar)), 8.10-7.98 (4H, m, CH (ar)), 7.83-7.75 (2H, m, CH (ar)), 4.78-
4.69 (4H, m, OCH2(CH2)2), 4.51-4.43 (3H, m, OCH2CH2NH, (1)), 4.31-4.24 (1H,
m, H (2)), 3.76-3.70 (2H, m, OCH2CH2NH), 3.40-3.35 (4H, m, OCH2CH2CH2),
3.18-3.09 (3H, m, H, (4, al)), 3.03-2.99 (2H, m, H, (al)), 2.90-2.86 (3H, m, H,
(3, al)), 2.73-2.71 (1H, m, H, (3)), 2.70-2.68 (2H, m, H, (al)), 2.53-2.43 (4H, m,
O(CH2)2CH2), 2.32-2.23 (2H, m, COCH2(CH2)3CH), 2.19-2.10 (2H, m, H, (al)),
1.72-1.40 (6H, m, COCH2(CH2)3CH);
13C-NMR (125 MHz, CD3OD) δC 174.0,
170.0, 168.1, 164.0, 150.9, 149.7, 144.2, 139.1, 138.3, 134.5, 127.6, 123.3, 121.3,
119.0, 113.8, 94.3, 68.1, 62.3, 60.8, 56.0, 54.2, 40.1, 39.2, 38.5, 37.0, 35.7, 29.0,
28.4, 26.9, 26.4, 25.8, 25.5, 25.2, 23.2; [α]20D =+50.3
◦ (c 100 µM, H2O); HRMS
(ES) calculated for C49H62N11O8 ([M+H]
+) m/z: 964.4505, found 964.4512.
4-(2-(+)Biotinylamido)ethoxy)-N 2,N 6-bis(4-(2-(pyrrolidin-1-
yl)ethoxy)quinolin-2-yl)-pyridine-2,6 dicarboxamide
(50)
NO O
HNNH
N N
O O NN
O
NH
O S
NHHN
O
H
H1
2 34
Compound 25 (20 mg,19.1 µmmol) and TEA (13 µl, 0.063 mmol) were dissolved
in DCM (1 ml). (+)-biotin N -hydroxysuccinimide ester (7 mg, 0.021 mmol) was
added and the solution allowed to stir for 2 h. The solvent was removed in vacuo
and the product purified by HPLC (gradient: 10% MeCN/90% H2O, 0.1% TFA
to 100% MeCN, 0.1% TFA over 30 min, Rt=15.0-15.5 min) to yield the TFA
salt of the product as a white solid (50·2CF3CO2H, 22 mg, 0.019 mmol, 99%).
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1H-NMR (500 MHz, CD3OD) δH 8.41 (2H, br d, J 8.0 Hz, CH (ar)), 8.13 (2H,
s, CH (ar)), 8.10-8.04 (2H, m, CH (ar)), 7.97-7.91 (2H, m, CH (ar)), 7.71-7.64
(2H, m, CH (ar)), 7.70-7.66 (2H, m, CH (ar)), 4.49-4.38 (6H, m, OCH2), 4.32-
4.27 (1H, m, H (1)), 4.24-4.19 (1H, m, H (2)), 4.01-3.96 (4H, m, NCH2(CH2)2),
3.94-3.85 (4H, m, NCH2(CH2)2), 3.73-3.68 (2H, m, OCH2CH2NH), 3.44-3.33 (4H,
m, OCH2CH2N), 3.22-3.09 (1H, m, H (4)), 3.00-2.95 (1H, m, H (3)), 2.86-2.80
(1H, m, H (3)), 2.31-2.06 (10H, m, COCH2, NCH2CH2CH2), 1.79-1.46 (6H, m,
COCH2(CH2)3);
13C-NMR (125 MHz, CD3OD) δC 176.6, 172.0, 170.0, 169.9,
166.8, 164.4, 152.3, 150.9, 143.0, 134.5, 127.9, 124.3, 120.0, 114.4, 95.6, 69.4, 66.8,
63.2, 61.5, 56.9, 56.3, 54.7, 41.1, 39.5, 36.8, 31.6, 29.4, 26.5, 24.0; [α]20D =+60.4
◦
(c 100 µM, H2O); HRMS (ES) calculated for C49H59N10O7S ([M+H]
+) m/z:
931.4283, found 931.4289.
4-(2-(6-((+)Biotinylamido)hexanamido)ethoxy)-N 2,N 6-bis(4-(2-
(pyrrolidin-1-yl)ethoxy)quinolin-2-yl)pyridine-2,6 dicarboxamide
(51)
NO O
HNNH
N N
O O NN
O
NH
O N
H
O
S
NH
HN OH
H1
2
3
4
Compound 25 (20 mg, 0.019 mmol) and TEA (13 µl, 0.063 mmol) were dissolved
in DCM (1 ml). (+)-biotinamidohexanoic acid N -hydroxysuccinimide ester (10
mg, 0.021 mmol) was added and the solution allowed to stir for 2 h. The sol-
vent was removed in vacuo and the product purified by HPLC (gradient: 10%
MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=15.0-
15.5 min) to yield the TFA salt of the product as a white solid (50·2CF3CO2H,
23 mg, 0.018 mmol, 94%). 1H-NMR (500 MHz, CD3OD) δH 8.45 (2H, br d, J
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8.5 Hz, CH (ar)), 8.16-8.10 (6H, m, CH (ar)), 8.02-7.97 (2H, m, CH (ar)), 7.76-
7.68 (2H, m, CH (ar)), 4.94-4.90 (4H, m, OCH2CH2NCH2), 4.49-4.45 (1H, m, H
(1)), 4.44-4.41 (2H, m, OCH2CH2NH), 4.26-4.20 (1H, m, H (2)), 4.02-3.96 (4H, m,
NCH2(CH2)2), 3.94-3.86 (4H, m, NCH2(CH2)2), 3.73-3.68 (2H, m, OCH2CH2NH),
3.42-3.32 (4H, m, OCH2CH2NCH2), 3.21-3.04 (4H, m, H (al)), 2.94-2.85 (1H, m,
H (4)), 2.72-2.59 (2H, m, H (3)), 2.31-2.04 (12H, m, COCH2, NCH2CH2CH2,
(al)), 1.68-1.40 (10H, m, COCH2(CH2)3CH);
13C-NMR (125 MHz, CD3OD) δC
176.6, 175.9, 171.9, 169.9, 167.3, 164.5, 152.3, 150.8, 141.9, 134.9, 128.2, 124.4,
123.4, 119.9, 114.5, 95.4, 69.3, 67.0, 63.3, 61.6, 57.0, 56.1, 54.6, 41.1, 40.3, 36.9,
36.7, 31.5, 30.1, 29.5, 27.5, 26.9, 26.5, 25.5, 24.1; [α]20D =+52.2
◦ (c 100 µM, H2O);
HRMS (ES) calculated for C55H70N11O8S ([M+H]
+) m/z: 1044.5124, found
1044.5171.
4-(2-(6-(6-((+)Biotinylamido)hexanamido)hexanamido)ethoxy)-
N 2,N 6-bis(4-(2-(pyrrolidin-1-yl)ethoxy)quinolin-2-yl)pyridine-2,6
dicarboxamide (52)
NO O
HNNH
N N
O O NN
O
NH
O N
H
O H
N O
S
N
H
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O
H
H
1
2
3
4
Compound 25 (20 mg, 0.019 mol) and TEA (13 µl, 0.063 mmol) were dissolved in
DCM (1 ml). (+)-biotinamidohexanoyl-6-aminohexanoic acid N -hydroxysuccini-
mide ester (12 mg, 0.021 mmol) was added and the solution allowed to stir for
2 h. The solvent was removed in vacuo and the product purified by HPLC
(gradient: 10% MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA over 30
min, Rt=15.0-15.5 min) to yield the TFA salt of the product as a white solid
(50·2CF3CO2H, 24 mg, 0.017 mmol, 90%). 1H-NMR (500 MHz, CD3OD) δH
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8.47 (2H, br d, J 8.5 Hz, CH (ar)), 8.18-8.10 (6H, m, CH (ar)), 8.03-7.98 (2H, m,
CH (ar)), 7.77-7.71 (2H, m, CH (ar)), 4.94-4.90 (4H, m, OCH2CH2NCH2), 4.50-
4.41 (3H, m, OCH2CH2NH, H (1)), 4.30-4.23 (1H, m, H (2)), 4.01-3.98 (4H, m,
NCH2(CH2)2), 3.95-3.85 (4H, m, NCH2(CH2)2), 3.72-3.67 (2H, m, OCH2CH2NH),
3.42-3.33 (4H, m, OCH2CH2NCH2), 3.20-3.07 (7H, m, H (4, al)), 2.94-2.85 (1H,
m, H (3)), 2.71-2.60 (1H, m, H (3)), 2.29-2.08 (14H, m, COCH2(CH2)3CH, H (al)),
1.77-1.39 (16H, m, COCH2(CH2)3CH, NCH2CH2CH2, H (al));
13C-NMR (125
MHz, CD3OD) δC 175.2, 174.4, 170.4, 168.8, 168.5, 166.0, 163.0, 150.9, 149.4,
140.6, 133.4, 126.6, 122.8, 122.0, 118.5, 112.9, 93.9, 68.0, 65.7, 62.0, 60.5, 55.7,
54.7, 53.2, 39.7, 38.7, 38.1, 35.5, 35.4, 35.3, 28.6, 28.3, 28.1, 26.2, 26.1, 25.6, 25.5,
25.3, 25.1, 23.9, 22.6; [α]20D =+55.5
◦ (c 100 µM, H2O); HRMS (ES) calculated
for C61H81N12O9S ([M+H]
+) m/z: 1157.5908, found 1157.5965.
4-(5-oxo-(+)Biotinyl)-9,12-dioxa-3,6,15-triazapentadecyloxy)-N 2,N 6-
bis(4-(2-(pyrrolidin-1 yl)ethoxy) quinolin-2-yl)pyridine-2,6
dicarboxamide (53)
NO O
HNNH
N N
O O NN
O
NH
O
N
H
O O
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N
H
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4
Compound 25 (20 mg, 0.019 mmol) was dissolved in DMF (5 ml). Triethylamine
(100 µl, 0.6 mmol) and (+)-biotin polyetheleneoxide iodoacetamide (21 mg, 0.039
mmol) were added. The reaction was stirred for 2 h at 100 ◦C. The solvent was re-
moved in vacuo to yield a yellow oil which was purified by HPLC (gradient: 10%
MeCN/90% H2O, 0.1% TFA to 100% MeCN, 0.1% TFA over 30 min, Rt=14.0-
14.5 min) to yield the TFA salt of the title compound (53·3CF3CO2H, 13 mg,
0.009 mmol, 47%) as a light yellow waxy solid. 1H-NMR (500 MHz, CD3OD)
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δH 8.46 (2H, br d, J 8.5 Hz, CH (ar)), 8.27 (2H, s, CH (ar)), 8.19 (2H, s, CH (ar)),
8.12 (2H, br d, J 8.5 Hz, CH (ar)), 8.01-7.96 (2H, m, CH (ar)), 7.75-7.70 (2H, m,
CH (ar)), 4.95-4.89 (4H, m, OCH2CH2NCH2), 4.75-4.70 (2H, m, OCH2CH2NH),
4.54-4.41 (1H, m, H (1)), 4.32-4.25 (1H, m, H (2)), 4.06-3.98 (6H, m, NCH2(CH2)2,
H (al)), 3.96-3.88 (4H, m, NCH2(CH2)2), 3.73-3.68 (2H, m, COCH2NH), 3.67-3.64
(4H, m, OCH2CH2N(CH2)2), 3.63-3.54 (6H, m, H (al)), 3.53-3.46 (4H, m, H (al)),
3.44-3.40 (2H, m, OCH2CH2NH), 3.24-3.14 (1H, m, H (4)), 2.96-2.86 (1H, m, H
(3)), 2.72-2.61 (1H, m, H (3)), 2.33-2.06 (10H, m, COCH2CH2, NCH2CH2CH2),
1.77-1.30 (6H, m, COCH2(CH2)3);
13C-NMR (125 MHz, CD3OD) δC 165.2,
162.8, 161.1, 160.6, 151.1, 150.0, 142.4, 132.8, 126.4, 123.4, 122.6, 118.8, 117.6,
116.9, 115.2, 112.8, 94.0, 69.9, 69.2, 68.9, 65.3, 64.6, 62.0, 60.2, 55.6, 54.8, 53.3,
46.3, 39.7, 39.2, 38.8, 35.3, 28.3, 28.1, 25.5, 22.6, 21.3; [α]20D +66.8
◦ (c 100 µM,
H2O); HRMS (ES) calculated for C57H75N12O10S ([M+H]
+) m/z: 1119.5444,
found 1119.5452.
4-(2-Benzyloxycarbonylaminoethoxy)pyridine-2,6-dicarboxylic acid
(54)
N COOH
O
HOOC
NHCbz
9 (1.0 g, 4.7 mmol), N -Cbz-ethanolamine (0.9 ml, 4.6 mmol) and 3.3 g triph-
enylphosphine polymer bound (1.6 mmol loading/g) were added to freshly dis-
tilled THF (50 ml) and cooled to 0 ◦C. DIAD (1.2 ml, 6.5 mmol) was added
dropwise under argon. The mixture was allowed to warm to rt and stirred for
3 d. The solution was filtered and the solvent was removed in vacuo and the
product purified by column chromatography (80% EtOAc, 20% petroleum ether)
to obtain the dimethyl ester of the title compound as a white powder. This
compound was dissolved in MeOH (50 ml) and deprotected by slowly adding a
solution of NaOH (0.3 g, 7.7 mmol) in H2O (50 ml). The solvent was evaporated
in vacuo and the remaining solid dissolved in H2O. The solution was acidified
with 5% HCOOH (aq.) and extracted with EtOAc. The organic layer was dried
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over MgSO4, filtered, and the solvent removed in vacuo to obtain the title com-
pound as a white powder (1.0 g, 2.7 mmol, 57%). 1H-NMR (500 MHz, CD3OD)
δH 7.85 (2H, s, CH (ar)), 7.38-7.22 (5H, m, CH (Cbz)), 5.07 (2H, s, CH2 (Cbz));
4.28 (2H, t, J 5.0 Hz, OCH2), 3.57 (2H, t, J 5.0 Hz, OCH2CH2);
13C-NMR (125
MHz, CD3OD) δC 169.3, 166.9, 159.0, 150.4, 138.3, 129.5, 129.0, 128.8, 115.2,
69.2, 67.6, 41.0; HRMS (ES) calculated for C17H16N2NaO7 ([M+Na]
+) m/z:
383.0849, found 383.0850.
4-(2-Benzyloxycarbonylaminoethoxy)-N 2,N 6-bis(4-(2-tert-
butyloxycarbonylamino-ethoxy)quinolin-2-yl)pyridine-2,6
dicarboxamide (55)
NO O
HNNH
N N
O O NHBocBocHN
O
NHCbz
54 (44 mg, 0.115 mmol) was dissolved in DCM (20 ml) and 1-chloro-N,N,-2-
trimethylpropenyl-amine (33 µl, 0.254 mmol) was added slowly and the reaction
allowed to stir at rt for 2 h. The solution was then cooled to 0 ◦C. TEA (35
µl, 0.254 mmol) was added dropwise and the solution was allowed to warm to rt
and stirred for 1 h. 5a (75 mg, 0.247 mmol) was added and the solution stirred
under argon at rt overnight. The solvent was removed in vacuo and the title
compound was precipitated from hot MeCN as a white powder (90 mg, 0.097
mmol, 84%). 1H-NMR (400 MHz, CD3OD) δH 8.26 (2H, br d, J 8.5, CH (ar)),
8.06 (2H, s, CH (ar)), 7.96 (2H, br d, J 8.5 Hz, CH (ar)), 7.93 (2H, s, CH (ar)),
7.83-7.77 (2H, m, CH (ar)), 7.56-7.50 (2H, m, CH (ar)), 7.39-7.27 (5H, m, CH
(Cbz)), 5.15 (2H, s, CH2 (Cbz)), 4.40-4.25 (6H, m, OCH2), 3.60-3.47 (6H, m,
OCH2CH2), 1.41 (18H, s, CH3);
13C-NMR (100 MHz, CD3OD) δC 171.3, 167.6,
163.5, 156.7, 156.2, 152.5, 151.2, 146.8, 137.5, 136.1, 131.4, 129.6, 128.7, 128.2,
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128.1, 125.2, 122.9, 119.3, 112.6, 95.4, 78.2, 68.6, 67.7, 65.9, 28.6, 28.4; HRMS
(ES) calculated for C49H54N8O11 ([M+H]
+) m/z: 931.3990, found 931.3985.
4-(2-Benzyloxycarbonylaminoethoxy)-N 2,N 6-bis(4-(3-tert-
butyloxycarbonylamino-propoxy)quinolin-2-yl)pyridine-2,6
dicarboxamide (56)
NO O
HNNH
N N
O O
O
NHCbz
NHBocBocHN
54 (70 mg, 0.141 mmol) was dissolved in DCM (20 ml) and 1-chloro-N,N,-2-
trimethylpropenyl-amine (53 µl, 0.402 mmol) was added slowly and the reaction
allowed to stir at rt for 2 h. The solution was then cooled to 0 ◦C. TEA (56
µl, 0.402 mmol) was added dropwise and the solution was allowed to warm to
rt and stirred for 1 h. 16a (120 mg, 0.310 mmol) was added and the solution
stirred under argon at rt overnight. The solvent was removed in vacuo and the
title compound was precipitated from hot MeCN as a white powder (137 mg,
0.147, mmol, 81%). 1H-NMR (400 MHz, CD3OD) δH 8.16 (2H, dd, J 8.5, 1.5
Hz, CH (ar)), 8.11 (2H, s, CH (ar)), 7.95 (2H, dd, J, CH (ar) 8.5, 1.5 Hz, CH
(ar)), 7.92 (2H, s, CH (ar)), 7.78 (2H, ddd, J 8.5, 6.5, 1.5 Hz, CH (ar)), 7.53 (2H,
ddd, J 8.5, 6.5, 1.5 Hz, CH (ar)), 7.39-7.27 (5H, m, CH (ar) (Cbz)), 5.06 (2H,
s, CH2 (Cbz)), 4.40-4.29 (6H, m, OCH2), 3.54-3.46 (2H, m, OCH2CH2NHCbz),
3.28-3.20 (4H, m, OCH2CH2CH2), 2.09-2.01 (4H, m, O(CH2)2CH2), 1.37 (18H, s,
CH3);
13C-NMR (100 MHz, CD3OD) δC 162.0, 161.1, 155.2, 154.6, 151.3, 150.0,
145.9, 140.0, 129.4, 127.2, 126.7, 125.8, 123.4, 120.7, 118.1, 116.8, 113.9, 112.5,
110.8, 93.8, 87.3, 76.5, 65.1, 64.4, 37.7, 27.7, 27.1; HRMS (ES) calculated for
C51H59N8O11 ([M+H]
+) m/z: 959.4455, found 959.4460.
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5.2 FRET-melting
100 µM stock solutions of oligonucleotides were prepared in molecular biology
grade DNase-free H2O (Sigma Aldrich R©). Further dilutions were carried out in 60
mM potassium cacodylate buffer, pH 7.4. FRET-melting experiments were car-
ried out with a 200 nM oligonucleotide concentration. Six DNA oligonucleotides
were used in these experiments: five were dual fluorescently labelled: H-telo (5′-
FAM-GGG TTA GGG TTA GGG TTA GGG-TAMRA-3′), C-myc (5′-FAM-TGA
GGG TGG GTA GGG TGG GTA A-TAMRA-3′), C-kit1 (5′-FAM-GGG AGG
GCG CTG GGA GGA GGG-TAMRA-3′), C-kit2 (5′-FAM-GGG CGG GCG
CGA GGG AGG GG-TAMRA-3′), ds-DNA (5′-FAM-TAT AGC TAT A-HEG-T
ATA GCT ATA-TAMRA-3′) and one was unlabelled: ds-DNA competitor (5′-
CAA TCG GAT CGA ATT CGA TCC GAT TG-3′).
The donor fluorophore was FAM, and the acceptor fluorophore was TAMRA.
The dual-labelled oligonucleotides were annealed at a concentration of 400 nM by
heating at 94 ◦C for 10 min followed by slow cooling to rt at a controlled rate of 0.1
◦C/min. 96-well plates were prepared by addition of 50 µl of the annealed DNA
solution to each well, followed by 50 µl solution of compound at the appropriate
concentration. For the competition experiments, ds-DNA competitor was added
to the dual-labelled oligonucleotides at an excess of 50 or 200 mole equivalents
and annealed in the same solution in order to produce an excess of at least 25
or 100 mole equivalents of double stranded DNA, respectively. Measurements
were made in triplicate with an excitation wavelength of 483 nm and a detection
wavelength of 533 nm. Final analysis of the data was carried out using OriginPro
7.5 data analysis and graphing software (OriginLab R©). All given values were
determined graphically from a dose-response fitting of ∆Tm against compound
concentration.
5.3 HyperChem R© modeling
Molecular modeling calculations were performed for molecules 1a, 2a and 3a
using HyperChem R©, v 8.1 in order to calculate the rotational barriers for C16-
C13, C8-C4, C2-C7 and C10-C15 bonds as depicted in Figure 2.3 for 1a.
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Figure 5.1: labelled bonds of 1a for the modeling studies.
Conformational search using the PM3 semi-empirical method with convergence
criteria of 0.025 kcal/mol/A˚ was performed for the bonds indicated above (si-
multaneous rotations). The conformations with the lowest energies were further
refined using PM3 with a convergence criteria of 0.01 kcal/mol/A˚. The optimised
structures were placed in a 42875/A˚3 water box containing 1378 H2O molecules.
The system was optimised using the MM+ force field with a convergence criteria
of 0.025 kcal/mol A˚. Pictures of the simulation of the molecules in a water box
are displayed in Figure 5.2.
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Figure 5.2: Optimised structures of top left: 1a; top right: 2a and bottom: 3a
placed in a 42875 A˚3 water box.
5.4 Cell studies
HT-1080 cells were cultured in T-75 flasks in media (DMEM, high L-glucose,
L-glutamine) supplemented with 10% fetal calf serum) and split at 70-80% con-
fluency using 0.25% trypsin 0.02% EDTA in 1 × PBS.
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5.4.1 Measurements of growth inhibition (GI50)
Growth inhibition was determined using the cell viability assay CellTiter-Glo
TM
(Promega R©). HT-1080, HeLa, U2OS or WI-38 cells were plated in 96 well plates
at a density of 4,000 cells per well in 100 µl media and incubated for 24 h. Com-
pounds were added in serial dilutions (in a range between 0-40 µM) at a volume
of 100 µl per well at the respective concentrations. Cell viability was measured
after 72 h using the manufacturers protocol. In brief, the media was removed
from the wells, and 100µl of media (rt) was added, followed by 100 µl of the
luminescence reagent (rt). Measurements were taken after 20 min incubation at
rt. All measurements were made in triplicate and the experiment repeated three
times. Luminescent readings were taken on a luminometer. Final analysis of the
data was carried out using OriginPro R© 7.5 data analysis and graphing software
(OriginLab R©). The GI50 was determined graphically from a dose-response fitting
of %luminescent signal against compound concentration.
5.4.2 Long term growth assay and cytotoxicity
HT-1080 cells were cultured in T-25 flasks as stated above and seeded at 300,000
cells per flask initially and incubated with 18-20, 22, 23, 25, 26, 31-33, 35-38,
44 or 53 at the respective GI50 concentrations, or no compound as control. The
cells were split after 3 to 4 days, counted with a hemicytometer and reseeded at
their initial density of 300,000 cells per flask. PDs were calculated as stated in
section 3.6. Toxicity was assessed using a Trypan blue exclusion assay. In brief,
10 µl of cell suspension was mixed with 10 µl of 0.4 % aq. Trypan blue solution
and cells counted with a hemicytometer. Dead cells were identified by blue nu-
clear staining. This procedure was repeated every third day. All experiments
were performed in triplicate. Final analysis was done using OriginPro R© 7.5 data
analysis and graphing software.
5.4.3 β-Galactosidase assay
Senescence was assessed using a senescence β-galactosidase staining kit (Cell Sig-
nalling Technology R©) according to the manufacturers protocol. In brief, HT-1080
cells were cultured in T-75 flasks for 1 d and incubated with 23, 25, 26, 31, 33, 44
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and 53 respectively for 4 d at their respective GI50. As a control, cells were incu-
bated without compound under the same conditions. Cells were split and seeded
at 4000 cells per well on a Cover Well
TM
microscopy slide chamber (Invitrogen R©)
and incubated with 23, 25, 26, 31, 33 44 and 53 at the aforementioned concen-
trations, or in the absence of compound, for another 4 d. Subsequently, the media
was removed and the wells washed twice with 1 × PBS. Cells were fixed with
2% formaldehyde and 0.2% glutaraldehyde in 1× PBS for 15 min. This solution
was then removed and the wells washed twice with 1 × PBS. Each well was in-
cubated with 800 µl staining solution (40 mM citric acid/sodium phosphate (pH
6.0), 0.15 M NaCl, 2 mM MgCl2, 5 mM potassium ferrocyanide, 5 mM potassium
ferricyanide, 1 mg/ml X-gal, 5% DMF) at 37 ◦C for 16 h. The staining solution
was removed and the cells stored in 70% glycerol.
5.5 Genomic DNA isolation
Genomic DNA was extracted from HT-1080 cells using QIAamp
TM
DNA Mini Kit
(Qiagen R©) according to the manufacturers protocol. The buffer content of the
supplied kit was not provided by the manufacturer. In brief, cells were isolated by
centrifugation (up to 5×106 per sample) after trypsinisation. 20 µl of proteinase
K solution (600 mAU/ml) and 6 µl RNAse A (20 mg/ml, Invitrogen R©) were
added to each sample. 200 µl of the supplied buffer AL were added and the
resulting solution mixed thoroughly. The samples were incubated at 56 ◦C for 10
min. Subsequently, 200 µl of EtOH were added and the resulting solution mixed
thoroughly. The solution was transferred into a QIAmp
TM
mini spin column and
centrifuged at 8,000 rpm for 1 min. The supernatant was discarded and 500 µl
of buffer AW1 were added to the column. The sample was centrifuged at 8,000
rpm for 1 min. The supernatant was discarded and 500 µl of buffer AW2 were
added and the column centrifuged at 13,700 rpm for 3 min. The supernatant
was discarded. 200 µl of molecular biology grade DNase-free H2O were added to
each column and the column centrifuged at 8,000 rpm for 1 min to elute the final
genomic DNA solution.
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5.6 Non-denaturing hybridisation assay
To detect the 3′-G-overhang a non-denaturing hybridisation assay was performed.
5 µg of undigested genomic DNA, extracted from cells treated with or without
compounds 23, 25, 26, 31, 33, 44 or 53 at the respective GI50 concentrations and
respective time points, were hybridised for 16 h at 50 ◦C with 0.5 pmol of [γ-32P]
ATP-labelled oligonucleotide of the sequence (5′-(CCCTAA)3CCC-3′) in 30 µl
hybridisation buffer (20 mM Tris.HCl (pH 8.0), 0.5 mM EDTA, 50 mM NaCl, 10
mM MgCl2). Radioactive oligonucleotides were prepared by incorporating [γ-
32P]
ATP using T4 polynucleotide kinase with 70-80% labeling efficiency. Labeling was
achieved at 37 ◦C for 1 h and 95 ◦C for 5 min and a typical labeling reaction
solution consisted of: 1.2 µl 10 × PNK buffer, 4.0 µl 5′-(CCCTAA)3CCC-3′
at 1 µM, 0.3 µl T4 polynucleotide kinase solution, 1.2 µl [γ-32P] ATP stock
solution and 5.3 µl biology grade H2O. Hybridisation reactions were stopped by
the addition of 9 µl loading buffer (20% glycerol, 1 mM EDTA, 0.2% bromophenol
blue) and size-fractioned on a 0.7% agarose gel for 3 h at 45 V. The gels were
subsequently stained with EBr. The bottom of the gel was cut to remove unbound
probe and thus increase resolution. Gels were dried on Whatman R© filter paper at
60 ◦C and exposed overnight on an autoradiography film. EBr fluorescence and
the autoradiography film were scanned with a phosphorimager (Typhoon
TM
9210,
Amersham Biosciences R©). Results were expressed as the relative hybridisation
signal normalised to the fluorescent signal of EBr.
5.7 Genomic DNA sonication
Isolated genomic DNA from HT-1080 cells was sheared with a Bioruptor
TM
(UCD
200) sonicator (Diagenode R©). 200 µl of DNA sample was sonicated at 0 ◦C for 60
min. Sonication was performed at intervals (30 s on and 30 s off). This procedure
yielded DNA fragment sizes of approximately 100-500 bp, as assessed by agarose
gel electrophoresis.
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5.8 Pull-down studies
5.8.1 Pull-down studies on synthetic oligonucleotides
Oligonucleotide stock solutions of 100 µM were prepared using molecular biology
grade DNase-free H2O. Further dilutions were carried out in annealing buffer con-
taining 10 mM Tris.HCl (pH 7.4) and 60 mM KCl. The samples were annealed
by heating at 94 ◦C for 10 min followed by slow cooling to rt at a controlled rate
of 0.1 ◦C/min.
The following protocol was used for the experiments described in section 4.3:
In a pull-down experiment, 50 µl of oligonucleotide at 2 µM was incubated with
47, 48, 49, 50, 51, 52 or 53 (0, 1.0, 2.0, 4.0, 6.0, 10.0 and 14.0 µM) for 15
min at rt. The streptavidin-coated magnetic beads (Sigma Aldrich R©) isolated by
magnetic separation from 100 µl of the supplied suspension were washed twice
with 100 µl of annealing buffer. They were then incubated with the DNA/ligand
solution for 15 min at rt. The supernatant was separated from beads through
magnetic separation and analysed by UV.
The following protocol was used for the experiments described in section 4.4:
In a pull-down experiment, 100 µl of oligonucleotide at 5 µM was incubated with
53 (0, 3.0, 4.5, 6.5, 10.0 and 15.0 µM) for 30 min at rt. In experiments involving
G-quadruplex DNA/ds-DNA mixtures, 50 µl of a 5 µM ds-DNA solution was
added to 50 µl of a 5 µM G-quadruplex DNA solution, and the mixture was
incubated with a defined quantity of 53 (0, 3.0, 4.5, 6.5, 10.0 and 15.0 µM)
for 30 min at rt. One vial of streptavidin-coated magnetic beads (Streptavidin
MagneSphere
TM
paramagnetic particles, Promega R©), which had been washed
twice with 300 µl of annealing buffer, was then incubated with the solution for
30 min at rt. The supernatant was separated from beads through magnetic sep-
aration and analysed by UV or gel electrophoresis. In a recovery experiment, the
beads collected after pull-down were washed twice with 100 µl of 10 mM Tris.HCl
(pH 7.4). For the experiments involving DNA, 100 µl of an 8 M aq. LiCl solution
was added per vial of beads and incubated for 30 min at rt. The beads were heated
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for 5 min at 60 ◦C and the solution was separated from beads through magnetic
separation. Before analysis by gel electrophoresis, the supernatant was purified
using Illustra MicroSpin
TM
G-25 columns to remove LiCl (GE-Healthcare R©). For
the experiments involving RNA, 100 µl of an 8 M aq. urea solution was added to
each vial of beads and incubated for 30 min at rt. The solution was separated via
magnetic separation and analysed by UV without further purification. The ex-
periments of longer synthetic oligonucleotides (50-101 mer) were performed with
0, 1 and 3 mole equivalents of 53. The DNA concentrations used were 5 µM for
50 and 51mers and 1 µM for 100 and 101-mers, respectively. For the experiments
in the presence of the complementary strand, the strands had been annealed in a
1:1 mixture of both strands. Experiments were performed with a 1 µM or 5 µM
concentration of the resulting double-stranded DNA.
5.8.2 Co-operativity pull-down
Pull-down experiments in the presence of 23 were performed in an analogous
manner to the procedures described in section 5.8.1. The DNA was incubated
with 0.0, 10.0 or 20.0 µM 23 prior to adding 0.0, 5.0 or 15.0 µM 53. The
UV spectra were blanked against the respective solutions with the appropriate
concentrations of 23.
5.8.3 Pull-down studies on genomic DNA
Sonicated genomic DNA was annealed at a concentration of 0.52 µM in annealing
buffer as described in section 5.8.1. In a pull-down experiment, 100 µl of genomic
DNA (0.52 µM) were incubated with 53 (0, 2.6, 5.2 and 10.4 µM) for 2 h at rt.
The solution was then incubated with one vial of streptavidin-coated magnetic
beads, which had been washed twice with 300 µl of annealing buffer, for 1 h
at rt. The supernatant was separated from beads through magnetic separation,
purified using the QIAquick
TM
Nucleotide Removal Kit (Qiagen R©) In a recovery
experiment, the beads collected after pull-down were washed twice with 100 µl
of 10 mM Tris.HCl (pH 7.4). A urea solution (100 µl, 8 M aq.) was added to
the each vial of beads and the solution was incubated for 30 min at rt. The
solutions were recovered through magnetic separation and purified using Illustra
MicroSpin
TM
G-25 (GE-Healthcare R©) columns.
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5.8.4 Agarose gel electrophoresis
Gels were prepared at the given percentage of agarose (by weight) in TBE buffer
by heating in a microwave until a clear solution was obtained. The solution was
poured into a gel tank of the appropriate size fitted with a comb, and the gel was
left to cool and set at rt between 30 and 60 min. The comb was removed and
the tank filled with 1 × TBE buffer. DNA samples (10-60 µl) were loaded and
the gel run at the appropriate voltage and time to separate the DNA samples. 6
× loading buffer (20% glycerol, 1 mM EDTA, 0.2% bromophenol blue) was used
and diluted as appropriate. DNA was visualised by staining the gels subsequently
with Sybr
TM
Gold or EBr for 15 min.
5.8.5 Polyacrylamide gel electrophoresis
Denaturing polyacrylamide gel electrophoresis was performed by using 20% pre-
cast gels (Invitrogen R©) and run with the appropriate gel tank. Non-denaturing
polyacrylamide gel electrophoresis was performed by pouring the gels (10 × TBE
buffer (1 ml) , proto-gel polyacrylamide (6.6 ml), biology grade H2O (2.7 ml),
50 µl 10% w/v ammonium persulfate and 5 µl TEMED) which were stand to
set for 1 h and run in the appropriate gel tank. Samples were loaded using the
following 6 × loading buffer: 25 mg bromophenol blue, 25 mg xylene cyanol and
1.5 g Ficoll in biology grade H2O (10 ml). Gels were pre-run for 30 min and then
run at 50-100 V for 1-3 h depending on gel size and DNA fragment sizes. PAGE
was performed at 4 ◦C or rt depending on the separation of the DNA fragments.
DNA was visualised by staining the gels subsequently with Sybr
TM
Gold or EBr
for 15 min.
5.9 qPCR studies on genomic DNA
The composition of the PCR reactions performed on telomere and 36B4 control
gene were identical except for the primers. In a typical PCR experiment, the final
concentration of reagents were 0.2 × Sybr Green I solution, 15 mM TRIS.HCl
(pH 8.0), 50 mM KCl, 2 mM MgCl2, 0.2 mM of each dNTP, 5 mM DTT, 1%
DMSO, 1.25 U AmpliTaq GoldtextsuperscriptTM DNA polymerase and 35 ng
of pull-down supernatant genomic DNA in a final volume of 50 µl. The final
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telomere primer concentrations were: tel 1: 270 nM and tel 2: 900 nM. The
final 36B4 primer concentrations were: 36B4u: 300 nM and 36B4d: 500 nM.
The PAGE purified primer sequences were: tel 1 (5′-GGT TTT TGA GGG TGA
GGG TGA GGG TGA GGG TGA GGG T-3′), tel 2 (5′-TCC CGA CTA TCC
CTA TCC CTA TCC CTA TCC CTA TCC CTA-3′), 36B4u (5′-CAG CAA GTG
GGA AGG TGT AAT CC-3′) and 36B4d (5′-CCC ATT CTA TCA TCA ACG
GGT ACA A-3′). We performed the following controls in all the PCR reactions
performed on the supernatants after pull-down and solutions after recovery from
beads: 1) no template DNA; 2) Escherichia coli genomic DNA which does not
contain telomeres; 3) no primers and 4) no polymerase. The PCR cycle conditions
were set as follows: a preincubation step for 10 min at 95 ◦C to activate the DNA
polymerase for both the telomere and 36B4 control gene PCRs followed by 1)
33 cycles at 95 ◦C for 15 s and 54 ◦C for 2 min for telomere PCR and 2) 33
cycles at 95 ◦C for 15 s and 58 ◦C for 1 min for 36B4 PCR. The number of
PCR cycles was set to 22 when the telomere specific qPCR was performed on
genomic DNA solutions obtained after recovery from beads. All measurements
were performed in triplicate. C p values were calculated using LightCycler R© 480
software using the second derivative method. The ∆Cp values were calculated
using the following formula (5.3):
∆Cp = Cp.CON − Cp.[53] (5.1)
C p.CON = C p of control experiment, C p.[53] = C p of an experiment performed
with a defined molarity of 53.
The PCR amplification efficiencies, calculated from standard curves were 1.96
and 1.94 for telomere and 36B4 PCRs, respectively. Relative percentage ratios
of telomere and 36B4 in the supernatant obtained after pull-down were calculated
by using the following formula (5.2):
%Ratio = p-∆Cp × 100 (5.2)
p = primer efficiency.
To assess the significance of the experiment, we performed an unpaired t-test.
The p-values were as follows:
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[53] in µM telomere qPCR p-value 36B4 qPCR p-value
0.0 - -
2.6 0.0278 0.7122
5.2 0.0100 0.7258
10.4 0.0001 0.2836
Table 5.1: p-values for qPCR experiments
Agarose gel electrophoresis (2%) was carried out to visualise the qPCR am-
plified product of telomeric DNA recovered from the beads. The gel was run at
80 V for 90 min in 1 × TBE buffer and then stained with EBr.
5.10 Error calculations
Errors were calculated as the standard deviation using the following formula:
σ = 2
√√√√ 1
N
N∑
i=1
(xi − µ)2 (5.3)
σ = standard deviation, N = sample size, x = sample value, µ = mean value.
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Appendix A
Additional FRET-melting data
The FRET melting thermal shift profiles for compounds 18-46 are displayed in
Figure A.1, Figure A.2 and Figure A.3. The used targets are: • H-telo, • C-kit1,
• C-kit2, • C-myc, • Bcl-2 and • K-ras.
Figure A.1: FRET-melting thermal shift profiles for 18-23.
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Figure A.2: FRET-melting thermal shift profiles for 24-38.
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Figure A.3: FRET-melting thermal shift profiles for 39-46.
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The ∆Tm-values at 1 µM compound 18-46 are displayed in Table A.1 for C-kit1,
C-kit2, C-myc, Bcl-2 and K-ras. The values for H-telo and ds-DNA can be found
in Chapter 3 (Table 3.1).
∆Tm (K)
Compound C-kit1 C-kit2 C-myc Bcl-2 K-ras
18 25.6±0.7 19.7±0.5 9.1±0.2 14.7±0.8 15.2±0.7
19 31.8±0.9 9.7±0.5 16.3±0.8 22.7±0.7 18.0±0.8
20 26.2±0.9 12.1±0.9 2.9±0.1 3.5±0.4 8.4±0.9
21 19.2±0.8 14.5±0.7 10.3±0.5 9.9±1.1 9.9±0.4
22 26.8±0.5 19.5±1.2 16.6±0.4 18.2±0.6 16.7±0.4
23 35.0±0.7 22.3±0.7 16.8±0.8 19.2±0.9 20.2±0.8
24 22.2±0.4 16.2±0.7 15.8±0.8 21.0±1.0 29.9±0.9
25 31.2±0.9 16.0±0.5 17.0±0.8 5.9±0.7 40.4±0.9
26 24.5±0.7 14.9±0.7 17.1±0.8 15.6±1.1 25.7±0.7
27 14.6±0.5 11.5±1.0 7.4±0.6 14.6±0.5 5.4±0.4
28 16.5±1.0 9.6±0.4 6.3±0.3 7.5±0.4 4.7±0.3
29 17.7±0.7 11.2±0.6 4.9±0.8 7.1±1.1 17.8±0.7
30 1.2±0.6 1.1±0.5 0.4±0.2 0.3±0.3 2.3±0.3
31 33.3±0.9 14.4±0.6 16.0±1.0 23.1±0.9 25.7±0.7
32 29.1±0.7 17.3±0.3 17.1±0.5 18.9±9.7 15.1±0.9
33 22.2±0.9 9.6±0.7 14.5±0.8 8.6±0.9 12.2±0.6
34 19.6±0.4 13.3±0.4 12.1±0.5 11.5±0.9 10.3±0.5
35 31.6±0.5 9.7±0.5 16.9±0.8 22.7±0.8 18.3±0.4
36 15.5±0.6 9.4±0.3 2.3±0.3 13.2±0.8 10.7±0.5
37 9.1±0.9 3.8±0.4 5.3±0.5 6.7±0.5 3.2±0.4
38 9.9±0.9 7.2±0.6 5.8±0.1 14.4±0.9 5.8±0.5
39 9.8±0.5 7.4±0.3 5.9±0.3 14.3±0.8 5.9±0.5
40 13.5±0.8 7.2±0.4 5.7±0.4 2.5±0.4 5.8±0.3
41 15.5±0.5 9.2±0.5 5.3±0.5 4.2±0.3 4.8±0.4
42 18.5±0.8 13.2±0.3 11.1±0.4 6.5±0.3 10.4±0.4
43 38.1±0.7 20.9±0.9 16.8±0.7 21.6±0.9 26.1±0.5
44 28.7±0.9 19.3±0.8 16.5±1.0 19.6±0.7 9.6±0.3
45 17.1±0.8 3.6±0.7 13.8±0.5 32.0±0.7 16.0±1.1
46 20.1±0.9 15.8±1.1 13.2±0.7 17.1±0.9 22.3±0.9
Table A.1: ∆Tm at 1µM compound 18-46.
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Appendix B
NCI growth arrest data
The data provided by the cell-line screen performed by the NCI are displayed in
this appendix. The growth curves of 60 cancer cell lines treated with different
doses of 20, 25, 26 and 31 are displayed. They were determined from five
doses of compound. The appendix also features tables listing the various GI50,
TGI and LC50 values. Furthermore, the appendix shows the mean values of the
aforementioned constants. The accumulative data describes and summarises the
effects these compounds have on the growth properties of the cancer cell lines
investigated.
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Figure B.1: Growth curves of various cancer cell lines treated with increasing molar-
ities of 20.
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Figure B.2: GI50, TGI and LC50 values of various cancer cell lines treated with 20.
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Figure B.3: Mean values of GI50, TGI and LC50 against various cancer cell lines
treated with 20.
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Figure B.4: Growth curves of various cancer cell lines treated with increasing molar-
ities of 25.
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Figure B.5: GI50, TGI and LC50 values of various cancer cell lines treated with 25.
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Figure B.6: Mean values of GI50, TGI and LC50 against various cancer cell lines
treated with 25.
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Figure B.7: Growth curves of various cancer cell lines treated with increasing molar-
ities of 26.
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Figure B.8: GI50, TGI and LC50 values of various cancer cell lines treated with 26.
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Figure B.9: Mean values of GI50, TGI and LC50 against various cancer cell lines
treated with 26.
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Figure B.10: Growth curves of various cancer cell lines treated with increasing mo-
larities of 31.
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Figure B.11: GI50, TGI and LC50 values of various cancer cell lines treated with 31.
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Figure B.12: Mean values of GI50, TGI and LC50 against various cancer cell lines
treated with 31.
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Appendix C
ADME studies
ADME studies were carried out on compounds 20, 21, 22 and 23 by Cancer
Research Technology R© Ltd. and the results are tabulated hereafter (Table C.1).
test target 20 21 22 23
solubility > 40 µM 151 µM < 5 µM 158 µM < 5 µM
permeability Caco 2-A-B >5×106 0.38×106 1.10×106 3.96×106 1.64×106
cm×s−1 cm×s−1 cm×s−1 cm×s−1 cm×s−1
eﬄux ratio <2 0.46 1.09 3.31 0.89
stability microsome <80% 2% 45% 0% 0%
turnover1
microsome <80% 48% 61% 22% 59%
turnover2
plasma protein <99% 100% 100% 100% 99%
binding
CyP450 1A2 >1 µM >10 µM >10 µM >10 µM >10 µM
inhibition 2D6 >1 µM >10 µM >10 µM >10 µM >10 µM
2C9 >1 µM >10 µM >10 µM >10 µM >10 µM
2C19 >1 µM >10 µM >10 µM >10 µM >10 µM
3A4 >1 µM >10 µM >10 µM >10 µM >10 µM
hERG binding <50% n.d. 40% 55% n.d.
inhibition at 10 µM
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test target 20 21 22 23
muscarinic M1 <50% n.d. 83% 84% n.d.
receptor at 10 µM
binding M2 <50% n.d. n.d. 78% n.d.
inhibition at 10 µM
M3 <50% n.d. 35% 60% n.d.
at 10 µM
Table C.1: ADME results for compounds 20, 21, 22 and 23.
1homo sapiens
2mus musculus
176
References
[1] J. Watson and F. Crick. Molecular structure of nucleic acids. Nature, 171:
737–738, 1953. 1
[2] M. H. F. Wilkins, A. R. Stokes, and H. R. Wilson. Molecular structure of
deoxypentose nucleic acids. Nature, 171:738–740, 1953.
[3] R. E. Franklin and R. G. Gosling. Molecular configuration in sodium thy-
monucleate. Nature, 171:740–741, 1953. 1
[4] I. Bang. Physiological action of guanylic acid. Z. Physiol. Chem., 32:201–
213, 1901. 1
[5] M. Gellert, M. N. Lipsett, and D. R. Davies. Helix formation by guanylic
acid. Proc. Natl. Acad. Sci. U.S.A., 48:2013–2018, 1962. 1
[6] K. Phillips, Z. Dauter, A. I. Murchie, D. M. Lilley, and B. Luisi. The crystal
structure of a parallel-stranded guanine tetraplex at 0.95 A˚ resolution. J.
Mol. Biol., 273:171–182, 1997. 1
[7] M. A. Read and S. Neidle. Structural characterization of a guanine-
quadruplex ligand complex. Biochemistry, 39:13422–13432, 2000.
[8] G. N. Parkinson, M. P. H. Lee, and S. Neidle. Crystal structure of parallel
quadruplexes from human telomeric DNA. Nature, 417:876–880, 2002. 2, 3
[9] N. H. Campbell and G. N. Parkinson. Crystallographic studies of quadru-
plex nucleic acids. Methods, 43:252–263, 2007.
[10] S. Neidle and G. N. Parkinson. Quadruplex DNA crystal structures and
drug design. Biochimie, 90:1184–1196, 2008. 1
177
REFERENCES
[11] Y. Wang and D. J. Patel. Guanine residues in d(T2AG3) and d(T2G4)
form parallel-stranded potassium cation stabilized G-quadruplexes with
anti-glycosidic torsion angles in solution. Biochemistry, 31:8112–8119, 1992.
1
[12] Y. Wang and D. J. Patel. Solution structure of a parallel-stranded G-
quadruplex DNA. J. Mol. Biol., 234:1171–1183, 1993.
[13] M. A. Keniry, G. D. Strahan, E. A. Owen, and R. H. Shafer. Solution
structure of the Na+ form of the dimeric guanine quadruplex [d(G3T4G3)]2.
Eur. J. Biochem., 233:631–643, 1995.
[14] Y. Wang and D. J. Patel. Solution structure of the Oxytricha telomeric
repeat d[G4(T4G4)3] G-tetraplex. J. Mol. Biol., 251:76–94, 1995.
[15] A. Ambrus, D. Chen, J. Dai, R. A. Jones, and D. Yang. Solution structure
of the biologically relevant G-quadruplex element in the human c-MYC
promoter. Implications for G-quadruplex stabilization. Biochemistry, 44:
2048–2058, 2005. 1, 14, 31, 46, 76
[16] V. Sasisekharan, S. Zimmerman, and D. R. Davies. The structure of helical
5’-guanosine monophosphate. J. Mol. Biol., 92:171–179, 1975. 1
[17] S. Arnott, R. Chandrasekaran, and C. M. Marttila. Structures for polyi-
nosinic acid and polyguanilyc acid. Biochem. J., 141:537–543, 1974. 1
[18] G. Laughlan, A. I. Murchie, D. G. Norman, M. H. Moore, P. C. Moody,
D. M. Lilley, and B. Luisi. The high-resolution crystal structure of a parallel-
stranded guanine tetraplex. Science, 265:520–524, 1994. 1
[19] J. R. Williamson. G-quartet structures in telomeric DNA. Annu. Rev.
Biophys. Biomol. Struct., 23:703–730, 1994. 1
[20] T. Simonsson. G-quadruplex structures - variations on a theme. Biol.
Chem., 382:621–628, 2001. 2
[21] S. Burge, G. N. Parkinson, P. Hazel, A. K. Todd, and S. Neidle. Quadruplex
DNA: sequence, topology and structure. Nucleic Acids Res., 34:5402–5415,
2006.
178
REFERENCES
[22] J. Dai, M. Carver, and D. Yang. Polymorphism of human telomeric quadru-
plex structures. Biochimie, 90:1172–1183, 2008. 2
[23] D. Miyoshi, A. Nakao, and N. Sugimoto. Structural transition from an-
tiparallel to parallel G-quadruplex of d(G4T4G4) induced by Ca
2+. Nucleic
Acids Res., 31:1156–1163, 2003. 2
[24] P. Hazel, J. Huppert, S. Balasubramanian, and S. Neidle. Loop-length-
dependent folding of G-quadruplexes. J. Am. Chem. Soc., 126:16405–16415,
2004. 2, 6
[25] A. Bugaut and S. Balasubramanian. A sequence-independent study of the
influence of short loop lengths on the stability and topology of intramolec-
ular DNA G-quadruplexes. Biochemistry, 47:689–697, 2008. 2, 6
[26] D.-H. Zhang, T. Fujimoto, S. Saxena, H.-Q. Yu, D. Miyoshi, and N. Sug-
imoto. Monomorphic RNA G-quadruplex and polymorphic DNA G-
quadruplex structures responding to cellular environmental factors. Bio-
chemistry, 49:4554–4563, 2010. 2
[27] L. Ying, J. J. Green, H. Li, D. Klenerman, and S. Balasubramanian. Studies
on the structure and dynamics of the human telomeric G quadruplex by
single-molecule fluorescence resonance energy transfer. Proc. Natl. Acad.
Sci. U.S.A., 100:14629–14634, 2003. 4
[28] A. M. Zahler, J. R. Williamson, T. R. Cech, and D. M. Prescott. Inhibition
of telomerase by G-quartet DNA structures. Nature, 350:718–720, 1991. 4,
5, 10, 64
[29] J. L. Huppert and S. Balasubramanian. G-quadruplexes in promoters
throughout the human genome. Nucleic Acids Res., 35:406–413, 2007. 4,
13
[30] D. Drygin, A. Siddiqui-Jain, S. O’Brien, M. Schwaebe, A. Lin, J. Bilesath,
C. B. Ho, C. Proffitt, K. Trent, J. O. Whitten, J. K. Lim, D. Von Hoff,
K. Anderes, and W. G. Rice. Anticancer activity of CX-3543: a direct
inhibitor of rRNA biogenesis. Cancer Res., 69:7653–7661, 2009. 4, 7, 10
179
REFERENCES
[31] Y. Wu, K. Shin-ya, and R. M. Brosh Jr. FANCJ helicase defective in
Fanconia anemia and breast cancer unwinds G-quadruplex DNA to defend
genome stability. Mol. Cell. Biol., 28:4116–4128, 2008. 4, 9, 13
[32] J. Christiansen, M. Kofod, and F. C. Nielsen. A guanosine quadruplex and
two stable hairpins flank a major cleavage site in insulin-like growth factor
II mRNA. Nucleic Acids Res., 22:5709–5716, 1994. 4, 17
[33] M. Wieland and J. S. Hartig. RNA quadruplex-based modulation of gene
expression. Chem. Biol., 14:757–763, 2007.
[34] S. Kumari, A. Bugaut, J. L. Huppert, and S. Balasubramanian. An RNA
G-quadruplex in the 5’-UTR of the NRAS proto-oncogene modulates trans-
lation. Nat. Chem. Biol., 3:218–221, 2007. 17, 78
[35] J. L. Huppert, A. Bugaut, S. Kumari, and S. Balasubramanian. G-
quadruplexes: the beginning and end of UTRs. Nucleic Acids Res., 36:
6260–6268, 2008. 17, 64
[36] A. Bugaut, R. Rodriguez, S. Kumari, S.-T. D. Hsu, and S. Balasubra-
manian. Small-molecule mediated inhibition of translation by targeting a
native RNA-G-quadruplex. Org. Biomol. Chem., 8:2771–2776, 2010. 4, 17,
21, 39, 62
[37] J. L. Huppert and S. Balasubramanian. Prevalence of quadruplexes in the
human genome. Nucleic Acids Res., 33:2908–2916, 2005. 5, 19, 64, 84, 95
[38] A. K. Todd, M. Hohnston, and S. Neidle. Highly prevalent putative quadru-
plex sequence motifs in human DNA. Nucleic Acids Res., 33:2901–2907,
2005. 5, 19
[39] D. Sun, B. Thompson, B. E. Cathers, M. Salazar, S. M. Kerwin, J. O.
Trent, T. C. Jenkins, S. Neidle, and L. H. Hurley. Inhibition of human
telomerase by a G-quadruplex-interactive compound. J. Med. Chem., 40:
2113–2116, 1997. 5, 6, 19
[40] R. T. Wheelhouse, D. K. Sun, H. Y. Han, F. X. Han, and L. H. Hurley.
Cationic porphyrins as telomerase inhibitors: the interaction of tetra-(N -
180
REFERENCES
methyl-4-pyridyl)porphine with quadruplex DNA. J. Am. Chem. Soc., 120:
3261–3262, 1998. 5, 6
[41] K. Shin-ya, K. Wierzba, K. Matsuo, T. Ohtani, Y. Yamada, K. Furihata,
Y. Hayakwa, and H. Seto. Telomestatin, a novel telomerase inhibitor from
Streptomyces anulatus. J. Am. Chem. Soc., 123:1262–1263, 2001. 5, 6, 12,
21
[42] D. Gomez, T. Wenner, B. Brassart, C. Douarre, M.-F. O’Donohue,
V. El Khoury, K. Shin-ya, H. Morjani, C. Trentesaux, and J.-F. Riou.
Telomestatin-induced telomere uncapping is modulated by POT1 through
G-overhang extension in HT1080 human tumor cells. J. Biol. Chem., 281:
38721–38729, 2006. 5, 6, 11, 37, 39, 55
[43] R. J. Harrison, S. M. Gowan, L. R. Kelland, and S. Neidle. Human telom-
erase inhibition by substituted acridine derivatives. Bioorg. Med. Chem.
Lett., 9:2463–2468, 1999. 6
[44] S. M. Gowan, J. R. Harrison, L. Patterson, M. Valenti, M. R. Read, S. Nei-
dle, and L. R. Kelland. A G-quadruplex-interactive potent small-molecule
inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.
Mol. Pharmacol., 61:1154–1162, 2002. 7, 39, 56
[45] R. A. Heald, C. Modi, J. C. Cookson, I. Hutchinson, C. A. Laughton,
S. M. Gowan, L. R. Kelland, and M. F. Stevens. Antitumour polycyclic
acridines. Synthesis and telomerease-inhibitory activity of methylated pen-
tacyclic acridinium salts. J. Med. Chem., 45:590–597, 2002.
[46] A. M. Burger, F. Dai, C. M. Schultes, A. P. Reszka, M. J. Moore, J. A.
Double, and S. Neidle. The G-quadruplex-interactive molecule BRACO-19
inhibits tumor growth, consistent with telomere targeting and interference
with telomerase function. Cancer Res., 65:1486–1496, 2005. 7, 11, 12
[47] M. J. B. Moore, C. M. Schultes, J. Cuesta, F. Cuenca, M. Gunaratnam,
F. A. Tanious, W. D. Wilson, and S. Neidle. Trisubstituted acridines as
G-quadruplex telomere targeting agents. Effects of extensions of the 3,6 and
9-side chains on quadruplex binding, telomerase activity, and cell prolifer-
ation. J. Med. Chem., 49:582–599, 2006.
181
REFERENCES
[48] M. Gunaratnam, O. Greciano, C. Martins, A. P. Reszka, C. M. Schultes,
H. Morjani, J.-F. Riou, and S. Neidle. Mechanism of acridine-based telom-
erase inhibition and telomere shortening. Biochem. Pharmacol., 74:679–689,
2007. 11, 12, 39
[49] C. Martins, M. Gunaratnam, J. Stuart, V. Makwana, O. Greciano,
A. P. Reszka, L. R. Kelland, and S. Neidle. Structure-based design of
benzylamino-acridine compounds as G-quadruplex DNA telomere target-
ing agents. Bioorg. Med. Chem. Lett., 17:2293–2298, 2007.
[50] R. Rodriguez, G. D. Pantos¸, D. P. N. Gonc¸alves, J. K. M. Sanders, and
S. Balasubramanian. Ligand-driven G-quadruplex conformational switch-
ing by using an unusual mode of interaction. Angew. Chem. Int. Ed., 46:
5404–5407, 2007. 20
[51] M. Laronze-Cochard, Y.-M. Kim, B. Brassart, J.-F. Riou, J.-Y.
Laronze, and J. Sapi. Synthesis and biological evaluation of novel
4,5-bis(dialkylaminoalkyl)-substituted acridines as potent telomeric G-
quadruplex ligands. Eur. J. Med. Chem., 44:3880–3888, 2009. 6
[52] P. J. Perry, S. M. Gowan, A. P. Reszka, P. Polucci, T. C. Jenkins, L. R.
Kelland, and S. Neidle. 1,4- and 2,6-disubstituted amidoanthracene-9,10-
dione derivatives as inhibitors of human telomerase. J. Med. Chem., 41:
3253–3260, 1998. 6
[53] P. J. Perry, A. P. Reszka, A. A. Wood, M. A. Read, S. M. Gowan, H. S.
Dosanjh, J. O. Trent, T. C. Jenkins, L. R. Kelland, and S. Neidle. Human
telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-
diones. J. Med. Chem., 41:4873–4884, 1998. 6
[54] P. J. Perry, M. A. Read, R. T. Davies, S. M. Gowan, A. P. Reszka, A. A.
Wood, L. R. Kelland, and S. Neidle. 2,7-disubstituted amidofluorenone
derivatives as inhibitors of human telomerase. J. Med. Chem., 42:2679–
2684, 1999. 6
[55] F. Koeppel, J.-F. Riou, A. Laoui, P. B. Arimondo, D. Labit, O. Petitgenet,
C. He´le`ne, and J.-L. Mergny. Ethidium derivatives bind to G-quartets,
182
REFERENCES
inhibit telomerase and act as fluorescent probes for quadruplexes. Nucleic
Acids Res., 29:1087–1096, 2001. 6
[56] A. Maraval, S. Franco, C. Vialas, G. Pratviel, M. A. Blasco, and B. Meu-
nier. Porphyrin-aminoquinoline conjugates as telomerase inhibitors. Org.
Biomol. Chem., 1:921–927, 2003. 6
[57] M. Y. Kim, M. Gleason-Guzman, E. Izbicka, D. Nishioka, and L. H. Hur-
ley. The different biological effects of telomestatin and TMPyP4 can be
attributed to their selectivity for interaction with intramolecular or inter-
molecular G-quadruplex structures. Cancer Res., 63:3247–3256, 2003. 6,
39, 56
[58] J. Seenisamy, S. Bashyam, V. Gokhale, H. Vankayalapati, D. Sun,
A. Siddiqui-Jain, N. Streiner, K. Shin-ya, E. White, W. D. Wilson, and
L. H. Hurley. Design and synthesis of an expanded porphyrin that has se-
lectivity for the c-MYC G-quadruplex structure. J. Am. Chem. Soc., 127:
2944–2959, 2005. 7, 14, 31
[59] G. N. Parkinson, R. Ghosh, and S. Neidle. Structural basis for binding of
porphyrin to human telomeres. Biochemistry, 46:2390–2397, 2007. 6, 19
[60] J.-L. Mergny, L. Lacroix, M.-P. Teulade-Fichou, C. Hounsou, L. Guittat,
M. Hoarau, P. B. Arimondo, J.-P. Vigneron, J.-M. Lehn, J.-F. Riou, T. Ger-
estier, and C. He´le`ne. Telomerase inhibitors based on quadruplex ligands
selected by a fluorescence assay. Proc. Natl. Acad. Sci. U.S.A., 98:3062–
3067, 2001. 6
[61] R. Samudrala, X. Zhang, R. M. Wadkins, and D. L. Mattern. Synthesis of a
non-cationic, water-soluble perylenetetracarboxylic diimide and its interac-
tions with G-quadruplex-forming DNA. Bioorg. Med. Chem., 15:186–193,
2007. 6
[62] C. Pivetta, L. Lucatello, A. P. Krapcho, B. Gatto, M. Palumbo, and C. Sissi.
Perylene side chains modulate G-quadruplex conformation in biologically
relevant DNA sequences. Bioorg. Med. Chem., 16:9331–9339, 2008. 6
183
REFERENCES
[63] J. H. Kim, J. H. Kim, G. E. Lee, S. W. Kim, and I. K. Jung. Identification
of a quinoxaline derivative that is a potent telomerase inhibitor leading to
cellular senescence of human cancer cells. Biochem. J., 373:523–529, 2003.
6
[64] V. Caprio, B. Guyen, Y. Opoku-Boahen, J. Mann, S. M. Gowan, L. M.
Kelland, M. A. Read, and S. Neidle. A novel inhibitor of human telomerase
derived from 10H -indolo[3,2b]quinoline. Bioorg. Med. Chem. Lett., 10:2063–
2066, 2000. 6, 20
[65] W. C. Drewe, R. Nanjunda, M. Gunaratnam, M. Beltran, G. N. Parkinson,
A. P. Reszka, W. D. Wilson, and S. Neidle. Rational design of substituted
diarylureas: a scaffold for binding to G-quadruplex motifs. J. Med. Chem.,
51:7751–7767, 2008. 6, 8, 30
[66] W. C. Drewe and S. Neidle. Click chemistry assembly of G-quadruplex lig-
ands incorporating a diarylurea scaffold and triazole linkers. Chem. Com-
mun., pages 5295–5297, 2008. 6, 45
[67] M. Bejugam, S. Sewitz, P. S. Shirude, R. Rodriguez, R. Shahid, and S. Bal-
asubramanian. Trisubstituted isoalloxazines as a new class of G-quadruplex
binding ligands: small molecule regulation of c-kit oncogene expression. J.
Am. Chem. Soc., 129:11890–11891, 2007. 6, 14, 64
[68] K. Jantos, R. Rodriguez, S. Ladame, P. S. Shirude, and S. Balasubrama-
nian. Oxazole-based peptide macrocycles: A new class of G-quadruplex
binding ligands. J. Am. Chem. Soc., 128:13662–13663, 2006. 6, 20, 32
[69] G. S. Minhas, D. S. Pilch, J. E. Kerrigan, E. J. LaVoie, and J. E. Rice.
Synthesis and G-quadruplex stabilizing properties of a series of oxazole-
containing macrocycles. Bioorg. Med. Chem. Lett., 16:3891–3895, 2006.
[70] D. A. Pilch, C. M. Barbieri, S. G. Rzuczek, E. J. Lavoie, and J. E. Rice.
Targting human telomeric G-quadruplex DNA with oxazole-containing
macrocyclic compounds. Biochimie, 90:1233–1249, 2008.
[71] A. Bugaut, K. Jantos, J.-L. Wietor, R. Rodriguez, J. K. M. Sanders, and
S. Balasubramanian. Exploring the differential recognition of DNA G-
184
REFERENCES
quadruplex targets by small molecules using dynamic combinatorial chem-
istry. Angew. Chem. Int. Ed., 47:2677–2680, 2008. 6, 20
[72] J.-F. Riou, L. Guittat, P. Mailliet, A. Laoui, E. Renou, P. Petitgenet,
F. Megnin-Chanet, C. He´le`ne, and J.-L. Mergny. Cell senescence and telom-
ere shortening induced by a new series of specific G-quadruplex DNA lig-
ands. Proc. Natl. Acad. Sci. U.S.A., 99:2672–2677, 2002. 6, 8, 12, 39, 56,
58
[73] D. Gomez, N. Aouali, A. Londono-Vallejo, L. Lacroix, F. Megnin-Chanet,
T. Lemarteleur, C. Douarre, K. Shin-ya, P. Mailliet, C. Trentesaux, H. Mor-
jani, J.-L. Mergny, and J.-F. Riou. Resistance to the short term antiprolif-
erative activity of the G-quadruplex ligand 12459 is associated with telom-
erase overexpression and telomere capping alteration. J. Biol. Chem., 278:
50554–50562, 2003. 6, 12
[74] R. J. Harrison, A. P. Reszka, S. M. Haider, B. Romagnoli, J. Morrell,
M. A. Read, S. M. Gowan, C. M. Incles, L. R. Kelland, and S. Neidle.
Evaluation of disubstituted acridone derivatives as telomerase inhibitors:
the importance of G-quadruplex binding. Bioorg. Med. Chem. Lett., 14:
5845–5849, 2004. 6
[75] F. Cuenca, M. J. B. Moore, K. Johnson, B. Guyen, A. De Cian, and S. Nei-
dle. Design, synthesis and evaluation of 4,5-di-substituted acridone ligands
with high G-quadruplex affinity and selectivity, together with low toxicity
to normal cells. Bioorg. Med. Chem. Lett., 19:5109–5113, 2009. 6, 8
[76] M. P. Teulade-Fichou, C. Carrasco, L. Guittat, C. Bailly, P. Alberti, J.-L.
Mergny, A. David, J.-M. Lehn, and W. D. Wilson. Selective recognition
of G-quadruplex telomeric DNA by a bis(quinacridine). Proc. Natl. Acad.
Sci. U.S.A., 98:3062–3067, 2001. 6
[77] C. Hounsou, L. Guittat, D. Monchaud, M. Jourdan, N. Saettel, J.-
L. Mergny, and M.-P. Teulade-Fichou. G-quadruplex recognition by
quinacridines: a SAR, NMR and biological study. ChemMedChem, 2:655–
666, 2007.
185
REFERENCES
[78] H. Bertrand, S. Bombard, D. Monchaud, and M.-P. Teulade-Fichou. A
platinum-quinacridine hybrid as a G-quadruplex ligand. J. Biol. Inorg.
Chem., 12:1003–1014, 2007. 6
[79] Z. A. E. Waller, P. S. Shirude, R. Rodriguez, and S. Balasubramanian. Tri-
arylpyridines: a versatile small molecule scaffold for G-quadruplex recogni-
tion. Chem. Commun., pages 1467–1469, 2008. 6, 32
[80] C. Leonetti, S. Amodei, C. D’Angelo, A. Rizzo, B. Banassi, A. Antonelli,
R. Elli, M. F. Stevens, M. D’Incalci, G. Zupi, and G. Biroccio. Biological
activity of the G-quadruplex ligand RHPS4 (3,11-difluoro-6,8,13-trimethyl-
8H -quino[4,3,2-kl ]acridinium methosulfate) is associated with telomere cap-
ping alteration. Mol. Pharmacol., 66:1138–1146, 2004. 6, 7
[81] M. A. Read, A. A. Wood, J. R. Harrison, S. M. Gowan, L. R. Kelland,
H. S. Dosanjh, and S. Neidle. Molecular modeling studies on G-quadruplex
complexes of telomerase inhibitors: structure-activity relationships. J. Med.
Chem., 42:4538–4546, 1999.
[82] W. Duan, A. Rangan, H. Vankayalapati, M. Y. Kim, Q. Zeng, D. Sun,
H. Han, O. Y. Fedoroff, D. Nishioka, S. Y. Rha, E. Izbicka, D. D. Von Hoff,
and L. H. Hurley. Design and synthesis of fluoroquinophenoxazines that
interact with human telomeric G-quadruplexes and their biological effects.
Mol. Cancer Ther., 1:103–120, 2001. 39, 56
[83] M. A. Read, R. J. Harrison, B. Romagnoli, F. A. Tanious, S. M. Gowan,
A. P. Reszka, W. D. Wilson, L. R. Kelland, and S. Neidle. Structure-
based design of selective and potent G-quadruplex-mediated telomerase in-
hibitors. Proc. Natl. Acad. Sci. U.S.A., 98:4844–4849, 2001.
[84] A. Siddiqui-Jain, C. L. Grand, D. J. Bearss, and L. H. Hurley. Direct
evidence for a G-quadruplex in a promoter region and its targeting with
a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci.
U.S.A., 99:11593–11598, 2002. 14, 15, 31, 46, 64
[85] S. Ladame, J. A. Schouten, J. Stuart, J. Roldan, S. Neidle, and S. Balasub-
ramanian. Tetrapeptides induce selective recognition for G-quadruplexes
186
REFERENCES
when conjugated to a DNA-binding platform. Org. Biomol. Chem., 2:2925–
2931, 2004.
[86] A. T. Phan, V. Kuryavyi, H. Y. Gaw, and D. J. Patel. Small-molecule in-
teraction with a five-guanine-tract G-quadruplex structure from the human
MYC promoter. Nat. Chem. Biol., 1:167–173, 2005. 6, 14, 31, 46
[87] D. Sun, K. Guo, J. J. Rusche, and L. H. Hurley. Facilitation of a structural
transition in the polypurine/polypyrimidine tract within the proximal pro-
moter region of the human VEGF gene by the presence of potassium and
G-quadruplex-interactive agents. Nucleic Acids Res., 33:6070–6080, 2005.
14
[88] J.-L. Zhou, Y.-J. Lu, T.-M. Ou, J.-M. Zhou, Z.-S. Huang, X.-F. Zhu, C.-J.
Du, X.-Z. Bu, L. Ma, L.-Q. Gu, Y.-M. Li, and A. S.-C. Chan. Synthesis
and evaluation of quindoline derivatives as G-quadruplex inducing and sta-
bilizing ligands and potential inhibitors of telomerase. J. Med. Chem., 48:
7315–7321, 2005.
[89] D. P. N. Gonc¸alves, R. Rodriguez, S. Balasubramanian, and J. K. M.
Sanders. Tetramethylpryidiniumporphyrazines - a new class of G-
quadruplex inducing and stabilising ligands. Chem. Commun., pages 4685–
4687, 2006.
[90] J. Hooda, D. Bednarski, L. Irish, and S. M. Firestine. Synthesis and testing
of a triaza-cyclopenta[b]phenanthrene scaffold as a DNA binding agent.
Bioorg. Med. Chem., 14:1902–1909, 2006.
[91] J. E. Reed, A. A. Arnal, S. Neidle, and R. Vilar. Stabilization of G-
quadruplex DNA and inhibition of telomerase activity by square-planar
nickel (II) complexes. J. Am. Chem. Soc., 128:5992–5993, 2006.
[92] T. Ou, Y. J. Lu, C. Zhang, Z. S. Huang, X. D. Wang, J. H. Tan, Y. Chen,
D. L. Ma, K. Y. Wong, J. C. Tang, A. S. Chan, and L. Q. Gu. Stabi-
lization of G-quadruplex DNA and down-regulation of oncogene c-myc by
quindoline derivatives. J. Med. Chem., 50:1465–1474, 2007. 14, 31
187
REFERENCES
[93] D. Monchaud and M.-P. Teulade-Fichou. A hitchhiker’s guide to G-
quadruplex ligands. Org. Biomol. Chem., 6:627–636, 2007. 20, 21, 32
[94] A. De Cian, E. DeLemos, J.-L. Mergny, M.-P. Teulade-Fichou, and D. Mon-
chaud. Highly efficient G-quadruplex recognition by bisquinolinium com-
pounds. J. Am. Chem. Soc., 129:1856–1857, 2007.
[95] G. Zagatto, C. Sissi, S. Moro, D. Dal Ben, G. N. Parkinson, K. R. Fox,
S. Neidle, and M. Palumbo. Amide bond direction modulates G-quadruplex
recognition and telomerase inhibition by 2,6 and 2,7 bis-substituted an-
thracenedione derivatives. Bioorg. Med. Chem., 16:354–361, 2008. 20
[96] J. Dash, P. S. Shirude, and S. Balasubramanian. G-quadruplex recognition
by bis-indole carboxamides. Chem. Commun., pages 3055–3057, 2008. 32
[97] J. Dash, P. S. Shirude, S.-T. D. Hsu, and S. Balasubramanian. Di-
arylethynyl amides that recognize the parallel conformation of genomic pro-
moter DNA G-quadruplexes. J. Am. Chem. Soc., 130:15950–15956, 2008.
20
[98] J.-H. Tan, T.-M. Ou, J.-Q. Hou, Y.-J. Lu, S.-L. Huang, H.-B. Luo, J.-Y.
Wu, Z.-S. Huang, K.-Y. Wong, and L.-Q. Gu. Isaindigotone derivatives: a
new class of highly selective ligands for telomeric G-quadruplex DNA. J.
Med. Chem., 52:2825–2835, 2009.
[99] Q. Li, J. Xiang, X. Li, L. Chen, X. Xu, Y. Tang, Q. Zhou, L. Li, H. Zhang,
X. Sun, A. Guan, Q. Yang, S. Yang, and G. Xu. Stabilising parallel
G-quadruplex DNA by a new class of ligands: two non-planar alkaloids
through interaction in lateral grooves. Biochimie, 91:811–819, 2009. 6, 19
[100] J. Debray, W. Zeghida, M. Jourdan, D. Monchaud, M.-L. Dheu-Andries,
P. Dumy, M.-P. Teulade-Fichou, and M. Demeunynck. Synthesis and eval-
uation of fused bispyrimidinoacridines as novel pentacyclic analogues of
quadruplex-binder BRACO-19. Org. Biomol. Chem., 7:5219–5228, 2009.
[101] J. E. Moses, D. J. Ritson, F. Zhang, C. M. Lombardo, S. Haider, N. Oldham,
and S. Neidle. A click chemistry approach to C 3 symmetric, G-quadruplex
stabilising ligands. Org. Biomol. Chem., 8:2926–2930, 2010. 45
188
REFERENCES
[102] M. Satyanarayana, Y.-A. Kim, S. G. Rzuczek, D. S. Pilch, A. A. Liu, L. F.
Liu, J. E. Rice, and E. J. LaVoie. Macroyclic hexaoxazoles: influence of
aminoalkyl substituents on RNA and DNA G-quadruplex stabilization and
cytotoxicity. Bioorg. Med. Chem. Lett., 20:3150–3154, 2010.
[103] S. G. Rzuczek, D. S. Pilch, A. Liu, L. Liu, E. J. LaVoie, and J. E. Rice.
Macrocyclic pyridyl polyoxazoles: selective RNA and DNA G-quadruplex
ligands as antitumor agents. J. Med. Chem., 53:3632–3644, 2010.
[104] M. Bejugam, M. Gunaratnam, S. Mu¨ller, D. A. Sanders, S. Sewitz, J. A.
Fletcher, S. Neidle, and S. Balasubramanian. Targeting the c-Kit promoter
quadruplexes with 6-substituted indenoisoquinolines, a novel class of G-
quadruplex stabilising small molecule ligands. ACS Med. Chem. Lett., DOI:
10.1021/ml100062z, 2010. 6, 14, 19
[105] E. Gavathiotis, R. A. Heald, M. F. Stevens, and M. S. Searle. Drug
recognition and stabilisation of the parallel-stranded DNA quadruplex
(TTAGGGT)4 containing the human telomeric repeat. J. Mol. Biol., 334:
25–36, 2003. 6, 7
[106] N. H. Campbell, M. Patel, C. B. Tofa, R. Ghosh, G. N. Parkinson, and
S. Neidle. Selectivity in ligand recognition of G-quadruplex loops. Bio-
chemistry, 48:1675–1680, 2009. 6, 19
[107] S. Cosconati, L. Marinelli, R. Trotta, A. Virno, S. De Tito, R. Romagnoli,
B. Pagano, V. Limongelli, C. Giancola, P. G. Baraldi, L. Mayol, E. Novel-
lino, and A. Randazzo. Structural and conformational requisites in DNA
quadruplex groove binding: another piece to the puzzle. J. Am. Chem.
Soc., 132:6425–6433, 2010. 6, 19
[108] J. Ren and J. B. Chaires. Sequence and structural selectivity of nucleic acid
binding ligands. Biochemistry, 38:16067–16075, 1999. 6
[109] P. Wang, L. Ren, H. He, F. Liang, X. Zhou, and Z. Tan. A phenol qua-
ternary ammonium porphyrin as a potent telomerase inhibitor by selective
interaction with quadruplex DNA. ChemBioChem, 7:1155–1159, 2006. 6
189
REFERENCES
[110] P. S. Shirude, E. R. Gillies, S. Ladame, F. Godde, K. Shin-ya, I. Huc, and
S. Balasubramanian. Macrocyclic and helical oligoamides as a new class of
G-quadruplex ligands. J. Am. Chem. Soc., 46:5404–5407, 2007. 6, 21, 32
[111] W. G. Rice, J. K. C. Lim, M. K. Schwabe, A. Siddiqui-Jain, N. H. Streiner,
K. B. Trent, J. P. Whitten, L. H. Hurley, and D. D. Von Hoff. Design
of CX-3543, a novel multi-targeting antitumor agent. Proc. Amer. Assoc.
Cancer. Res., 46, 2005. 7
[112] A. Rizzo, E. Salvati, M. Porru, C. D’Angelo, M. F. Stevens, M. D’Incalci,
C. Leonetti, E. Gilson, G. Zupi, and A. Biroccio. Stabilization of quadruplex
DNA perturbs telomere replication leading to the activation of an ATR-
dependent ATM signaling pathway. Nucleic Acids Res., 37:5353–5364, 2009.
7, 13, 64
[113] E. Salvati, C. Leonetti, A. Rizzo, M. Scarsella, M. Mottolese, R. Galati,
I. Sperduti, M. F. Stevens, M. D’Incalci, M. Blasco, G. Chiorino,
S. Bauwens, B. Horard, E. Gilson, A. Stoppacciaro, G. Zupi, and A. Biroc-
cio. Telomere damage induced by the G-quadruplex ligand RHPS4 has an
antitumor effect. J. Clin. Invest., 117:3236–3247, 2007. 7, 11
[114] C. Leonetti, M. Scarsella, G. Riggio, A. Rizzo, E. Salvati, M. D’Incalci,
L. Staszewsky, R. Frapolli, M. F. Stevens, A. Stoppacciaro, M. Mottolese,
B. Antoniani, E. Gilson, G. Zupi, and A. Biroccio. G-quadruplex ligand
RHPS4 potentiates the antitumor activity of camptothecins in preclinical
models of solid tumors. Clin. Cancer. Res, 14:7284–7291, 2008. 7
[115] P. Yang, A. De Cian, M.-P. Teulade-Fichou, J.-L. Mergny, and D. Mon-
chaud. Engineering bisquinolinium/thiazole orange conjugates for fluores-
cent sensing of G-quadruplex DNA. Angew. Chem. Int. Ed., 48:2188–2191,
2009. 8
[116] Y.-C. Tsai, H. Qui, C.-P. Lin, R.-K. Lin, J. E. Kerrigan, S. G. Rzuczek,
E. J. LaVoie, J. E. Rice, D. S. Pilch, Y. L. Lyu, and L. F. Lui. A G-
quadruplex stabilizer induces M-phase cell cycle arrest. J. Biol. Chem.,
284:22535–22543, 2009. 8
190
REFERENCES
[117] G. Pennarun, C. Granotier, L. R. Gauthier, D. Gomez, F. Hoffschir,
E. Mandine, J.-F. Riou, J.-L. Mergny, P. Mailliet, and F. D. Boussin.
Apoptosis related to telomere instability and cell cycle alterations in human
glioma cells treated by new highly selective G-quadruplex ligands. Onco-
gene, 24:2917–2928, 2005. 8, 21
[118] H. J. Lipps and D. Rhodes. G-quadruplex structures: in vivo evidence and
function. Trends in Cell Biol., 19:414–422, 2009. 9
[119] C. Schaffitzel, I. Berger, J. Postberg, J. Hanes, H. J. Lipps, and A. Plu¨ck-
thun. In vitro generated antibodies specific for telomeric guanine-
quadruplex DNA react with Stylonychia lemnae macronuclei. Proc. Natl.
Acad. Sci. U.S.A., 98:8572–8577, 2001. 9
[120] K. Paeschke, T. Simonsson, J. Postberg, D. Rhodes, and H. J. Lipps. Telom-
ere end-binding proteins control the formation of G-quadruplex DNA struc-
tures in vivo. Nat. Struct. Mol. Biol., 12:847–854, 2005. 9
[121] G. Fang and T. R. Cech. The β subunit of Oxytricha telomere-binding
protein promotes G-quartet formation by telomeric DNA. Cell, 74:875–
885, 1993. 9
[122] G. Fang and T. R. Cech. Characterization of a G-quartet formation reac-
tion promoted by the β-subunit of the Oxytricha telomere-binding protein.
Biochemistry, 32:11646–11657, 1993. 9
[123] H. Sun, J. K. Karow, I. D. Hickson, and N. Maizels. The Bloom’s syndrome
helicase unwinds G4 DNA. J. Biol. Chem., 273:27587–27592, 1998. 9, 13
[124] M. Fry and L. A. Loeb. Human Werner syndrome DNA helicase unwinds
tetrahelical structures of the fragile X syndrome repeat sequence d(CGG)n.
J. Biol. Chem., 274:12797–12802, 1999. 9, 13
[125] V. A. Soldatenkov, A. A. Vetcher, T. Duka, and S. Ladame. First evidence
of a functional interaction between DNA quadruplexes and poly(ADP-
ribose) polymerase-1. ACS Chem. Biol., 3:214–219, 2008. 9
191
REFERENCES
[126] C. Schaeffer, B. Bardoni, J.-L. Mandel, B. Ehresmann, C. Ehresmann, and
H. Moine. The fragile X mental retardation protein binds specifically to its
mRNA via a purine quartet motif. EMBO J., 20:4803–4813, 2001. 9, 17
[127] S. J. McKay and H. Cooke. hnRNP A2/B1 binds specifically to single
stranded vertebrate telomeric repeat (TTAGGG)n. Nucleic Acids Res., 20:
6461–6464, 1992. 10
[128] M. Paramasivam, A. Membrino, S. Cogoi, H. Fukada, H. Nakagama, and
L. E. Xodo. Protein hnRNP A1 and its derivative Up1 unfold quadruplex
DNA in the human KRAS promoter: implications for transcription. Nucleic
Acids Res., 37:2841–2853, 2009. 10
[129] V. Gonza´lez, K. Guo, L. H. Hurley, and D. Sun. Identification and charac-
terization of nucleolin as a c-myc G-quadruplex binding protein. J. Biol.
Chem., 284:23622–23635, 2009. 10
[130] D. Liu, M. S. O’Connor, J. Qin, and Z. Sonyang. Telosome, a mammalian
telomere-associated complex formed by multiple telomeric proteins. J. Biol.
Chem., 279:51338–51342, 2004. 10
[131] T. de Lange. Shelterin: the protein complex that shapes and safeguards
human telomeres. Genes. Dev., 19:2100–2110, 2005. 10
[132] E. H. Blackburn. Structure and function of telomeres. Nature, 350:569–573,
1991. 10
[133] J. D. Henson, A. A. Neumann, T. R. Yaeger, and R. R. Reddel. Alternative
lengthening of telomeres in mammalian cells. Oncogene, 21:598–610, 2002.
10
[134] S. A. Steward and R. A. Weinberg. Telomeres: cancer to human aging.
Annu. Rev. Cell. Dev. Biol., 22:531–557, 2006. 10
[135] A. Sancer, L. A. Lindsey-Boltz, K. Unsal-Kac¸maz, and S. Linn. Molecular
mechanisms of mammalian DNA repair and the DNA damage checkpoints.
Ann. Rev. Biochem., 73:39–85, 2004. 11
192
REFERENCES
[136] A. De Cian, L. Lacroix, C. Douarre, N. Temime-Smaali, C. Trentesaux, J.-
F. Riou, and J.-L. Mergny. Targeting telomeres and telomerase. Biochimie,
90:131–155, 2008. 11
[137] P. Phatak, J. C. Cookson, F. Dai, V. Smith, R. B. Gartenhaus, M. F.
Stevens, and A. M. Burger. Telomere uncapping by the G-quadruplex
ligand RHPS4 inhibits clonogenic tumour cell growth. Br. J. Cancer, 96:
1223–1233, 2007. 11
[138] T. Tauchi, K. Shin-Ya, G. Sashida, M. Sumi, A. Nakajima, T. Shimamoto,
J. H. Ohyashiki, and K. Ohyashiki. Activity of a novel G-quadruplex-
interactive telomerase inhibitor, telomestatin (SOT-095), against human
leukemia cells: involvement of ATM-dependent DNA damage response
pathways. Oncogene, 22:5338–5347, 2003. 11, 39, 56
[139] N. Temime-Smaali, L. Guittat, A. Sidibe, K. Shin-ya, C. Trentesaux, and
J.-F. Riou. The G-quadruplex ligand telomestatin impairs binding of topoi-
somerase IIIα to G-quadruplex-forming oligonucleotides and uncaps telom-
eres in ALT cells. PLOS, 4:e6919, 2009. 12
[140] D. Gomez, T. Lemarteleur, L. Lacroix, P. Mailliet, J.-L. Mergny, and J.-
F. Riou. Telomerase downregulation induced by the G-quadruplex ligand
12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nu-
cleic Acids Res., 32:371–379, 2004. 12
[141] D. Gomez, A. Gue´din, J.-L. Mergny, B. Salles, J.-F. Riou, M.-P. Teulade-
Fichou, and P. Calsou. A G-quadruplex structure in the 5’-UTR of TRF2
mRNA represses translation in human cells. Nucleic Acids Res., 2010
doi:10.1093/nar/gkq563. 12, 17, 62
[142] J. D. Griffith, L. Comeau, S. Rosenfield, R. M. Stansel, A. Bianchi, H. Moss,
and T. de Lange. Mammalian telomeres end in a large duplex loop. Cell,
97:503–514, 1999. 12
[143] R. M. Stansel, T. de Lange, and J. D. Griffith. T-loop assembly in vitro
involves binding of TRF2 near the 3’ telomeric overhang. EMBO J., 20:
5532–5540, 2001. 12
193
REFERENCES
[144] R. Rodriguez, S. Mu¨ller, J. A. Yeoman, C. Trentesaux, J.-F. Riou, and
S. Balasubramanian. A novel small molecule that alters shelterin integrity
and triggers a DNA-damage response at telomeres. J. Am. Chem. Soc.,
130:15758–15759, 2008. 12, 21, 32, 36, 37, 38, 39, 53, 55, 61, 62, 90, 95
[145] S. Neidle. Human telomeric G-quadruplexes: the current status of telomeric
G-quadruplexes as therapeutic targets in human cancer. FEBS J., 277:
1118–1125, 2010. 12
[146] A. T. Phan, Y. S. Modi, and D. J. Patel. Propeller-type parallel-stranded
G-quadruplexes in the human c-myc promoter. J. Am. Chem. Soc., 126:
8710–8716, 2004. 14, 31, 46
[147] S. Rankin, A. P. Reszka, J. L. Huppert, M. Zloh, G. N. Parkinson, A. K.
Todd, S. Ladame, and S. Balasubramanian. Putative DNA quadruplex
formation within the human c-kit oncogene. J. Am. Chem. Soc., 127:10584–
10589, 2005. 14, 31
[148] A. T. Phan, V. Kuryavyi, S. Burge, S. Neidle, and D. J. Patel. Structure of
an unprecedented G-quadruplex scaffold in the human c-kit promoter. J.
Am. Chem. Soc., 129:4386–4392, 2007. 46
[149] H. Fernando, A. P. Reszka, J. L. Huppert, S. Ladame, S. Rankin, A. R.
Venkitaraman, S. Neidle, and S. Balasubramanian. A conserved quadruplex
motif located in a transcription activation site of the human c-kit oncogene.
Biochemistry, 45:7845–7860, 2006. 14, 31, 46
[150] J. Dai, D. Chen, R. A. Jones, L. H. Hurley, and D. Yang. NMR solution
structure of the major G-quadruplex structure formed in the human BCL2
promoter region. Nucleic Acids Res., 34:5133–5144, 2006. 14, 46
[151] T. S. Dexheimer, D. Sun, and L. H. Hurley. Deconvoluting the structural
and drug-recognition complexity of the G-quadruplex-forming region up-
stream of the bcl-2 P1 promoter. J. Am. Chem. Soc., 128:5404–5415, 2006.
14
194
REFERENCES
[152] S. Cogoi and L. E. Xodo. G-quadruplex formation within the promoter of
the KRAS proto-oncogene and its effect on transcription. Nucleic Acids
Res., 34:2536–2549, 2006. 14, 31, 46
[153] S. Cogoi, M. Paramasivam, B. Spolaore, and L. E. Xodo. Structural poly-
morphism within a regulatory element of the human KRAS promoter: for-
mation of G4-DNA recognized by nuclear proteins. Nucleic Acids Res., 36:
3765–3780, 2008. 14, 31, 46
[154] Y. Qin, J. S. Fortin, D. Tye, M. Gleason-Guzman, T. A. Brooks, and
L. H. Hurley. Molecular cloning of the human platelet-derived growth factor
receptor β (PDGFR-β). Promoter and drug targeting of the G-quadruplex-
forming region to repress PDGFR-β expression. Biochemistry, 49:4208–
4219, 2010. 14
[155] R. M. Howell, K. J. Woodford, M. N. Weitzmann, and K. Usdin. The
chicken-globin gene promoter forms a novel ”cinched” tetrahelical structure.
J. Biol. Chem., 271:5208–5214, 1996. 14
[156] S. P. Clark, C. D. Lewis, and G. Felsenfield. Properties of BGP1, a
poly(dG)-binding protein from chicken erythrocytes. Nucleic Acids Res.,
18:5119–5126, 1990. 14
[157] T. Shalaby, A. O. von Bueren, M.-L. Hu¨rlimann, G. Fiaschetti, D. Castal-
letti, T. Masayuki, K. Nagasawa, A. Arcaro, I. Jelesarov, K. Shin-ya, and
M. Grotzer. Disabling c-Myc in childhood medulloblastoma and atypi-
cal tetratoid/rhabdoid tumor cells by the potent G-quadruplex interactive
agent S2T1-6OTD. Mol. Cancer Ther., 9:167–179, 2010. 14
[158] M. Gunaratnam, S. Swank, S. M. Haider, K. Galesa, A. P. Reszka, M. Bel-
tran, F. Cuenca, J. A. Fletcher, and S. Neidle. Targeting human gastroin-
testinal stromal tumor cells with a quadruplex-binding small molecule. J.
Med. Chem., 52:3774–3783, 2009. 14
[159] X.-D. Wang, T.-M. Ou, Y.-J. Lu, Z. Li, Z. Xu, C. Xi, J.-H. Tan, S.-L.
Huang, L.-K. An, D. Li, L.-Q. Gu, and Z.-S. Huang. Turning off transcrip-
tion of the bcl-2 gene by stabilizing the bcl-2 promoter quadruplex with
quindoline derivatives. J. Med. Chem., 53:4390–4398, 2010. 14
195
REFERENCES
[160] P. Bucek, J. Jaumot, Avino, R. Eritja, and R. Gargallo. pH-Modulated
Watson-Crick duplex-quadruplex equilibria of guanine-rich and cytosine-
rich DNA sequences 140 base pairs upstream of the c-kit transcription ini-
tiation site. Chem. Eur. J., 15:12663–12671, 2009. 15
[161] D. Sun and L. H. Hurley. The importance of negative superhelicity in induc-
ing the formation of the G-quadruplex and i-motif structures in the c-Myc
promoter: Implications for drug targeting and control of gene expression.
J. Med. Chem., 52:2863–2874, 2009. 15
[162] S. Dhakal, J. D. Schonhoft, D. Koirala, Z. Yu, S. Basu, and H. Mao. Coex-
istence of an ILPR i-motif and a partially folded structure with comparable
mechanical stability revealed at the single-molecule level. J. Am. Chem.
Soc., 2010: DOI: 10.1021/ja100944j. 15
[163] E. F. Michelotti, T. Tomonaga, H. Krutzsch, and D. Levens. Cellular nu-
cleic acid binding protein regulates the CT element of the human c-Myc
protooncogene. J. Biol. Chem., 270:9494–9499, 1995. 15
[164] M. Takimoto, T. Tomonaga, M. Matunis, M. Avignan, H. Krutzsch,
G. Dreyfuss, and D. Levensevens. Specific binding of heterogeneous ri-
bonucleoprotein particle protein K to the human c-Myc promoter, in vitro.
J. Biol. Chem., 268:18249–18258, 1993. 15
[165] G. A. Michelotti, E. F. Michelotti, A. Pullner, R. C. Duncan, D. Eick,
and D. Levens. Multiple single-stranded cis elements are associated with
activated chromatin of the human c-Myc gene in vivo. Mol. Cell. Biol., 16:
2656–2669, 1996. 15
[166] G. Pesole, F. Mignone, C. Gissi, G. Grillo, F. Licciulli, and S. Liuni. Struc-
tural and funtional features of eukaryotic mRNA translated regions. Gene,
276:73–81, 2001. 16
[167] B. Mazumder, V. Seshadri, and P. L. Fox. Translational control by the
3’-UTR: the ends specify the means. Trends Biochem. Sci., 28:91–98, 2003.
16
196
REFERENCES
[168] S. Kumari, A. Bugaut, and S. Balasubramanian. Position and stability are
determining factors for translation repression by an RNA G-quadruplex-
forming sequence within the 5’-UTR of the NRAS proto-oncogene. Bio-
chemistry, 47:12664–12669, 2008. 17
[169] M. J. Morris and S. Basu. An unusually stable G-quadruplex within the
5’-UTR of the MT3 matrix metalloproteinase mRNA represses translation
in eukaryotic cells. Biochemistry, 47:53193–5319, 2009. 17
[170] G. D. Balkwill, K. Derecka, T. P. Garner, C. Hodgman, A. P. F. Flint, and
M. S. Searle. Repression of translation of human estrogen receptor α by
G-quadruplex formation. Biochemistry, 48:11487–11495, 2009. 17
[171] M. J. B. Moore, F. Cuenca, M. Searcey, and S. Neidle. Synthesis of dis-
tamycin A polyamides targeting G-quadruplex DNA. Org. Biomol. Chem.,
4:3479–3488, 2006. 19, 20
[172] E. M. Rexler, J. Seenisamy, S. Bashyam, M.-Y. Kim, E. White, D. Wilson,
and L. H. Hurley. Telomestatin and diseleno sapphyrin bind selectively to
two different forms of the human telomeric G-quadruplex structure. J. Am.
Chem. Soc., 127:9439–9447, 2005. 20
[173] C. Granotier, G. Pennarun, L. Riou, F. Hoffschir, L. R. Gauthier, A. De
Cian, D. Gomez, E. Mandine, J.-F. Riou, J.-L. Mergny, P. Mailliet,
B. Dutrillaux, and F. D. Boussin. Preferential binding of a G-quadruplex
ligand to human chromosome ends. Nucleic Acids Res., 33:4182–4190, 2005.
21, 37
[174] S. Mu¨ller, S. Kumari, R. Rodriguez, and S. Balasubramanian. Small
molecule-mediated G-quadruplex isolation from human cells. Nature
Chem., 2010 in press. 21
[175] V. Berl, I. Huc, R. G. Khoury, and J.-M. Lehn. Helical molecular
programming: supramolecular double helices by dimerization of helical
oligopyridine-dicarboxamide strands. Chem.-Eur. J., 7:2810–2820, 2001.
21
197
REFERENCES
[176] H. Liang, J.-M. Leger, and I. Huc. Aromatic delta-peptides. J. Am. Chem.
Soc., 125:3448–3449, 2003. 23
[177] L. Xing, U. Ziener, T. C. Sutherland, and L. A. Cuccia. Hydrogen bond
directed synthesis of pyridazine and naphthyridine containing macrocycles.
Chem. Commun., pages 5751–5753, 2005. 21
[178] S. Yagi, I. Yonekura, M. Awakura, M. Ezoe, and T. Tagagishi. Facile
synthesis of cofacial porphyrin dimer and trimer using a diarylurea linkage.
Chem. Commun., pages 557 – 558, 2001. 21
[179] J. J. P. Steward. Optimization of parameters for semiempirical methods I.
Method. J. Comput. Chem., 10:209–220, 1989. 24
[180] J. J. P. Steward. Optimization of parameters for semiempirical methods II.
Applications. J. Comput. Chem., 10:221–264, 1989. 24
[181] J.-L. Mergny and J.-C. Maurizot. Fluorescence resonance energy transfer
as a probe for G-quartet formation by a telomeric repeat. ChemBioChem,
2:124–132, 2001. 29, 32
[182] V. Berl, I. Huc, R. G. Khoury, M. J. Krische, and J.-M. Lehn. Interconver-
sion of single and double helices formed from synthetic molecular strands.
Nature, 407:720–723, 2000. 36
[183] S. L. Jain, P. Bhattacharyya, H. L. Milton, A. M. Z. Slawin, J. A. Crayston,
and J. D. Woollins. New pyridine carboxamide ligands and their complex-
ation to copper(II). X-ray structures of mono-, di,- tri- and tetranuclear
copper complexes. Dalton Trans., pages 862–871, 2004. 36
[184] G. Chessa, G. Marangoni, and B. Pitteri. Cross-linked polystyrene resins
with 2,6-diformylpyridine bis(2’-pyridylhydrazone) groups. Synthesis and
metal ion chelation properties. Reactive Polymers, 12:219–228, 1990. 41,
106
[185] Protocol (Promega): http://www.promega.com/tbs/tb288/tb288.pdf. 49
[186] W. F. Scherer, J. T. Syverton, and G. O. Gey. Studies on the propagation
in vitro of poliomyelitis viruses: IV. Viral multiplication in a stable strain of
198
REFERENCES
human malignant epithelial cells (strain HeLa) derived from an epidermoid
carcinoma of the cervix. J. Exp. Med., 97:695–715, 1953. 49
[187] S. Rasheed, W. A. Nelson-Rees, E. M. Toth, P. Arnstein, and M. B. Gard-
ner. Characterization of a newly derived human sarcoma cell line (HT-
1080). Cancer, 33:1027–1033, 1973. 49
[188] J. Ponte´n and E. Saksela. Two established in vitro cell lines from human
mesenchymal tumours. Int. J. Cancer, 2:434–447, 1967. 49
[189] L. Hayflick and P. S. Moorhead. The serial cultivation of human diploid
cell strains. Exp. Cell. Res., 25:585–621, 1961. 49
[190] A. J. Nakamura, Y. J. Chiang, K. S. Hathcock, I. Horikawa, O. A. Sedel-
nikova, R. J. Hodes, and W. M. Bonner. Both telomeric and non-telomeric
DNA damage are determinants of mammalian cellular senescence. Epigen.
Chrom., 1, 2008. 49
[191] T. Velderman, K. T. Etheridge, and C. M. Counter. Loss of hPot1 function
leads to telomere instability and a cut-like phenotype. Curr. Biol., 14:
2264–2270, 2004. 56
[192] G. P. Dimri, C. Lee, G. Basile, M. Acosta, G. Scott, C. Roskelly, E. E.
Medrano, M. Linskens, I. Rubelj, O. Pereira-Smith, M. Peacocke, and
J. Campisi. A biomarker that identifies senescent human cells in culture
and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A., 92:9363–9367,
1995. 56
[193] A. G. Bodnar, M. Ouelette, M. Frolkis, S. E. Holt, C. P. Chiu, G. B. Morin,
C. B. Harley, J. W. Shay, S. Lichtsteiner, and W. E. Wright. Extension of
life-span by introduction of telomerase into normal human cells. Science,
279:349–352, 1998. 58, 90
[194] NCI website: http://dtp.cancer.gov/branches/btb/ivclsp.html. 58, 59
[195] M. C. Sanguinetti and M. Tristani-Firouzi. Review article hERG potassium
channels and cardiac arrhythmia. Nature, 440:463–469, 2006. 61
199
REFERENCES
[196] J. Taunton, C. A. Hassig, and S. L. Schreiber. A mammalian histone
deacetylase related to the yeast transcriptional regulator Rpd3p. Science,
272:408–411, 1996. 64
[197] D. R. Bentley et al. Accurate whole human genome sequencing using re-
versible terminator chemistry. Nature, 456:53–59, 2008. 64, 96
[198] A. Barski, S. Cuddapah, K. Cui, D. E. Schones T.-Y. Roh, Z. Wang, G. Wei,
L. Chepelev, and K. Zhao. High-resolution profiling of histone methylations
in the human genome. Cell, 129:823–837, 2007. 64, 65, 77, 79
[199] D. S. Johnson, A. Mortazavi, R. M. Myers, and B. Wold. Genome-wide
mapping of in vivo protein-DNA interactions. Science, 316:1497–1502, 2007.
64, 65, 77, 79
[200] P. C. Weber, D. H. Ohlendorf, J. J. Wendoloski, and F. R. Slemme. Struc-
tural origins of high-affinity biotin binding to streptavidin. Science, 243:
85–88, 1989. 66
[201] I. V. Smirnov and R. H. Shafer. Electrostatics dominate quadruplex sta-
bility. Biopolymers, 85:91–101, 2006. 76
[202] A. Wong and G. Wu. Selective binding of monovalent cations to the stacking
G-quartet structure formed by guanosine 5‘-monophosphate: a solid-state
NMR study. J. Am. Chem. Soc., 125:13895–13905, 2003. 76
[203] C. Cawthon. Telomere measurement by quantitative PCR. Nucleic Acids
Res., 30:e47, 2002. 94
200
